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1 INTRODUCTION 
In recent years there has been a considerable rise in development of biopharmaceutical 
products containing monoclonal antibodies (mAb) and antibody fragments (Hong et al., 
2012). Monoclonal antibodies have a unique feature to bind with a certain specificity and 
high affinity to different molecular targets. Thus, this ability of monoclonal antibodies has 
been exploited in order to develop and produce recombinant monoclonal antibodies for 
specified molecular targets and formulate them in bio-therapeutics, which have rapidly 
improved patient care for a variety of diseases (Shire et al., 2004). 
 
Furthermore, detection and characterization of protein degradation or aggregation, as well 
as other monoclonal antibodies’ structural variants, is essential during development, 
production and quality control of therapeutic proteins (Curtis et al., 1998; Kastelic et al., 
2015; Chi et al., 2003; Arosio et al., 2013). This concern is relevant from the safety point 
of view because protein self-association or aggregation within biopharmaceutical products 
can cause adverse toxicological and immunological effects (Kastelic et al., 2015; 
Obrezanova et al., 2015). Moreover, monoclonal antibodies as large multi-domain 
molecules and an important class of therapeutic proteins can form various aggregates that 
differ in size and morphology (Shire et al., 2004; Curtis et al., 1998; Skamris et al., 2016; 
Van Buren et al., 2009). Even if mAb aggregates are considered as inactive, it is possible 
that a large number of molecules present in microscopic protein aggregates’ surface could 
represent the triggering ligands for antigen-presenting cells to B-cell epitopes. In addition, 
this process could trigger anti-drug antibody (ADA) formation in patients by receptor 
clustering and subsequent activation of B-cells (Rombach-Riegraf et al., 2014).  
 
Hence, all biopharmaceutical companies that manufacture monoclonal antibodies have a 
common goal to produce safe and stable biotherapeuticals with a desired biological effect 
(Kohli et al., 2015). Thus, detection and quantification of recombinant monoclonal 
antibodies’ structural variant species is obligatory during development as this enables the 
mitigation and control of the potential risks (Zhang et al., 2014). During fermentation, 
purification, formulation, upon storage, and handling, therapeutic proteins may undergo a 
number of modifications and degradations (Liu et al., 2005; Kanai et al., 2008; Luo et al., 
2011). The main degradation pathways include enzymatic or chemical post-translational 
modification, aggregation or proteolytic cleavage (Haverick et al., 2014). All harmonized 
guidelines and drug agencies globally address the necessity for performing all possible 
analysis in order to detect, control and monitor potential structural defects and 
abnormalities during manufacturing of bio-therapeutics (Latypov et al., 2012; Sahin et al., 
2012; Chennamsetty et al., 2009). Accordingly, there is a constant need for development 
and improvement of analytical methods that could be used for detection of protein 
structural abnormalities and impurities. One of widely used and robust methods for 
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separation, detection, and quantification of monomeric and multimeric forms of 
monoclonal antibodies based on their hydrodynamic radius is size exclusion 
chromatography on high performance liquid chromatography system (SEC-HPLC) (Fekete 
et al., 2014; Goyon et al., 2017). On the other hand, a better understanding and 
characterization of potential structural variants is possible upon using an additional 
orthogonal hydrophobic interaction chromatography (HIC) technique (Valliere-Douglass et 
al., 2008). In a way, HIC can be compared to high performance liquid chromatography on 
reversed-phase technique (RP-HPLC), because the retention of different protein variants 
obtained with HIC chromatography is dependent on the different hydrophobic character of 
amino-acid residues located on the surface of the molecule and their interaction with the 
column matrix. Generally, changes within protein structures are due to hydrolysis, post-
translational modifications, or aggregation and this influences the differences in their 
retention times (Haverick et al., 2014). 
 
Among all possible side effects upon drug consumption, a potential immunogenicity due to 
heterologous mAbs structure is of greater concern and tremendous efforts should be made 
in order to minimize alterations and retain desired protein structure during production of 
active pharmaceutical ingredient (API) and its formulation (Franey et al., 2010). On the 
other hand, not all deviated protein forms are immunogenic (Gilliland et al., 1999). In 
parallel with the development of analytical techniques, an in vitro cell-based technology, 
which relies on interrogation of the early DC-driven events that initiate CD-4 T-cell 
dependent humoral adaptive immune responses was integrated into the monitoring of 
potential immunogenicity. Moreover, there are reports that highly aggregated proteins 
could induce in vitro T-cell response that might lead to the formation of specific antibodies 
against target protein (Rombach-Riegraf et al., 2014). 
 
The frame of this doctoral dissertation involves both development and optimization of 
separation methods and immune-cell in vitro techniques with the aim of determination of 
structural isoforms, which could potentially represent basis for occurrence of unwanted 
immunogenicity. Hence, detection, characterization and evaluation of aggregated as well 
as other modified forms of chosen IgG monoclonal antibody (named mAb1 in continuation 
of the text, due to Novartis company’s position) is proposed by using, size-exclusion 
chromatography (SEC), analytical ultracentrifugation, hydrophobic interaction 
chromatography (HIC), sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE), capillary electrophoresis (CE), and dynamic light scattering (DLS). After 
isolation and separation, selected aggregates, and modified forms of mAb1 were subjected 
to the dendritic cells (DC) protein examination experiment by using dendritic cells as the 
most efficient antigen-presenting cell population. Additionally, potential innate immune 
response of peripheral blood mononuclear cells (PBMC) cultures to mAb1 aggregate 
fractions was also evaluated by measuring pro-inflammatory cytokine response during 
early exposure of PBMC and the effect on their proliferation. 
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1.1 AIM 
Within this doctoral dissertation, we will develop and optimize separation methods and 
immune-techniques in order to determine those structural isoforms, which could 
potentially represent basis for occurrence of unwanted immunogenicity. 
 
Development and optimizations of analytical and immunological techniques, which could 
be applied as certain platform approaches for addressing monoclonal antibody structural 
variants' separation, identification, characterisation and determining their potential for 
immunogenicity, represent a great impact in the field of safety, quality and effectiveness in 
biopharmaceutical industry. Therefore, developing and proposing such a comprehensive 
platform that consists of certain analytical and immunological techniques that jointly 
provide deep insights and connection of monoclonal antibody structural variants to their 
potential for immunogenicity and which could be applied at early stages in bio-
pharmaceutical product development is the main aim of this doctoral dissertation. 
1.2 RESEARCH HYPOTHESIS 
Based on literature data and personal research experience we hypothese that using selected 
analytical methods and immune-techniques we could: 
 
• designate and separate critical structural variants sets for selected mAb1, such are 
mAb1 aggregates or degradation products, from the intact mAb1, 
• separate and characterize individual peaks of mAb1 aggregates within the profile of 
mAb1 aggregates’ structural variants, 
• determine potential capacity of the mAb1 aggregates to induce maturation of DC in 
terms of phenotype and cytokine producing capacity, 
• determine the capacity of the mAb1 aggregates to induce short-term (innate) immune 
responses in PBMC. 
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2 REVIEW OF PUBLICATIONS 
2.1 IMMUNE RESPONSE 
The main function of the immune system is to protect the host against pathogenic 
microorganisms and pathologically altered cells. Therefore, immunity could be defined as 
resistance to disease, particularly to infective one. Cells, tissues, and molecules, which 
assure resistance to infection, together represent immune system. Similarly, coordinated 
reaction of those cells and molecules to infective microorganisms is defined as immune 
response. Physiological function of immune response is of utmost importance to prevent 
and eradicate infections. 
 
There are two types of immune responses: innate immunity, which is obtained at birth, and 
specific immunity, which is acquired through person's lifetime. Natural (innate) immunity 
represents the first line of defence against the pathogenic organisms or cells. Characteristic 
of natural immunity is that it causes rapid and non-specific response, which involves 
anatomical and mechanical barriers, different non-specific bactericidal substances, genetic 
factors, phagocytosis, and various effector mechanisms. Representative cells of innate 
immune system are dendritic cells and macrophages, which are able to release 
inflammatory cytokines, antibacterial proteins and nitric-oxide (Abbas et al., 2014). 
Specific immunity is also called adaptive due to its feature to adapt to infection of 
microorganisms through proliferation and differentiation of lymphocytes, which are 
fighting those microorganisms in an antigen-specific manner (Burnet, 1957). 
 
First line of defence of innate immunity represent epithelial barriers of skin and mucous 
membranes as they prevent entry of any microorganism. However, if microorganisms 
penetrate epithelial barriers and enter tissues or circulation, they are attacked by 
phagocytes, natural killer cells, or specific proteins of plasma and complement system 
(Dale et al., 2008; Holers, 2014). All mechanisms of innate immunity recognize invasive 
microorganisms and react against them. 
 
On the other hand, adaptive immune system consists of lymphocytes and their products – 
set of monoclonal antibodies, represented as a pool (polyclonal antibodies). Even though 
mechanisms of innate and specific immunity recognize some common structures of 
different classes of microorganisms, cells of specific immune response – lymphocytes, 
express a variety of receptors that contain huge number of different molecules, which in a 
way alert that microorganisms are present inside the cells (Yin et al., 2015). Any 
substance, which is specifically recognized by lymphocytes or antibodies, is determined as 
antigen (Ag) (Jerne, 1955). 
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There are two types of adaptive immunity: humoral and cellular immune response. The 
main differences between them are in the cells and molecules that participate in immune 
response. Cells that provide defence from extracellular microorganisms, are connected to 
humoral immunity, on the other hand, cells responsible for defence from intracellular 
microorganisms, are part of cellular immunity. Monoclonal antibodies that are produced by 
B-lymphocytes participate in humoral immunity. They enter the circulation or mucous 
secret and neutralize or eliminate microorganisms and their toxins. One of the main 
functions of monoclonal antibodies is blocking pathogens in mucus or circulation and 
therefore preventing colonization of healthy cells and tissues. However, monoclonal 
antibodies are not capable of neutralizing pathogens that are present in infected cells. 
Defence against intracellular pathogens is conducted via T-lymphocytes, which are the 
main components of cellular immune response (Boehm, 2008). T-lymphocytes can activate 
phagocytes to destroy microorganisms, which already have been present in phagocytic 
vesicles or they can kill any other infected immune and non-immune cells, which present 
pathogenic antigens on cellular surface in complex with major histocompatibility complex 
(MHC) molecules (Klein et al., 2014). In any case, T-lymphocytes recognize pathogen-
related antigens, which are expressed on the surface of host T-cells, which implies that the 
pathogen is present in the cell (Surh et al., 2008; Dale et al., 2008). 
 
In case that antigen is repeatedly present in the host, immune response has the specificity 
to react more effectively. This feature of immune response is referred to as immunogenic 
memory since immune system memorizes previous exposure to same antigen (Mueller et 
al., 2013). By analogy, within the first exposure of antigen main participants in immune 
response are lymphocytes, which are in the contact with the antigen for the first time. The 
term naive lymphocyte is used for those lymphocytes that are immunologically 
inexperienced since they have not responded to any antigen previously (Surh et al., 2008; 
Sprent et al., 2011). In the next contact of lymphocytes with the same antigen, secondary 
immune response takes place, which is much faster, more effective, and stronger 
comparing to the primary response (Chen et al., 2013). Secondary immune response is a 
result of activation of memory lymphocytes, which are long living cells created during 
primary immune response (Farber et al., 2014). The term memory signifies that those cells 
have to memorize previous contact with the antigen and provide better response during 
potential future contact with the same antigen (Malissen et al., 2015).  
 
The cells included in the immune system are present in different tissues and have several 
roles for host defence. The main mediators of immune response are, as mentioned before, 
lymphocytes that circulate in lymphoid system and non-lymphoid tissues. Their main 
function is to recognize antigens and initiate adaptive immune response. There are two 
types of lymphocytes: B-lymphocytes that are mediators of humoral immune response and 
T-lymphocytes, which are mediators of cellular immune response (Bronte et al., 2013; 
Drayton et al., 2006). On the other hand, dendritic cells, macrophages, B-cells, and 
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follicular dendritic cells have the purpose of collecting the antigens and presenting them to 
lymphocytes (Reth et al., 2014). This is why this group of cells is referred to as antigen 
presenting cells. Antigen presenting cells are present in tissues and their main role is 
detection of microorganisms and initiation of reaction against them. Dendritic cells seize 
microorganisms and present their antigens to lymphocytes in order to initiate immune 
response. Accordingly, dendritic cells are considered as main antigen presenting cells.  
 
Moreover, also other cell types such as T-lymphocytes, macrophages, and granulocytes 
have the function in elimination of antigen. In specific, T-lymphocytes are responsible for 
phagocyte activation and elimination of infected cells. Macrophages perform process of 
phagocytosis of microorganism and non-native substances (Flannagan et al., 2012). In 
addition, also phagocytes, which include neutrophils and monocytes, are rapidly drawn to 
infection point in the process determined as inflammation (Amulic et al., 2012; Mócsai, 
2013). Those type of cells ingest microorganisms and then begin the process of reparation 
of damaged tissues. Since phagocytes and some T-lymphocytes participate in the 
elimination of the microorganisms, they are referred to as effector cells.  
2.1.1 Antigen-presenting cells (APC)  
Skin, gastrointestinal, or respiratory tract are the main entry points for microorganisms, 
because they are in direct contact with the exterior influences. Accordingly, antigen-
presenting cells are present in skin and epithelium of respiratory and gastrointestinal tract. 
Their role is collecting and transportation of antigens to peripheral lymphoid tissues and 
presenting them to lymphocytes. This feature of collection and transportation of antigens is 
thoroughly studied within dendritic cells (Bousso, 2008). 
 
Dendritic cells are specific cells of immune system, which have characteristic extensions 
of cytoplasmic membrane that resemble dendrites. Consequently, these cells are named 
dendritic cells. They are responsible for collecting protein antigens from microorganisms 
that have already passed epithelium and to transport them to neighbouring lymph nodes 
where antigens are being presented to T-lymphocytes (Collin et al., 2013). In case when 
microorganisms penetrate epithelium, macrophages could also initiate process of 
phagocytosis and presentation of antigens (Merad et al., 2013). However, dendritic cells 
are most effective antigen-presenting cells during initiation of immune response. 
 
Commonly, all cells that have the feature for antigen presentation to T-lymphocytes also 
have the property of stimulating T-cells (Masopust et al., 2013). Those cells' reaction to 
microorganisms includes production of specific proteins on the surface or secreted 
proteins, which are together with antigens necessary for activation of naive T-lymphocytes, 
their proliferation and differentiation in effector cells (Durand et al., 2015; Mildner et al., 
2014). Thus, the term professional antigen-presenting cells refers to dendritic cells, 
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macrophages, and B-cells, which all can present antigens to T-cells and provide additional 
activation signals for initiation of immune response (Heath et al., 2009).  
 
In addition, B-lymphocytes have the ability to directly recognize unknown antigens, such 
as those on the surface of the microorganisms. Moreover, macrophages could seize 
antigens within lymph nodes and present them to B-cells (Gonzalez et al., 2011). Follicular 
dendritic cells that are present in lymph system present antigens and stimulate B-cells in 
lymph follicules (Shortman et al., 2007; McHeyzer-Williams et al., 2012). However, those 
types of cells cannot stimulate T-cells. 
2.1.2 Peripheral blood mononuclear cells (PBMC) 
Neutrophils and monocytes represent two types of circulating phagocytes, which are drawn 
to infection location where they recognize and inactivate microorganisms in the process of 
intracellular ingestion (Ley et al., 2007). Monocytes have distinctive ellipsoidal nucleus. 
During inflammation, they enter extravascular tissue spaces and differentiate into 
macrophages (Varol et al., 2015). Therefore, monocytes in blood and macrophages in 
tissues represent different stages of development of the same cell line of mononuclear 
phagocytes (Roederer et al., 2015). 
 
Macrophages have several important roles, such as cytokine production, which initiate and 
regulate inflammation, ingest and destroy microorganisms, elimination of dead tissues and 
tissue reparation (Varol et al., 2015). Macrophages express receptors on their surface that 
have functional and activational role. Phagocytosis is mediated by surface receptors such 
are receptors for mannose and scavenger receptors, which are directly bound to 
microorganisms, or receptors for activation of complement system or antibodies (Ley et 
al., 2007; Carroll et al., 2011). Macrophages can be activated by classical or alternative 
activation process. Classical activation of macrophages is initiated with signals of innate 
immune response i.e. with signals from toll-like receptors (TLR) and interferon γ (IFN-γ) 
(Rock et al., 2009). Macrophages, which have undergone classical activation process, are 
named M1 and take part in inflammation initiation and elimination of microorganisms. In 
the case of stimulation with cytokines IL-4 and IL-13 with no intense signal from TLR, 
alternative activation of macrophages takes place (Blasius and Beutler, 2010). Those 
activated macrophages are referred to as M2 and they are involved in tissue reparation and 
inflammation control.  
2.1.3 Role of dendritic cells (DC) in immune response 
Since microorganisms can enter host system through close contact with skin, by ingestion, 
inhalation, or directly enter circulation upon stings or bites, practically microorganism 
antigens could be present in any infected tissue. Those antigens are taken over in lymphatic 
Ignjatović J. Detection and immunogenicity evaluation of recombinant monoclonal antibodies’ structural variants. 
   Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty, 2019 
 
8 
system. This process begins with contact of microorganism and dendritic cells, then their 
activation and migration of activated dendritic cell with antigen to lymph nodes and 
presentation of those antigens to T-lymphocytes (Bousso, 2008). In response to 
microorganisms, dendritic cells produce specific cytokines with two main functions: 
initiation of inflammation or stimulation of adaptive immune response (Bajénoff et al., 
2007). As dendritic cells detect microorganisms and interact with lymphocytes, they 
represent an important link between innate and specific immune response. 
 
Epithelial cells cover all surfaces and therefore represent physical barrier against infection. 
Immature dendritic cells are settled in epithelial tissues and build dendritic cell network 
with their long cytoplasmic extensions. There are two basic populations of dendritic cells – 
myeloid and plasmocytiod. Both differ in location in body and response type. However, 
majority of dendritic cells present in different tissues and lymph organs belong to myeloid 
subdivision of dendritic cells. Classical dendritic cells highly express surface markers 
CD11b, CD11c, Toll-like receptors (TLR) 4, 5, 8 and cytokines: TNF (tumour necrosis 
factor), interleukins (IL) IL-6 and IL-12 (Brubaker, 2015). For this reason, it is presumed 
that they are able to induce T-cell response against vast majority of antigens. Epidermal 
dendritic cells in skin are named Langerhans cells. On the other hand, plasmocytoid cells 
have been named because of morphological similarities with plasma cells and are primarily 
located in blood. Plasmocytiod cells characteristically have lower expression of surface 
markers CD11b, CD11c and have greater expression of TLR 7, 9 and interferon (IFN) type 
I (Brubaker et al., 2015; Takeuchi et al., 2010). Hence, their presumed function, besides 
activation of T-cells, is also inducing antivirus innate immune response (Klotman et al., 
2006; Pichlmair et al., 2007). Similarly, mature dendritic cells inhabit T-cell zones of 
lymphatic nodes. 
 
Dendritic cells bind different microorganism glycoproteins with lectin membrane 
receptors, which are specific for carbohydrate structures. Microorganism and their antigens 
enter the cell in the process of phagocytosis or receptor-mediated endocytosis. As dendritic 
cells uptake the antigens, microorganism products bind and activate Toll-like receptors and 
other receptors for recognising of microorganism molecules. In this manner, dendritic cells 
are activated via mechanisms of innate immunity (Abbas et al., 2014). This influences 
production of inflammatory cytokines such as TNF and IL-1 (Yin et al., 2015; Franchi et 
al., 2012; Netea et al., 2015). This combination of activation of TLR receptors and 
cytokines causes further activation of dendritic cells, which influences different changes in 
their phenotype, migration, and function (Takeuchi et al., 2010; Bromley et al., 2008). 
 
Upon activation of classical dendritic cells in epithelium, they lose their adhesion function 
and affinity for epithelial cells. Then dendritic cells start to produce chemokine receptor 
CCR7 to which chemotactic cytokines bind. Chemotactic cytokines (also known as 
chemokines) are produced by endothelial cells of lymph vessels in T-cell zones of lymph 
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nodes (Masopust et al., 2013). Aim of these chemokynes is to direct dendritic cells to exit 
epithelium and move to lymph nodes and vessels (Sokol et al., 2015). During this process, 
dendritic cells mature to antigen-presenting cells and are able to stimulate T-cells. 
Maturation is measured in increased synthesis and expression of MHC molecules, which 
present antigens to T-cells (Purcell et al., 2008). Along this process, dendritic cells also up-
regulate surface expression of co-stimulatory molecules, namely CD80 and CD86, which 
are necessary for complete T-cell response (Roche et al., 2015). Hence, as a final result of 
described processes, protein antigens of microorganisms which have entered the organism 
are transported and compiled in lymph nodes where there is greatest probability of contact 
with T-cells. Naive T-lymphocytes recirculate through lymph nodes and secrete CCR7, 
which assists them in entering T-cell zones of lymph nodes (Zlotnik et al., 2012). 
Accordingly, dendritic cells which have taken over antigens meet naïve T-lymhocytes in 
lymph nodes where T-cell response to specific antigen iniciates. 
2.1.4 Antibodies and their role in immune response 
It is commonly known that both B and T-lymphocytes produce different receptors for 
recognition of antigens. Those are antibody receptors that are connected to cell membrane 
on B-cells (BCR) or on T-lymphocytes (also known as TCR) (Davis et al., 2003). 
Receptors have the function to uncover external stimulus such as presence of different 
antigens and subsequently activate the response of the cell to which membrane they are 
connected (Klein et al., 2009). In order to recognise a variety of different antigens, such 
receptors have to be capable of binding and distinguishing between many compounds with 
very similar chemical structures. 
 
In addition to being produced as membrane receptors, antibodies, which are also referred 
to as immunoglobulins, can be secreted out of the lymphocyte cells. However, 
immunoglobulins on T-cell membrane are never secreted and can only be presented as 
membrane proteins (Rossjohn et al., 2015). In order to activate the signal, it is necessary 
that many receptors are activated with the same antigen (Kuhns et al., 2006). 
 
Specifically, membrane antibodies on B-Cells are capable of recognition of many different 
antigens of different chemical structures, while those on T-cells can recognise peptides, 
which are bound to major histocompatibility complex (MHC) molecules (Bjorkman et al., 
1987; Blum et al., 2013). Advantage of antigen receptors on B-Cells is that they could also 
recognize different conformations of macromolecules, such as lipids, proteins, 
carbohydrates, or nucleic acids. Given this capability of diverse antigen type recognitions, 
B-cells are responsible for binding to microorganisms and its toxins in their native form. 
On opposite side, since antigen receptors on T-cells mainly bind to peptides within MHC 
on antigen presenting cells (APC) they are limited to recognizing of microorganisms that 
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are present inside the antigen presenting cells (Blum et al., 2013; Trombetta et al., 2005; 
Rudolph et al., 2006).  
 
Any type of antibody receptor contains variable (V) and constant (C) regions. Parts of 
antibody, which recognize the antigens, are referred as variable regions. Moreover, within 
every variable region, the majority of amino acid variations are concentrated in so-called 
hypervariable regions or complementary determining regions (CDR) (Corti et al., 2013). 
Hypervariable regions are forming receptor part, which binds to the antigens. In addition, 
polypeptide chains of antigen receptor are connected with proteins within the cell 
membrane, which have the function of delivering activation signals initiated by antigen 
binding inside the cell. Briefly, the function of antigen receptors connected to B- or T-cell 
membrane is specific binding of the antigens and conducting the signals inside the cell. 
 
On the other hand, B-cells have the capability of secreting antibodies (immunoglobulins) 
as soluble proteins which are therefore present in blood and mucosal secrets where they 
can inactivate microorganisms and their toxins (Goodnow et al., 2010). Similarly, to 
antigen antibody receptors, soluble antibodies recognise and bind to antigens with their 
variable regions, while constant regions of antibodies are able to bind to some molecules of 
complement system or receptors of phagocytes, which also take part in antigen elimination 
(Shlomchik et al., 2012; Carroll et al., 2011). To sum up, antibodies have many functions 
in different phases of humoral immune response: membrane antibodies on B-cells 
recognise antigens and activate humoral immune response; secreted antibodies neutralize 
microorganisms and toxins within effector phase of humoral immunity while antigen 
receptors on T-cells are only responsible for recognising of antigens and activation of T-
cells (Nutt et al., 2015). 
 
Structurally, antibodies consist of four amino-acid polypeptide chains, two of them are 
referred to as heavy chains (H) and other two are light chains (L). Both heavy chains are 
identical, analogly, both light chains are also the same. All four chains are connected in a 
shape of letter Y, therefore, one heavy and one light chain are closely connected and both 
heavy chains are connected via disulphide bonds (Figure 1). Each light and heavy chain 
consist of one constant (C) and one variable (V) region. However, light chain has only one 
variable and one constant region, while heavy chain has one variable and 3 or 4 constant 
regions. Furthermore, each domain is folded specifically and forms 3D structure that 
consists of 2 β-plates connected with disulphide bonds. Chains of neighbouring β-plates 
are also connected with short loops. Moreover, in variable domains of immunoglobulins 
those loops are forming 3 CDR regions which recognize the antigens (Abbas et al., 2014). 
Binding place for antigen on antibody consists of variable regions present in both heavy 
and light chain. However, one antibody has two identical places for antigen binding. 
Furthermore, each variable region of heavy or light chain has 3 hypervariable regions. 
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Figure 1: Simplified presentation of antibody (immunoglobulin) structure. 
Slika 1: Poenostavljen prikaz strukture protitelesa (imunoglobulina).  
Antibody fragment that consists of complete light chain, one variable and first constant 
region of heavy chain is reffered to as fragment antigen binding (Fab). The rest of the 
constanst regions of the both heavy chains are forming the so-called fragment 
crystallizable (Fc). Therefore, in each antibody there are two identical Fab regions and 
only one Fc fragment (Law et al., 2008). Moreover, in between Fc and Fab regions, there is 
a flexible joint that enables free movement of Fab fragments so that they can bind 
independently to the antigens (Figure 1). At the very end of Fc fragment, carboxyterminal 
part of the antibody could be ancored in the cell mebrane, which is the case with B-cell 
receptors, or it can end without this part for acoring into the membrane, hence that type of 
antibody is secreted. Light chains of antibody are never bound to the cell membrane. 
 
In general, we can differ between five types of heavy chains: µ, δ, γ, ε, and α. This 
classification of heavy chain type is maily performed based on the structure of constant 
regions. Human antibodies can have four subtypes of γ chains (γ1, γ2, γ3 or γ4) and two 
subtypes of α chain (α1 or α2) (Nimmerjahn et al., 2010). Correspondingly, antibodies can 
consist of different types of heavy chains and are thus divided into classes named 
according to the heavy chain type: IgM, IgD, IgG, IgE, and IgA (Abbas et al., 2014; 
Vidarsson et al., 2014). Each antibody isotype has specific fuctions, which are dependent 
on its physical and biological features. Moreover, IgD, IgE and IgG antibody types are 
present in monomeric form only, while IgA can be monomeric, dimeric or trimeric and 
IgM is in petameric form (Fagarasan, 2008; Schwab et al., 2013). On the other hand, based 
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on differences in light chain constant regions, there can be two types of light chains: λ and 
κ. One B-cell can secrete antibodies with only one type of constant regions of light chain. 
 
The reason why antibodies can bind to such a variety of molecules with different sizes is 
that CDR hinges which bind to the antigen, are able to come closer to capture small 
molecule or they can also form a greater surface, which can specifically bind to large parts 
of macromolecules, such as proteins. Antibodies are able to bind to the antigens with 
reversible, non-covalent bonds such are electostatic interactons, hydrophobic interactions 
or hydrogen bonds. Parts and regions of the antigens that are recognized and bound by the 
antibodies are called epitopes. Protein epitopes can be recognised according to antigen 
shape or according to the amino-acid sequence; hence, some of the epitopes present in the 
inner part of the protein structure can only be available for antibody binding only after 
physical or chemical stress and denaturation of protein.  
 
Antibodies bind to the antigen with certain strength, which is defined as affinity of the 
antibody for the antigen. This affinity is evaluated using a constant of dissociation Kd. Kd 
represents a molar concentration required to saturate the half of the available antibody 
receptors in a solution. Certain antibodies have a feature of enhancing their affinity to 
antigens upon the repeated exposure to the same antigen. In addition, as example one IgG 
molecule is monomeric and has two binding places for the antigen, accordingly one IgM 
antibody is pentameric and has 10 binding places for the antigen, so there is a need to 
define total binding power of antibody to antigen. This total binding power of all antibody 
CDRs to antigen is refferd to as avidity of interaction. 
 
An important scientific discovery was that one clone of B-cells can produce only one type 
of antibody with certain specificity (Goodnow et al., 2010; McHeyzer-Williams et al., 
2012). This means that it is possible to produce antibodies against any antigen and this 
discovery was heavily exploited in the production of monoclonal antibodies. 
2.1.5 Influence of different stress factors on proteins and monoclonal antibodies 
Comparing to small molecules that are used as API, therapeutical proteins are much more 
complex and sensitive to different types of stress conditions. Especially monoclonal 
antibodies that are used as API for biotherapeuticals, are susceptible to formation of 
aggregates or degradation products consisting of smaller peptides when different stress 
conditions are applied (Wang, 2000). Nevertheless, formation of protein aggregates poses a 
critical concern in pharmaceutical industry since there is raising number of scientific 
papers with data on immunogenicity potential of mAb aggregates.  
 
Process of protein aggregation is dependent on majority of factors, which can generally be 
intrinsic or extrinsic. Intrinsic factors for protein aggregation include modifications within 
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protein primary, secondary, tertiary or quaternary structure. On the other hand, extrinsic 
factors are manufacturing conditions, differences in handling of the protein or environment 
in which mAb is suspended, in specific, differences in solution, its excipients, buffers, pH 
value, etc. (Wang et al., 2010). Therefore, it can be expected that mAb aggregates may 
have potential for immunogenicity, cause side effects or reduced biological activity (Wang 
et al., 2009). This is why process and mechanisms of protein aggregation are under 
intensive research. Authors suggest that different aspects have to be considered for 
complete understanding of process of protein aggregation. Those considerations are 
physical forces that are influencing protein aggregation, aggregation theory, kinetics, 
mechanisms, predictions, etc. (Hamada et al., 2009; Wang, 2005; Chi et al., 2003; Philo 
and Arakawa, 2009; Morris et al., 2009; Weiss et al., 2009; Gsponer and Verdruscolo, 
2006). 
 
Main pathways and mechanisms for protein aggregation are: aggregation through chemical 
degradation processes, aggregation facilitated by chemical linkages, aggregation as a 
protein self-association and aggregation through unfolding intermediates (Wang et al., 
2010). All aggregation mechanisms can lead to formation of physically or chemically 
linked protein aggregates, which could also be seen as visible particles in solution. 
Moreover, process of aggregate forming and its dissociation into monomeric forms is in 
constant equilibrium. Furthermore, protein aggregation or self-association is mainly driven 
by hydrophobic interactions between protein subunits (Weiss et al., 2009). As hydrophobic 
bonds are weaker than covalent ones, protein aggregates may also demonstrate reversibility 
behaviour into its monomeric form. On the other hand, under certain conditions, some 
chemical degradation pathways could cause direct cross-linking of the protein chains and 
lead to subsequent aggregation. Most frequent cross-linking type is intermolecular 
disulphide bond formation.  This phenomenon mainly occurs between cysteine residues 
that are located on the surface of the protein. Other types of non-disulphide cross-linking 
mechanisms that lead to protein aggregation include oxidation, dityrosine formation, cross-
linking facilitated by formaldehyde, etc. (Cabra et al., 2008). Furthermore, proteins that are 
sensible to light and irradiation aggregate because of the process of photo-induced cross-
linking reactions that leads to formation of covalent bonds (Redecke et al., 2009; Qi et al., 
2008). Davies et al., (2003) found that UV radiation induces cross-linking between 
cysteine and tryptophan residues with the possibility of photolysis of native disulphide 
bonds and subsequent formation of additional disulphide bonds. Newly established bonds 
within protein aggregates by cross-linking may increase immunogenicity potential of 
protein aggregates in comparison to its monomeric form, as cross-linked locations on 
aggregate's subunits may lead to alterations within antigen presentation process and 
activation of immune response.  
 
There are considerable evidences that show how different factors influence protein 
aggregation in development and manufacturing of biopharmaceuticals. Wang et al., (2010) 
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have systematically divided factors that cause protein degradation and aggregation into 
several categories: general environmental factors, solution factors and processing factors. 
 
General factors are temperature, light and container closure systems. Among them, 
temperature is crucial one and has to be controlled since it induces partial or complete 
protein unfolding, enhances chemical degradations and protein aggregation. Irradiation or 
light stress eventually leads to chemical degradation and induces cross-linking reactions 
that promote protein aggregation (Davies, 2003). Container closure systems are also 
critical as they may leach substances that are influencing protein stability. Otherwise, 
container closure systems induce protein adsorption on their surface that might also 
enhance protein aggregation (Joshi et al., 2008; Holmberg and Hou, 2009). 
 
Main solution factors are protein concentration in solution, excipients, pH value, buffer 
type, buffer concentration and ionic strength. As expected, higher protein concentration 
promotes hydrophobic interactions between proteins and influences their aggregation. 
Another concern in this case is the solubility of highly concentrated protein solutions 
(Kanai et al., 2008). In general, excipients influence overall stability of the protein in 
solution. Commonly, excipients are added in final drug product in order to promote protein 
solubilisation and stability. However, if excipients are present in higher concertations, they 
may also be adsorbed on protein surface, thus causing changes in protein conformations 
and activity. Solution pH value potentially enhances protein aggregation as it alters 
colloidal stability by inducing partial or complete protein unfolding (Krebs et al., 2007). 
Buffer concentration and its ionic strength cause variable effects by altering not only 
protein–protein interactions, but also buffer ion–protein interactions. 
 
Processing factors that influence protein stability include fermentation, unfolding, 
refolding, purification, freeze/thawing, shaking, shearing, drying, pressurization, 
formulation processes, filling and handling within a variety of analytical methods (Wang et 
al., 2010; Philo, 2009). In general, fermentation and purification processes cause variable 
effects which are dependent on expression host system and conditions for fermentation and 
purification (Hao et al., 2007; Bahrami et al., 2009; Heavner et al., 2007). Freezing and 
thawing cycles cause protein interaction with ice, cryoconcentration effects upon freezing 
with subsequent changes in ionic strength and pH of the solution that leads to cold 
denaturation of protein, its absorption, unfolding and enhanced protein aggregation 
(Pivarova et al., 2007; Kueltzo et al., 2008).  In addition, shaking processes trigger protein 
unfolding and enhance aggregation processes since air is introduced in the system during 
shaking which induces air–liquid interfacial protein adsorption (Bee et al., 2009). Shearing 
stress potentially exposes hydrophobic regions of proteins, which might enhance protein 
self-association (Serno et al., 2009). Low or moderate pressure within protein drug product 
manufacturing has no observable effect on protein structure. However, higher pressure 
(above 100 MPa) leads to loss of protein structure and affects protein aggregation (Seefeldt 
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et al., 2005; Considine et al., 2007; Huppertz et al., 2006). During drying processes loss of 
protein hydration layer causes disruption of protein structure and enhances protein 
aggregate formation (Mukherjee et al., 2009; Kumar et al., 2009).  
 
All mentioned factors have to be considered during protein production, formulation, 
manufacturing and storage time. However, among them temperature and pH value are the 
most critical ones which influence protein stability in solution and both have to be 
controlled (Singh et al., 2009; Macchioni et al., 2008; Reese and Robertson, 2001). Since 
proteins are diverse, it is common that one factor may potentially have opposite effect on 
different proteins depending on experimental conditions. This is why scientist focus on 
inhibition of protein aggregation and degradation by adding compatible excipients or 
additives in suitable concentrations with the aim of changing the immediate environment 
of the protein and thus stabilizing it. Frequently used additives for stabilization of the 
proteins in solution are surfactants, salts, sugars, polyols, amino acids and metal ions 
(Hoffmann et al., 2009; Long et al., 2008). 
2.1.6 Immunogenicity potential of biotherapeutical drugs and aggregated monoclonal                                                                                                                                                                          
____ antibodies  
Clinical use of biotherapeutics increased dramatically after the breakthrough of 
recombinant DNA technology (Ratanji et al., 2014). Non-human protein therapeutics that 
were used previously, have been expected to induce immune response, because they would 
be recognized as foreign molecules in human body. For example, proteins that are derived 
from non-human sources such as streptokinase, staphylokinase, bovine adenosine 
deaminase and salmon calcitonin, have higher immunogenicity potential upon 
administration in patients (Rosenschein et al., 1991; Vanderschueren et al., 1994; Chaffee 
et al., 1992; Grauer et al., 1994). On the other hand, also recombinant human 
biotherapeuticals might trigger immune response (Wadhwa and Thrope, 2007). Clinical 
cases have been reported that high levels of antibody production have been reported after 
administration of protein therapeutics derived from human organs and cells such as factor 
VIII, growth hormone and IFN-β (Gilles et al., 1997; Dummer et al., 1991). There are 
reports that even biopharmaceuticals produced on the basis of recombinant DNA 
technology, e.g. erythropoietin and recombinant IFN-β15, have induced immune response 
(Prabhakar et al., 1997; Zang et al., 2000). Moreover, there are rising reports for 
immunogenicity potential of modern biopharmaceuticals that contain mAb as API. For 
example, IgG1 antibody Rituximab was proven to induce immunogenicity in some 
rheumatoid arthritis patients (Van Vollenhoven et al., 2010; Mok et al., 2014). Furthermore 
there is high interest in assessing immunogenicity potential of Infliximab, IgG1 antibody 
type, using immunogenicity prediction software and search of knowledge databases due to 
mAb complexity and brother understanding of its effects in patients (Cassinotti and Travis, 
2009). 
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One of the main concerns upon administration of biotherapeutical drugs in patients is 
developing ADA which may lead to complete drug inactivation or different side effects 
such as hypersensitivity or infusion reactions (Gallais et al., 2017; Sauerborn et al., 2010). 
There are indications and suggestions for testing immunogenicity potential of protein 
aggregates, as they present occurring risk for promoting immunogenicity by enforcing 
production of ADA (Baker et al., 2010; Vultaggio et al., 2010). Among all available 
biotherapeutical drugs present on market, those that contain mAb are in particular risk due 
to their structural complexity and conformational varieties, which mAb can have in 
solution. 
 
A variety of factors influence immunogenicity potential of mAb. Those can be inherent 
structural properties - i.e. sequence in mAb primary structure that is different comparing to 
the human one, glycosylation patterns and different physical abnormalities or 
conformations of mAb (Hermeling et al., 2004). Moreover, immunogenicity is also 
determined by drug product formulation, potential contaminants and impurities, route of 
application, dosage, length of treatment or patient characteristics (Schellekens, 2002). 
 
In general, one of the most common abnormalities of mAb as an API is its aggregated 
form, which may be due to manufacturing processes or intrinsic mAb features, since 
protein aggregation may also happen by non-specific hydrophobic association of multiple 
protein monomers (Wang et al., 2010). On the other hand, there are many reports that 
aggregation mechanisms could include several chemical and physical interactions, which 
overall contribute to high aggregate structure heterogeneity (Mahler et al., 2009; Wang et 
al., 2005; Cromwell et al., 2006). That is the main reason for continuous need for 
development of different analytical methods for mAb aggregate determination and 
characterization. 
 
As already mentioned, a correlation between the presence of mAb aggregates in 
biotherapeutical drugs and the development of immune response when administered in 
patients has been observed throughout the years. For example, upon administration of 
human gamma globulins or human growth hormone, aggregated forms can be detected in 
patient serum (Ellis et al., 1969; Moore et al., 1980). Moreover, presence of aggregates and 
upregulation of ADA was also confirmed in recent scientific papers, where authors have 
tested relation of injection of aggregated proteins in transgenic mice and ADA 
development (Maas et al., 2007; Human et al., 2015; Van Beers et al., 2010). Specifically, 
ADA production in mice was evident even when IFN-α and IFN-β aggregates were 
administered, as well as upon administration of mAb aggregates (Freitag et al., 2015; 
Filipe et al., 2012). However, magnitude of immunogenic response was dependent of 
aggregate type. 
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Investigations of cellular mechanisms that are included in immunogenicity of mAb 
aggregates are rather limited, although two main approaches are under increasing interest 
for research. First one investigates possibilities of mAb aggregates binding to B-cell 
receptors, direct activation of B-cells and production of antibodies with low affinity. It is 
suggested that this process is not dependent on T-cells. Other approach implies B-cell 
activation which is dependent on CD4+ T‐cells, since high affinity ADA are present in 
patients after contact with mAb aggregate products. On the other hand, many authors 
emphasize the impact of mAb aggregates on innate immune response, in specific on 
PBMC cells and their cytokine production when in contact with mAb aggregates (Brennan 
et al., 2010; Sauerborn et al., 2010). In that case, activation of CD4+ T-cells is performed 
by main antigen presenting cells – dendritic cells (Bartelds et al., 2010; Benucci et al., 
2013; Reding et al., 2002; Deisenhammer et al., 2001).  
 
Moreover, mAb aggregates may bind to pathogen recognition receptor or any other 
receptor on DC, thus causing its activation, accompanied with DC maturation and their 
migration to lymph nodes where activation of CD4+ T-cells happens (Joubert et al., 2012). 
Activation of DC can be accomplished by producing specific cytokines, expressing co-
stimulatory molecules and by presenting processed peptides from ingested aggregates to 
naïve T cells (Walsh et al., 2013; Joffre et al., 2009). Recent studies have been 
investigating influence of protein aggregates on PBMC and monocyte-derived DC 
(Ahmadi et al., 2015). Authors have observed maturation of DC, altered cytokine 
production and different peptides presented by HLA-DR molecules upon contact with 
protein aggregates (Rombach‐Riegraf et al., 2014).  
 
Overall, there are raising evidences and concerns for immunogenicity potential of different 
mAb aggregates. As presence of mAb aggregates even in lower concentrations in 
biotherapeutic products may influence activation of immune response by different 
mechanisms and subsequent side effects, there is a constant need for addressing 
immunogenicity potential of protein aggregates by employing different assays and 
understanding processes that may lead to aggregate formation. 
2.2 OVERVIEW OF SELECTED ANALYTICAL METHODS AND TECHNIQUES 
FOR PROTEIN CHARACTERIZATION 
2.2.1 Size exclusion chromatography (SEC) 
Chromatography as a general term is used for common laboratory analytical techniques for 
separation of different components present in one sample. Moreover, it includes movement 
of diluted sample components in the flow of the mobile phase through stationary phase, 
which is packed in analytical column. Stationary phases are made of particular materials, 
which can have a variety of ligands on the surface of stationary phase. Based on affinity of 
Ignjatović J. Detection and immunogenicity evaluation of recombinant monoclonal antibodies’ structural variants. 
   Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty, 2019 
 
18 
different sample components between mobile and stationary phase, components are 
separated and isolated. Therefore, chromatography refers to separation methods, which are 
based on different distribution of sample components between stationary and mobile 
phases. 
 
On the contrary to conventional chromatographic methods, in size exclusion 
chromatography separation of components is dependent on their size. In that case, 
stationary phase is in a form of porous gel material or specific polymeric resins. In SEC, 
the components with bigger hydrodynamic radius are eluted first since their greater size 
does not allow them to enter and penetrate in the porous gel. On the other hand, 
components, which have smaller size, are able to enter the porous stationary phase and are 
retained as they have to overpass many obstacles therefore having longer elution path 
through the column (Figure 2). This is the main reason why this technique is referred to 
also as gel filtration оr exclusion chromatography. Therefore, this method is suitable for 
separation of proteins based on their size. 
 
Development of SEC technique has begun in 1950s by Wheaton et al., (1953) leading to 
the commercial use in bio-pharmaceutical and polymer industry in 21st century with 
development of new column matrices by eminent analytical corporations. For example, 
Waters corporation introduced SEC columns filled with particles with special bonding 
instead of using columns based on traditional silica matrix. More importantly, this enabled 
specified design of the pore volume between column particles and this feature is crucial for 
better resolution between aggregates, monomeric and fragment entities of proteins. 
Separation based by size occurs almost fully among impartible pores and separating 
capacity is dependent on the particles with greater pore volume. One other consideration is 
that there has to be a balance between pore size and their mechanical strength to withstand 
the high pressure within column. Good example of this balance in pore size and endurance 
even in that case of analysis on Ultra High Performance (Pressure) Liquid Chromatography 
systems (UHPLC) are Waters columns filled with bridged-ethyl hybrid (BEH) particles in 
size even of 1.7µm, which can be used under high pressure. 
 
Molecules may have affinity for charged surface within the SEC stationary phase and those 
non-covalent interactions can be electrostatic or hydrophobic (Arakawa et al., 2010; Dubin, 
et al., 1993; Ricker et al., 1996). This is the reason why mobile phases with high ionic 
strength and concentration of salts are proposed since this influences the reduction of non-
binding secondary interactions, improves the peak shapes and aggregate recovery 
(Kamberi et al., 2004). Some authors suggest using arginine or organic modifiers such as 
methanol or ethanol in order to lower hydrophobic interactions and improve the peak 
shapes (Striegel et al., 2009). 
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Detection of protein variants can be obtained on different detector types, but most 
commonly used are the UV absorbance detectors. Acquisition is possible using wavelength 
of 280 nm as it is typical for detection of tyrosine and tryptophan (Grimsley et al., 2003). 
Another proposed possibility is using wavelength of approximately 214 to 220 nm, which 
is covering UV absorbance of the peptide bond. This usually provides better sensitivity and 
detection but with a greater possibility of baseline noise. Alternatively, if it is not possible 
to detect proteins in UV range, fluorescence detection can be employed (Gunturi et al., 
2007; Demeule et al., 2007). In addition, direct characterization of molecular weight of 
peaks separated by size exclusion chromatography could be accomplished using multi 
angle light scattering detector (MALS) in combination with UV and refractive index (RI) 
detector (Folta-Stogniew et al., 1999; Oliva et al., 2001). 
 
Figure 2: Principles of size exclusion chromatography. Large particles cannot enter the porous 
stationary phase and are eluter earlier in comparison to small particles that enter pores and need more 
time for elution. 
Slika 2: Načela izključitvene kromatografije po velikosti. Veliki delci ne morejo vstopiti v porozno 
stacionarno fazo in se eluirajo prej v primerjavi z majhnimi delci, ki vstopajo v pore in potrebujejo več 
časa za elucijo. 
Bouvier et al., (2014) differ between two variants of the same technique type: size-
exclusion chromatography (SEC) and gel-permeation chromatography (GPC) as the 
difference between both is their application area. Specifically, size-exclusion 
chromatography is frequently used for separation of proteins and biomolecules, on the 
contrary, gel-permeation chromatography is mostly used for separation of polymers which 
can be natural of synthetic. Specificity of the SEC and GPC technique is that separation of 
molecules happens in just one column volume comparing to other types of gradient 
chromatographic methods where separation occurs in more than one column volume. 
Therefore, the flow rate of the mobile phase in SEC technique should be low in order to 
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allow proper protein separation. Still, SEC method is one of the first choices in 
determining percentage of protein monomeric form and its aggregation and degradation 
products, which both have an influence in overall product quality.  
 
Through the processes of purification, formulation and production of biotechnological 
drugs, protein aggregation is strictly controlled and there is a need to understand the 
kinetics behind the process of aggregate generation (Das et al., 2008; Mahler et al., 2009; 
Wang 2005, 2010). When present in final biotherapeutical drug product at minimum 
percentage, aggregates are characterized as impurities that should be controlled at 
relatively low levels (Cleland et al., 1993). When analysing drug products, which contain 
bioproteins as active pharmaceutical ingredients , SEC method provides information about 
low valency aggregates such as dimers that might be generated during manufacturing 
process from the initial cell culture used to synthesize the protein to the final drug 
production and filling (Cromwell et al., 2006). Complexity of protein APIs, especially 
monoclonal antibodies (mAbs) and its potential for structural changes during production 
lead to additional testing of the final drug quality as protein aggregates may induce 
inactivity or potential immune response when administered to patients. In addition, it is of 
critical concern to determine and understand the origin of generation of high valency 
aggregates, also known as high-molecular-weight (HMW) proteins since those have been 
potentially determined to influence immune response by contributing to the immunological 
pathways that are independent from T-cells (Rosenberg, 2006; Phillo, 2006). Fekete et al., 
(2014) propose differentiation between soluble oligomers, soluble and stable high 
molecular weight aggregates and large insoluble particles. Those soluble particles are 
dispersed in solution; on the contrary, insoluble entities collide into separated aggregates 
and particles. Brummitt et al., (2011) suggest that protein aggregates may reversibly transit 
from soluble to insoluble stages.   
 
As already mentioned, protein molecules in size exclusion chromatography are separated 
according to their hydrodynamic radii using aqueous buffers as mobile phases that force 
proteins thought the stationary phase, which consists of porous particles with controlled 
pore size. Fekete et al., (2014) explain that basically separation is entropically controlled 
process where molecules are separated on the basis of their molecular size and not by their 
molecular properties, taking into consideration that there is no adsorption of the molecules 
to the column. This enables application of calibration curve, which is constructed on the set 
of proteins of known sizes, which allows calculation of the approximate molecular size of 
unknown analyte (Hong et al., 2012). 
 
Nevertheless, SEC is widely used method in characterisation and determination of 
aggregate levels in biopharmaceutical drugs as it has been proven to be sensitive, 
reproducible and allows high throughput of samples. On the other hand, it may seem that a 
limitation for this method may be an inaccurate determination of high-molecular-weight 
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(HMW) aggregates due to non-specifical binding to the column matrix or filtration in the 
column (Den Engelsman et al., 2011). Advantage of SEC method is applying mild 
conditions for separation by using mobile phases which do not contain organic solvents, 
this allows for proper separation of protein and its structural forms in native state, with low 
impact on its structure and conformation, which allows further characterization of 
separated entities (Fekete et al., 2013; Diederich et al., 2011). 
2.2.2 Hydrophobic interaction chromatography (HIC) 
Proteins could be easily defined as a series of connected amino-acids with peptide bond 
that altogether determine primary structure of the protein. Elements of protein secondary 
structure are α-helix and β-sheet, which are both dependent of peptide bonds and their 
interconnections primarily by hydrogen bonding. This influences the formation of the 
protein compact shape, however due to many amino-acid moieties, additional interactions 
take place and lead to further stabilization of the protein, which defines its tertiary structure 
(Bowie, 1991). Forces that are responsible for tertiary structure are mainly influenced by 
hydrophobic interactions of amino-acid moieties, but also by additional hydrogen bonding, 
ionic and disulphide interactions. Finally, proteins form quaternary structure by joint 
interactions of several amino-acid chains. Those separated chains of amino-acids are 
referred to as protein subunits which can be covalently connected or connected by 
disulphide bonds that keep several subunits together. However, proteins that do not have 
quaternary structure are characterised as monomers, accordingly proteins that have two or 
more connected subunits are referred to as multimers. In specific, if there are two subunits 
protein is dimeric, if there are three subunits, protein is trimeric etc. 
 
All proteins have exposed hydrophobic regions on their surface consisting of non-polar and 
hydrophobic amino-acid moieties of alanine, tryptophan, methionine and phenylalanine, 
which are scattered between polar and hydrophilic regions. Size of this superficial 
hydrophobic regions, their number and distributions represent a characteristic for each 
protein (Cummins et al., 2011). Accordingly, it is possible to separate different proteins in 
biological matrices based on their hydrophobic characteristics by means of hydrophobic 
interaction chromatography (HIC) (Queiroz et al., 2001; Eisenberg et al., 1986). In HIC, 
the analysis separation of different proteins occurs due to the affinity between hydrophobic 
regions on protein surface and column matrix, which is mostly consisting of hydrocarbon 
chains (butyl, hexyl or octyl) or aromatic (phenyl) moieties immobilized on stationary 
column matrix (Figure 3). Typically, for all types, there is tricarbon chain joining inert 
particle and hydrophobic groups without any ionic properties and this allows contact of the 
hydrophobic surfaces of the protein and column matrix.  
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Figure 3: Typical ligands for HIC stationary pahses – representation of butyl-, phenyl-, and octyl-
chemical groups covalently linked to sepharose matrix (indicated as red spheres). 
Slika 3: Ligandi značilni za HIC stacionarne faze - reprezentacija butil-, fenil- in oktil-kemičnih 
skupin, kovalentno vezanih na sefarozni matriks (označeno z rdečimi sferami).  
Mobile phases that are used in hydrophobic interaction chromatography contain 
ammonium sulphate, sodium chloride, or potassium chloride, which in proper 
concentrations can salt-out proteins in the sample upon injection on the column. The main 
mechanism of salting out is that ions within mobile phase increase surface tension by 
decreasing availability of water, which leads to overall increase of hydrophobic 
interactions of the proteins and column matrix (Porath, 1990) (Figure 4). On the other 
hand, increased concentrations of salts in mobile phases may cause partial unfolding or 
denaturation of the proteins as this also enhances hydrophobic interactions within protein 
tertiary structure. The effect of salts on hydrophobicity is also determined by lyotropic 
series for protein precipitation in aqueous solutions. Anions with increasing salting out 
effect are: SCN- < I- < ClO4
- < NO3
- < Br- < Cl- < CH3COO
- < SO4
2- < PO4
3- ; cations with 
increasing salt out effect are: Ba2+ < Ca2+ < Mg2+ < Li+ < Na+ < K+ < Rb+ < NH4
+ (Queiroz 
et al., 2001). In the presence of aqueous salt solution, anions and cations electrostatically 
bind to positive and negative charges on the protein surface, thus neutralizing it and 
preventing aggregation (Duong-Ly et al., 2014). If the concentration of salt increases even 
more proteins may aggregate because its surface may become charged again (Scopes, 
2013). This is the reason why suitable concentration of HIC mobile phases should be used 
in order to enhance hydrophobic interactions between protein surface and column matrix 
but not to cause protein structural changes nor aggregation. After salting out on HIC 
column, elution is performed by negative salt gradient which allows resolution of different 
proteins by their hydrophobic properties (Roettger et al., 1989). Nevertheless, conditions 
within HIC analysis are considered as relatively mild, which enables further 
characterization of separated protein fractions.  
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Figure 4: Protein salt-out effect enhances hydrophobic interactions of hydrophobic amino-acid moeties 
on protein surface and column matrix. 
Slika 4: Z izsoljevanjem beljakovin se povečujejo hidrofobne interakcije hidrofobnih aminokislinskih 
ostankov na površini beljakovin in matriksu kolone.  
In addition, there are reports of other successful applications of HIC method, such as in 
large scale purifications within downstream processes (Evans et al., 2008; Sunasara et al., 
2003; Shukla et al., 2001), especially as a polishing step for reducing the levels of protein 
aggregates (Jiang, 2010) and clearance of different process impurities (Follman and 
Fahrner, 2004; Shukla et al., 2007; Shukla and Thommes, 2010). In addition, HIC can also 
be employed in assessment of purity and quantification of plasmid DNAs (Diogo, 2003) 
etc. 
Ignjatović J. Detection and immunogenicity evaluation of recombinant monoclonal antibodies’ structural variants. 
   Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty, 2019 
 
24 
2.2.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Main characteristic of electrophoresis as analytical technique is that it enables separation of 
analytes based on their molecular mass and mobility in electric field. However, sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is used to denature 
secondary and tertiary structure of protein in a way that SDS coats proteins with negative 
charge in correlation to their length, which enables separation of proteins by their size (Zhu 
et al., 2012). This is because matrix in SDS-PAGE method is based on polyacrylamide gel 
and sodium dodecyl sulphate is used as detergent which generally binds to a protein in a 
ratio 1.4 g of SDS for 1 g of protein (Reynolds et al., 1970; Staikos et al., 2009) and thus in 
a way neutralizes protein charge. Therefore, when electric field is applied, proteins covered 
with negatively charged SDS migrate toward the anode in a speed dependent to their mass. 
Logically, smaller proteins migrate faster comparing to the larger proteins, which allows 
separation. 
 
SDS-PAGE analysis includes preparation of the gel, buffers and samples, performance of 
the electrophoresis, then protein fixation and staining. Afterwards, separated proteins could 
be further isolated and additionally characterised. 
 
Crucial step is gel preparation, which could be divided into two parts: stacking and 
separating gel preparation. Two gel types are employed so that large volumes of samples 
could be easily concentrated in to zones, which has been proven as a pre-requisite for 
suitable separation. In stacking gel samples are introduced, hence it has different pH and is 
positioned above separating gel. Upon application of electric field negatively charged 
proteins coated with SDS and Cl- and also glycine ions from buffer start moving toward 
anode. Chloride ions have greater mobility comparing to other proteins, therefore all 
proteins concentrate in zones and upon reaching separating gel mobility change due to the 
different pH value set for the separating gel. There glycine ion front pushes proteins coated 
with SDS allowing separations of protein zones by their mass and charge (Smith, 1994). 
Generally, gels are prepared in a process of polymerization between two glass plates. 
 
After both gels were prepared and immersed in suitable buffer, preparation of samples 
occurs in a way that sample buffer containing SDS is added to protein samples, then 
mixture is heated so as to disrupt protein structure and allow SDS to bind to the protein. 
Afterwards, samples are introduced in pockets within the stacking gel (Figure 5). Also, 
suitable type of molecular size marker should be used and analysed together with samples 
so that it could serve as a reference sample. Then electrophoresis is started by applying 
voltage to the system. Accordingly, all proteins, which have negative charge due to SDS 
binding migrate to the positively charged anode. Duration of electrophoresis process 
generally lasts up to one hour but it should be adjusted in dependence to gel size and 
sample type. 
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Figure 5: Steps in SDS-PAGE analysis: introducing the samples in the stacking gel, application of 
electric field that enables electrophoresis in separating gel and subsequent staining and analysis of 
results. 
Slika 5: Koraki v analizi SDS-PAGE: nanos vzorcev na gel, aplikacija električnega polja, ki omogoča 
elektroforezo v ločevalnem gelu in naknadno obarvanje ter analiza rezultatov. 
Finally, after separation of analytes is over, the protein staining is performed using 
different dyes and reagents. Most frequently, Commassie staining is used (Wilson, 1979), 
but also silver staining (Lelong et al., 2009; Rabilloud, 1992) and staining with 
fluorescence dyes (Chevalier et al., 2004; Hawe et al., 2008). Additionally, at this point it 
is also possible to employ immunological detection within techniques such as western blot 
(Welinder et al., 2011; Mahmood et al., 2012; MacPhee, 2010). Western blot includes 
transfer of separated proteins on SDS-PAGE to nitrocellulose membrane by means of 
electrophoresis. Then, different immunochemical techniques can be applied in order to 
visualise separated proteins and characterize them. Moreover, there are also reports for 
using stain-free protein marking (Gilda et al., 2013). Protein staining procedure also 
enables fixation of the proteins within gel, which enables further analysis end evaluation of 
results. Afterwards, relative migration distances of different proteins are measured and 
relative mobility (Rm) is determined. Relative mobility represents a ratio between 
migration distance of the protein of interest and the distance of the buffer front measured 
from the beginning of the gel (Neville, 1971; Fling et al., 1986; Weber et al., 1972). The 
same calculations are performed also for the proteins with known molecular weight within 
the molecular weight marker. Then, molecular weights in reference to relative mobility are 
plotted in a function, which allows reading the molecular weight of an unknown protein 
based on its relative mobility (Guan et al., 2015). 
 
Alternatively, SDS-PAGE can be performed in two dimensions (2D-PAGE) for the 
purpose of complex protein sample separations. Within this alternative method, proteins 
are separated in one dimension as previously described based one protein feature. 
However, some of the proteins have similar characteristics, thus an additional gel 
electrophoresis is employed in the direction of 90° but based on second characteristic. This 
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allows additional separation and understanding of the protein characteristics within the 
mixture since it is very unlikely that proteins could be similar in two distinct properties 
(Hardt et al., 2005; Raikos et al., 2006; Issaq et al., 2008; Reisinger et al., 2007; Rosenfeld 
et al., 1992). Additional advancement of this technique is difference gel electrophoresis 
(DIGE) where two or more samples are separated on the same gel and specifically labelled 
with fluorescence dyes prior performing second dimensional electrophoresis – 2-DE. The 
important aspect of the DIGE is the ability to label two or more samples with different 
dyes and separate them on the same gel, eliminating gel-to-gel variability (Timms et al., 
2008; Minden et al., 2009; Ünlü et al., 2002). 
 
As such practical technique, SDS-PAGE and its variations are widely employed in 
processes of measuring molecular weight, addressing protein structural variations such are 
aggregates and multimers, determining protein purity, peptide mapping, western blotting, 
proteomics and many others. 
2.2.4 Capillary electrophoresis (CE) 
SDS-PAGE has been widely used technique, however its limitations such as usage of toxic 
reagents, high gel variability, timely preparation and execution of analysis, variability in 
protein staining led to the development of high-throughput and more automatized sodium 
dodecyl sulphate polyacrylamide gel capillary electrophoresis, CE-SDS (Shi et al., 2012). 
CE as a technique enables electrophoresis practice shift from manual to instrumental and 
automatized method for analytes on a micro scale (Guo et al., 2008; Hjertén, 1967). This 
useful feature is employed for biomolecular characterisation in biotechnological and 
pharmaceutical industry (Rustandi et al., 2008, 2011). In addition, CE-SDS has been 
successfully applied for analysis of different protein therapeutics, including complex 
monoclonal antibodies (Ma et al., 2001; Hunt et al., 1999; Lee, 2000) and vaccines 
(Farchaus et al., 1998). In addition, several CE methods are frequently used in 
biomolecules characterization: aforementioned capillary electrophoresis sodium dodecyl 
sulphate – CE-SDS, capillary zone electrophoresis - CZE and capillary isoelectric focusing 
– CIEF (Meert et al., 2007; Santora et al., 1999). Briefly, CE-SDS is used in order to 
separate proteins within a sample based on their hydrodynamic size, while CZE and CIEF 
are employed in order to separate proteins on basis of their charge and isoelectric point 
(pI). Therefore, all three types of CE analysis can be used as methods for purity 
determination, while CZE and CIEF can also be used as methods for identity confirmation 
(Guo et al., 2008). 
 
Capillary electrophoresis at first glimpse represents a combination of electrophoretic 
technique and liquid chromatography. In capillary electrophoresis, separation takes place 
in very thin silica fused capillary filled with replaceable agarose or polyacrylamide gel. 
This set up allows the application of high voltage that is required for separation. Hence, 
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capillary's both ends, are immersed in buffer or sample vial. Besides the capillary in each 
of the buffer vials there is an electrode: cathode in one and anode at the other end (Figure 
6). Those electrodes enable employment of electric field and difference in voltage at both 
ends of the capillary, which is driving force for separation of analytes within the sample. 
Separated analytes are detected by the optical detector, which lies on the capillary window. 
Mainly, UV detectors are suitable for measuring the absorbance of the analytes in the 
capillary. Prerequisite for this is that capillary coating is usually burned and peeled off in 
the area of detection window allowing required transparency and measuring of analytes 
absorbance according to Lambert-Beer law. 
 
Figure 6: Simplified scheme for capillary electrophoresis system, which contains samples and waste 
trays in which capillary and electrodes are immersed. 
Slika 6: Poenostavljena shema sistema kapilarne elektroforeze, ki vsebuje pladnje za vzorce in odpad, 
v katerih so potopljene kapilare in elektrode.  
Within the capillary, analyte migration is dependent on their size and applied electric field, 
however also electroosmotic flow (EOF) of the buffer should not be neglected. Generally 
electroosmotic flow of the buffer solution is in direction from the source to destination 
vial, therefore specifically toward the cathode. Hence, analytes within the sample are 
positively and negatively charged and they both are attracted to the electrode of the 
opposite charge. In specific, analytes with positive charge migrate toward the cathode; on 
the other hand analytes with negative charge are drawn to the anode which is counter-
direction of the electroosmotic flow. However, EOF of the buffer is greater comparing to 
mobility of all analytes, which are therefore carried by EOF toward the cathode. Logically, 
analytes with negative charge are retained in the capillary as they have opposite 
electrophoretic mobility compared to EOF (Altria, 1999; Skoog et al., 2017). Smaller 
analytes with greater positive charge have greater velocity toward the cathode, on the 
contrary, smaller analytes which are more negative are retained longer in the capillary 
(Figure 7). 
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Figure 7: Migration propensity of large or small particles, which are neutral (N), positively, or 
negatively charged within the electroosmotic flow (EOF) in the capilallary.  
Slika 7:  Nagnjenost k migraciji velikih ali majhnih delcev, ki so nevtralni (N), pozitivno ali negativno 
nabiti v elektroosmotskem toku (EOF) v kapilari.  
Specifically for capillary electrophoresis is that EOF has flat profile because it is driven by 
electric field and there is no mass transfer between the phases as in HPLC techniques 
which are driven by pressure. For all liquid chromatography (LC) techniques laminar flow 
is typical (Figure 8). This feature of CE technique allows for greater efficiency of 
separation comparing to liquid chromatography (LC) techniques. 
Figure 8: A: Electroosmotic velocity profile, driven by electric field. B: Hydrodynamic velocity profile 
(laminar flow), driven by pressure. 
Slika 8:  A: Elektroosmotični profil hitrosti, ki ga poganja električno polje. B: hidrodinamični profil 
hitrosti (laminarni tok), ki ga poganja tlak.  
CE-SDS method is heavily employed in its reduced and non-reduced form for the 
monoclonal antibody characterisation (Han et al., 2006). Specifically, non-reduced CE-
SDS can be used for determination of glycosylation profile of mAbs since they contain up 
to 3% of glycans by mass, which are attached to the Fc region of the mAbs (Jefferis, 2006). 
Glycans attached to mAbs determine protein stability and biological activity by influencing 
their physical and chemical stability (Jefferis, 1998). Non-reduced CE-SDS is capable of 
separating glycosylated heavy chain (HC) peaks from non-glycosylated heavy chain peaks 
of mAbs (Rustandi et al., 2008). In addition, non-reduced CE-SDS is used also for purity 
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determination, as it can detect product related mAb impurities such are: heavy and light 
chain fragments, dimers, multimers, mAb structural artefacts, etc. 
2.2.5 Dynamic light scattering (DLS) 
Dynamic light scattering (DLS) is a technique, which allows determination of particle size 
and distribution in a solution. Within this technique monochromatic light form light source 
is let through a sample which contains particles of different sizes. Subsequently, light that 
has hit the particles is diffracted in all directions. However, some of the particles absorb 
the light while others scatter it. This scattered, the so-called static light, is multiplied using 
photomultiplier and its intensity and fluctuations are further analysed. This scattered light 
can be used to calculate the molar mass of the particles and the radius of gyration 
(Harding, 1994; Jumel et al., 1996). Indeed, if concentration of the analyte is known as 
well as its refractive index and if all measurements are done under the same angle, it is 
possible to determine the molecular size based on the intensity of the scattered light 
(Nobbmann et al., 2007; Chu, 2007; Jumel et al., 1991; Murdock et al., 2008). 
  
For DLS it is typical to detect also the fluctuations of the signal of scattered light as it is 
connected to the Brownian movement of the molecules in a solution (Berne et al., 2000). 
This feature of the scattered light is then correlated within the mathematical function in 
order to define size distribution of the molecules in a solution (Figure 9) (Saridakis et al., 
2002; Wilson, 2003).  Brownian motion of spherical particles influences Doppler shift of 
the laser beam, which enables diffusion constant of the particles to be measured and 
incorporated in Stokes-Einstein relation from which particle size can be calculated (Liu et 
al., 2008; Berne et al., 2000).  
 
Nobbmann et al., (2007) propose DLS method for determining structural integrity of the 
monoclonal antibodies as their stability can be assessed using only analytical 
centrifugation and combining it with DLS. Moreover, DLS could be employed for 
temperature dependence studies or using light scattering technique in combination with 
size exclusion chromatography. In addition, DLS technique is fast, easy and non-
destructive for the analytes since they are analysed in buffer in their native conditions. 
These features make DLS pretty applicable for characterization of proteins. For example, 
DLS can be used as a quick technique for determining the stability of the proteins as it can 
detect the proteins that have aggregated. Hence, if proteins aggregate, their size changes 
and differences in overall particle sizes are detectable. 
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Figure 9: Comparison of output signal detected from dynamic light scattering of larger (above) and 
smaller protein particles (below). 
Slika 9: Primerjava izhodnega signala, detektiranega iz dinamične razpršitve svetlobe večjih (zgoraj) 
in manjših beljakovinskih delcev (spodaj).  
2.2.6 Techniques for protein mass determination 
Mass spectrometry has a crucial role in understanding the structure and functions of 
proteins. There are several developed techniques for determining the mass of the proteins 
and their characterization. Protein type and purpose of the analysis in a way determine 
which of the analytical techniques should be used. Concerning the proteins, type of the 
technique is dependent of the approximate protein size (for example if small peptide or 
complex monoclonal antibody is analysed) and the approach to protein preparation for 
analysis. Two main approaches are common: top-down – in which protein is analysed 
intact, or a bottom-up – where protein is digested using enzymes and then its fragments are 
analysed (Trauger et al., 2002). Therefore, through mass spectrometry one can have 
information about the protein structure as well as its mass and concentration. 
 
Prerequisite for the majority of mass spectrometry techniques is converting analytes in 
ionised gas state with positive or negative charge. Then it is possible to introduce the ions 
in the mass analyser where they are separated based on their mass to charge ratio (m/z) (Ho 
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et al., 2003). Afterwards, detector collects and converts data of different protein masses 
and charges and accordingly plots the relative abundance dependence to protein m/z ratio. 
Moreover, tandem mass spectrometry technique (MS/MS) utilises the process of collision-
induced dissociation in order to additionally break down protein ions into fragments which 
are then further analysed using MS detectors (Rauh, 2012; Cottrell, 2011; Bantscheff et al., 
2007; Petrović et al., 2005). Then the profile of fragment masses can be compared to 
available databases with the aim of confirming the structure (Figure 10). 
 
Typically, two methods are used for protein ionization: electrospray ionization (ESI) and 
matrix-assisted laser desorption and ionization (MALDI) (Chait, 2011). Characteristic for 
electrospray ionization is that ions are generated directly after the solution is sprayed from 
the capillary end in the intense electric field (Fenn et al., 1989; Keith-Roach, 2010). In this 
way, a solution carrying the analytes evaporates thus concentrating the protein in strong 
electric filed which enables process of ionization. This practical feature of ESI makes it 
possible to couple ESI mass determination to any liquid chromatography system (HPLC / 
UPLC) under condition that organic volatile mobile phases are used. 
 
Other technique – MALDI employs different way of ionization of analytes. Here sample is 
loaded in an excess of matrix, which is then eradiated with the pulses of intense laser light, 
which enables formation of the ions of analytes present in the loaded sample (Hillenkamp 
et al., 1991; El-Aneed et al., 2009; Lee et al., 2009). Then in an electric field, generated 
ions are accelerated based on their mass/charge ratio and are propelled accordingly to the 
MS detector (Figure 11). That allows further separation, which is also based on particles 
time of flight within the vacuum tube to the detector (Wieser et al., 2012). After analytes 
are converted into ions, different types of mass detectors are used such are: time of flight 
(TOF) detector, quadrupole mass analysers, ion trap mass analysers, orbitrap mass 
analyser, magnetic sector instruments and ion cyclotron analysers (ICR) which are both 
based on Fourier transformation mass spectrometry (FTMS) (De Hoffmann, 2005; Domon 
et al., 2006). 
 
One of the newest trends in mass detection is electronic axially harmonic orbital trapping, 
so called orbitrap detection, which is based on unique principles of separation (Olsen et al., 
2009; Makarov, 1999, 2000). Generally, ions for this detection type are generated using 
ESI source (Hardman et al., 2003). Within this technique, detection type is performed only 
by using the electrostatic potential in specially shaped electrodes (Figure 12). Outer 
electrode is shaped as a barrel and divided by half, both parts are separated by a gap, while 
inner parts of the electrode follow the shape of the outer electrode (Hu et al., 2005; 
Makarov, 2006). 
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Figure 10: Simplified scheme of mass spectrometer components where protein ionization is performed 
using electrospray ionization (ESI) technique. 
Slika 10: Poenostavljena shema komponent masnega spektrometra, kjer se ionizacija proteinov izvaja 
s pomočjo tehnike elektrosprejske ionizacije (ESI).  
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Figure 11: Matrix-assisted laser desorption and ionization (MALDI) technique for ionization of 
analytes for mass spectrometry. 
Slika 11: Tehnika za lasersko desorpcijo in ionizacijo s pomočjo matriksa (MALDI) za ionizacijo 
analitov za masno spektrometrijo.  
 
Figure 12: Sheme of specially shaped electrodes, which are used in electronic axially harmonic orbital 
trapping mass detection. 
Slika 12:  Shema posebno oblikovanih elektrod, ki se uporabljajo v elektronski aksialno harmonični 
detekciji mase pri zajetju orbite.  
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In orbital instrument ions are passed through space in between halves of the outer 
electrode. Meanwhile, a suitable electrostatic potential is established between two inner 
electrodes which causes ions to rotate around central r axis but with the possibility to 
oscillate also on the z axis depending on the frequencies of ion mass to charge ration (m/z) 
and kinetic energy of the ions which they have upon the injection. Those oscillations can 
be detected by modes of current amplification, which they induce in the space between two 
halves of the electrodes. Frequencies coming from the ions are measured without 
destruction of the ions by acquisition of time-domain image current transients (Hu et al., 
2005). Moreover, this allows a Fourier transformation algorithm (FFT) to be applied on 
this induced current and its characterisation by modes of frequency and intensity (De 
Hoffmann, 2005). Furthermore, additional conversion of recorded time-domain signal can 
be employed and converted to m/z ratio mass spectrum (Marshall et al., 2006). 
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3 MATERIALS AND METHODS 
3.1 ACTIVE PHARMACEUTICAL INGREDIENT 
Experimental IgG monoclonal antibody (named mAb1), used in this scientific research, 
was produced and purified in Novartis Biopharmaceutics Downstream department in 
Mengeš, Slovenia. Final concentration of active material was 116.94 mg/ml which was 
determined using affinity liquid chromatography. 
3.2 FORMATION AND ISOLATION OF MAB1 AGGREGATES AND ISOFORMS 
Monoclonal antibody - mAb1 was divided into two parts and exposed to physical stress 
conditions such as freeze/thaw stress cycles and light stress, in order to generate 
aggregated protein mAb1 samples, that could be easily detected comparing to other mAb1 
structural variants. 
 
First fraction of original mAb1 sample, filled in 20R glass vials in volume of 5 ml, was 
conducted to light stress conditions using instrument SunTest XLS+ for 22 h on 40º C 
black standard temperature (BST) while energy of radiation was 750 W/m2. In the 
continuation of the text, this light stressed sample was named mAb1-LS. 
 
Second fraction of mAb1 sample was subjected to intense freeze/thaw stress consisting of 
up to 18 freeze/thaw cycles for which the temperature was changing from -70º C to 35º C 
within one cycle. In specific, one freeze thaw cycle consisted of initial 2 hours of shock 
freeze to -70º C followed by quick thawing on 35º C for 4 hours. Experiments were 
performed on Celsius S3 Freeze/Thaw Cryo Pilot instrument, with mAb1 sample, which 
was filled in 30 ml instrument bags equipped with temperature probe. For simplification in 
further text, mAb1 fraction, which has undergone 18 stressful cycles of freeze and thawing 
was named mAb1-F/T18. 
3.3 CHARACTERIZATION METHODS AND MATERIALS FOR MAB1 
AGGREGATES AND ISOFORMS 
In addition, both light stressed and freeze/thaw stressed mAb1 samples containing 
aggregates were separated by means of SEC and HIC methods and have been further 
characterised. Robust structure in terms of monomeric or multimeric mAb1 forms was 
determined. Moreover, the selected mAb1’s aggregates and other differentiated forms were 
used for structure determination studies and biological-cell assays. 
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3.3.1 Size exclusion chromatography (SEC) 
SEC-HPLC method was performed on Agilent 1200/1260 HPLC instrument (Agilent 
Technologies, Santa Clara, CA, USA) on a TSKgel G3000SWXL analytical column 
(7.8x300 mm, Tosoh Corporation, Tokyo, Japan) at 30º C. Used mobile phase was 150 
mM potassium phosphate buffer, pH=6.5 at a flow rate 0.4 ml/min. 10 µl of mAb1 samples 
with concentration 0.75 mg/ml were injected on the column. Run time was 35 min. The 
UV absorbance was measured at 280 nm (Rombach-Riegraf et al., 2014) and alternative 
proposed detection wavelength of 210 nm was tested. Acquired data has been processed 
using Empower 3 software. 
 
SEC-HPLC analysis was performed under the same chromatographic conditions also on 
Wyatt Technology Corporation miniDAWN TREOS 427-TS Multi-angle static light 
scattering detector (MALS) combined with RI Wyatt Optilab rEX instrument with the aim 
of mAb1 aggregates size characterization. After chromatographic separation on HPLC 
system, peaks have been analysed on MALS detector equipped with Fused Silica sample 
cell on 656 nm. Detector has also acquired an additional data from Generic UV instrument 
collected at 280 nm in 1 cm length cell and temperature of 25º C. RI detection has been 
performed at 658 nm and temperature 25° C. All data from MALS detector has been 
processed using Astra software by setting the adequate normalization, baseline and band 
broadening parameters for UV, RI and light scattering signals. 
 
As an optimization and comparison to SEC-HPLC method, a SEC-UPLC method under 
similar conditions was performed on ACQUITY UPLC H-Class Bio System (Waters 
Milford, Massachusetts, USA) on ACQUITY UPLC Protein BEH SEC column, 200Å, 1.7 
µm, 4.6mm x 300mm, 1/pkg) at 30º C. Mobile phase was also 150mM potassium 
phosphate buffer, pH=6.5 at a flow rate 0.4 ml/min. 5 µl of mAb1 samples with 
concentration 0.75 mg/ml were injected on the column. Run time was 15 min. The UV 
absorbance was measured at 210 nm. Data has been processed using Empower 3 software. 
 
Fraction collection of total mAb1 aggregate samples was performed using developed SEC-
UPLC method on ACQUITY UPLC H-Class system upgraded with Waters Fraction 
Manager module. Detection prior fraction collection was performed on 210 nm while 
analysing and collecting of fractions was performed from 50 µl sample load of 
concentration up to 116.94 mg/ml. In addition, 15 ml and 4 ml Amicon Ultra 50 kDa 
centrifugal filter devices were used for the purpose of mAb1 total aggregate fraction 
concentration. Accordingly, final volume of concentrated total mAb1 aggregates sample 
from light stressed (mAb1-LS) and 18 cycles of freeze/thaw stressed sample (mAb1-
F/T18) were used for additional fraction collection of individual aggregates using SEC-
UPLC fraction collection method.  
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As expected, with every fraction collection cycle, concentration of initial injected sample 
was diluted multiple times. Therefore, concentration determination of total mAb1 
aggregate fractions was performed before additional fraction re-analysing and collecting of 
individual aggregate fractions. In addition, 15 and 4 ml Amicon Ultra 50 kDa centrifugal 
filter devices were used for the purpose of mAb1 total aggregate fraction concentration. In 
detail, approximately 31 ml of collected fraction of total aggregates for light stressed 
mAb1 sample (mAb1-LS) was gradually concentrated to a final volume of cca. 800 µl in 
15 ml Amicon filter device using centrifuge on 4000 rpm for total time of 60 min. 
Concentrate was then transferred into 4 ml Amicon Ultra 50 kDa centrifugal filter, while 
15 ml Amicon filter washing was performed using 200 µl of SEC mobile phase, which was 
then added to 4 ml Amicon filter. Sample was centrifuged for 30 min in 4 ml Amicon Ultra 
50 kDa centrifugal filter to a final volume of 200 µl and was pipetted to vial. 4 ml Amicon 
filter washing was performed using 150 µl of SEC mobile phase after which, the eluate 
was added to vial containing concentrated sample. Accordingly, final volume of 
concentrated total mAb1 aggregates sample from light stress (mAb1-LS) was used for 
additional fraction collection of individual aggregates using SEC-UPLC fraction collection 
method described above.  
 
In parallel, approximately 27 ml of total aggregate sample from mAb1 sample that had 
undergone 18 cycles of freeze/thaw stress (mAb1-F/T18) was gradually concentrated to a 
final volume of 300 µl in 15 ml Amicon filter device using centrifuge on 4000 rpm for 
total time of 40 min. After that, the concentrate was transferred into 4 ml Amicon Ultra 50 
kDa centrifugal filter, while 15 ml Amicon filter washing was performed using 200 µl of 
SEC mobile phase. After washing, eluate was added to 4 ml Amicon filter. Sample was 
then centrifuged for 15 min in 4 ml Amicon Ultra 50 kDa centrifugal filter to a final 
volume of 100 µl and was pipetted to vial. 4 ml Amicon filter washing was performed 
using 200 µl of SEC mobile phase, which was added to vial which already contained 
concentrated sample. Therefore, 300 µl of concentrated total aggregate fraction of mAb1 
sample (mAb1-F/T18), which has been exposed to freeze/thaw stress was used for 
additional fraction collection of individual aggregates using afore mentioned SEC-UPLC 
fraction collection method. 
 
Moreover, additional fraction collection method using size exclusion chromatography 
principles for collecting total aggregates fractions in greater volumes was also performed 
on ÄKTA Explorer 10S protein purification system, controlled with Unicorn software, on 
Superdex 200 10/300GL column using phosphate-buffered saline (PBS) with pH value 7.4. 
Proposed optimization for this method included usage of 150 mM potassium-phosphate 
buffer, pH 6.5 as mobile phase to obtain better resolution parameters between monomer 
and aggregate species. As any SEC technique, also SEC-ÄKTA was chosen for fraction 
collection as it was possible to collect intact monomer and total aggregate fractions which 
were then used for further characterization and immunological tests. SEC-ÄKTA was 
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performed on isocratic conditions and flow of 0.5 ml/min. Furthermore, mAb1 monomer 
and total aggregate fractions were also collected using proposed SEC-ÄKTA method under 
same conditions, with 150 mM potassium phosphate buffer, pH=6.5 as mobile phase, 
instead of using phosphate-buffered saline (PBS).  
3.3.2 Methods for fast protein concentration determination 
Monoclonal antibody 1 (mAb1) protein concentration has been determined in triplicates on 
280 nm using NanoDrop 8000 device by applying 2.5 µl of samples, including sample 
blank. Extinction coefficient was set at appropriate value for mAb1 and normalization 
parameter was set at 340 nm. In addition, mAb1 protein concentration has also been 
determined at 280 nm using Trinean Xpose system by applying 2.5 µl of samples in Xpose 
200 slide, where micro cuvette path length was 0.5 mm.  
3.3.3 Non-reductive capillary electrophoresis analysis (non-red CE-SDS) 
CE SDS analysis was executed on instrument Beckman Coulter PA800i using Beckman 
Coulter capillary tubing with diameter of 50 µm and length of 30 cm, where separation 
pathway was 20 cm. Running and sample buffer were used from SDS-MW Beckman 
coulter analysis kit, as well as 0.1 M HCl and 0.1 M NaOH for capillary washing. 
Concentration of samples was 1 mg/ml treated with iodide-acetamide for non-reductive CE 
SDS analysis.   
3.3.4 Hydrophobic Interaction Chromatography (HIC) 
HIC analysis was performed using Agilent 1260 HPLC instrument (Agilent Technologies, 
Santa Clara, CA, USA). Moreover, separation was accomplished by means of 
commercially available HIC column TSK gel Butyl 2.5 µm; 4.56 mm ID × 10.0 cmL from 
manufacturer Tosoh, temperature set at 25º C and at flow of 1 ml/min, using gradient 
conditions of mobile phase A (consisting of 1.5 M ammonium-sulphate / 50 mM sodium-
phosphate buffer pH=7.00) and mobile phase B (which included 50 mM sodium phosphate 
buffer pH=7.00). Specific gradient conditions were applied and followed a 1 min hold at 
0% of mobile phase B, when approximately 50 µg of injected mAb1 protein sample was 
eluted using a linear gradient from 0 to 100% of mobile phase B in 15 min. The column 
was then washed with 100% of mobile phase B for 5 min and re-equilibrated to 0% of 
mobile phase B for additional 5 min prior to the injection of next mAb1 sample. The 
separation was monitored by DAD detector at 210 nm.  
3.3.5 Dynamic light scattering (DLS) 
Dynamic light scattering was used as a quick method for estimating size of mAb1 and its 
structural variants. In order to perform dynamic light scattering, Zetasizer instrument ZS 
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(Malvern Instruments GmbH, Herrenberg, Germany) was used, equipped with a 633 nm 
He-Ne laser (4 mW) and a 633 nm Avalanche photodiode, positioned at 90º angle, for 
detection of scattered light. The instrument was switched on for 30 min prior the analysis. 
300 µl of each sample was measured in UV cuvettes at 25º C. After measurements, 
hydrodynamic radius was calculated. Data was obtained using Malvern software. The 
percentage of polydispersity (PD%) value was ranked from 0% to 100%, describing size 
distribution of the sample in the following way: PD%˂25 predominantly monodisperse; 
PD% from 25 to 40 monodisperse sample containing small amounts of polydisperse 
species and PD%>40 increasing polydispersity indicating presence of high molecular 
weight (MW) species. 
3.3.6 SDS-PAGE - sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SDS-PAGE analysis has been performed using 10% separating gel, which consisted of 
40% acrylamide/bis-acrylamide 37 in ratio 5:1 in total volume of 877 µl, 1.5 M Tris HCl 
(pH 8.8) in volume of 877 µl, 10% ammonium-persulphate (35 µl), 10% SDS (35 µl), 3.5 
µl TEMED and 1670 µl of ultrapure water. Separating gel was left to solidify between 
SDS PAGE kit’s glass plates. Approximate gel thickness was 0.75 mm. After solidification 
of separating gel, 5% stacking gel was prepared with 250 µl of 40% acrylamide/bis-
acrylamide 37 in ratio 5:1, 250 µl of 1.5 M Tris HCl (pH 8.8), 20 µl of 10% ammonium-
persulphate, 20 µl of 10% SDS, 2 µl of TEMED and 1460 µl of ultrapure water and poured 
on the top of separating gel. Subsequently, a gel comb was inserted in the stacking gel. 
Glass plates have been taken out of the casting frame and set in the cell buffer dam, 
afterwards the running buffer, consisting of 24 mM Tris, 190 mM glycine and 3.5 mM 
SDS with pH value 8.3, was poured into the inner chamber until buffer surface reached 
adequate level in the outer chamber. 
 
Native and denaturised samples have been diluted in loading buffer, which composition 
was 10 mM imidazole, 50 mM sodium phosphate, 300 mM NaCl with pH = 7.4. Native 
samples have been prepared using 10 µl of each individual aggregate fraction (except for 
monomer fraction for which used volume was 2 µl due to higher monomer sample 
concentration) and were diluted in 5.3 µl of loading buffer and 2.7 µl ultrapure water. 
Similarly, reduced samples have been prepared using 10 µl of each individual aggregate 
fraction (except for monomer fraction for which used volume was 2 µl due to higher 
monomer sample concentration) which was diluted in 5.3 µl of loading buffer, 2.7 µl 
ultrapure water and 2.7 µl 1 M Dithiothreitol (DTT). Moreover, 5 µl of SeeBlue2 size 
marker was used. All prepared native and denatured samples were loaded in lanes, as well 
as size marker. Plates were sealed, anodes connected and 100 V voltage was set. Protein 
electrophoreses was performed in a 120 min run. Then, 15 min protein fixation was 
performed with solution containing 40% ethanol and 10% acetic acid, subsequently 
Ignjatović J. Detection and immunogenicity evaluation of recombinant monoclonal antibodies’ structural variants. 
   Doct. dissertation. Ljubljana, University of Ljubljana, Biotechnical Faculty, 2019 
 
40 
colouring with Coomasie brilliant blue dye was executed for 24 h, after which 
discolouration with water for 3 h was performed. 
3.3.7 Orbitrap mass spectrometry 
Specific SEC-UPLC analysis combined with orbitrap mass spectrometry detection was 
used as a testing method for determining of potential mAb1 monomer and mAb1 
aggregates molecular masses and types of molecular bonds between them.  
 
For that purpose, individual aggregate samples from SEC-UPLC method fraction 
collection have been desalted using ultrapure water in ratio 1:8 in 0.5 ml 30 kDa Amicon 
Ultracel filters on 13 rpm centrifugal force on Eppendorf Minispin device for 8 min. 
Afterwards the protein concentration was determined with Xpose 200 Slide on Trinean 
Xpose device at 280 nm.  
 
Analysis was performed using modified SEC-UPLC method for Mass detection on LC 
instrument Thermo Scientific UltiMate 3000 UHPLC+ focused and Thermo Scientific 
MAbPACTM SEC-1 Size Exclusion LC Column, PEEK, 4 mm × 300 mm, 300 Å, 5 µm 
column tempered on 30º C and on isocratic conditions using 20% acetonitrile / 0.1% 
formic acid / 0.05% tetrafluoroacetic acid mobile phase at flow of 0.2 ml/min. Run time 
was set on 20 min. After additional separation of desalted samples on SEC column by 
injecting 5 µg of sample load, orbitrap mass spectrometry detection has been performed 
using instrument Thermo Scientific Q Exactive Plus with HESI-II probe as ESI source, 
under positive polarity, 80 eV isCID, 17500 (at 200 mz) resolution, 2000–4200 m/z scan 
range, 3×106 AGC target, 150 ms maximum IT, 25 sheath gas flow rate, 10 aux gas flow 
rate, 4.00 kV spray voltage, 250º C capillary temperature, 300º C heater temperature and 
70S-lens RF level. 
3.4 IMMONOLOGICAL ASSAYS ON MAB1 STRUCTURAL VARIANT'S 
FRACTIONS 
3.4.1 In vitro DC maturation and DC stimulation assays                                                           
Different concentrations of selected samples were assessed for their capacity to induce 
maturation or in any other way modulate the activation state of immature monocyte-
derived dendritic cells (iDC). Briefly, peripheral blood mononuclear cells (PBMC) were 
isolated from buffy coats obtained from venous blood of healthy donors at the Blood 
transfusion centre of Slovenia, according to institutional guidelines and complying with the 
ethical permit for this experiment with number 0120-279/2017-3 KME 74/06/17 issued by 
the National Medical Ethics Committee (KME). Monocytes were isolated from PBMC by 
immunomagnetic sorting using CD14 microbeads (MACS, Miltenyi Biotec). 
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Differentiation of monocytes to iDC was induced in a 5-day culture using granulocyte-
monocyte colony stimulating factor (GM-CSF) and interleukin (IL)-4, as described 
previously by Švajger et al., (2014). 
To assess the immunogenic capacity of mAb1 aggregate samples in terms of DC 
maturation, iDC were treated with 100 µg/ml of mAb1 aggregate preparations. Afterwards, 
maturation process was monitored by immunophenotyping using fluorescence activated 
cell sorting analysis (FACS) or flow-cytometric quantitative tests (Švajger et al., 2015). 
Potentially immunogenic forms of mAb1 would presumably upregulate the maturation 
markers and CD4 T-cell co-stimulatory molecules CD80, CD40 and CD86 (relative to 
blank negative control or properly folded mAb1). In addition, surface molecules also 
associated with DC maturation such as the lymph node-homing chemokine receptor CCR7 
and HLA-DR were measured.  
 
In order to assess the capacity of stimulated DC to produce pro-inflammatory cytokines, 
DC supernatants 48 hours after stimulation were analysed for the presence of IL-1β, IL-6, 
IL-8, IL-10, IL-12p70 and TNF-α (Švajger et al., 2011). Cytokine levels in the 
supernatants were analysed by flow cytometry using Human Inflammatory Cytometric 
Bead Array (CBA) Kit (Human Inflammatory Cytokines Kit Instruction Manual, 2017. 
San Diego, BD Biosciences). 
 
In all assays, monomer mAb1 fraction and SEC mobile phase were used as controls. For 
positive control, classical immunogen was used such as lipopolysaccharide (LPS, 20 
ng/ml) for DC maturation and stimulation assay. 
3.4.2 In vitro PBMC stimulation assay and PBMC proliferation assay 
The purpose of the assays was to evaluate potential of innate immune response of 
peripheral blood mononuclear cells cultures to mAb1 aggregate fractions. Therefore, pro-
inflammatory cytokine response during early exposure (48 hours) of PBMC to mAb1 
samples was measured. Buffy coats from venous blood of normal healthy donors were 
obtained at the Blood Transfusion Centre of Slovenia, according to institutional guidelines 
and complying the ethical permit for this experiment with number 0120-279/2017-3 KME 
74/06/17 issued by the National Medical Ethics Committee (KME). PBMC were isolated 
by ficoll density gradient centrifugation, counted and plated in 96-wells at 3×105 cells/well. 
Acclimatized PBMC were challenged with 100 µg/ml of mAb1 aggregate sample 
fractions.  
 
Within PBMC simulation assay for determination of innate immune reactivity, the cells 
were cultured for an additional 48 hours. After challenge, cell culture supernatants were 
harvested and analysed for the presence of IL-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α 
(Švajger et al., 2011). Multiple cytokines were measured simultaneously using Human 
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Inflammatory Cytometric Bead Array (CBA) Kit (Human Inflammatory Cytokines Kit 
Instruction Manual, 2017. San Diego, BD Biosciences). Results were analysed by flow 
cytometry. 
 
Within PBMC proliferation assay, PBMC cells were similarly isolated and incubated with 
total and individual mAb1’s structural variants fractions. Obtained results were presented 
as counts of cells per minute. For negative controls, the cells were left untreated or treated 
with normal mAb1 monomer. On the other hand, cells were also treated with a positive 
control immunogen (lipopolysaccharide – LPS, 20 ng/ml) for PBMC-related cytokine 
production assay, as well as with phytohemagglutinin (PHA, 2 µg/ml) in PBMC 
proliferation assay. 
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4 RESULTS AND DISCUSSION 
Firstly, SEC-UPLC, SEC-HPLC, and CE-SDS analysis have been performed on mAb1 
protein sample so as to determine the capacity and analytical method suitability for 
separating mAb1 monomer and aggregate species.  
 
Thus, original starting material, IgG type monoclonal antibody – mAb1, has been analysed 
using both SEC-UPLC and SEC-HPLC methods to determine the initial profile of 
aggregates and percentage of total aggregate species present in the starting mAb1 material. 
As it can be observed from the chromatograms in Figure 13, the profile of aggregates is 
comparable since aggregate products 1, 2 and 3 (AP1, AP2 and AP3) were present in both 
SEC-UPLC (Figure 13A) and SEC-HPLC (Figure 13B). Total area percentage for all 
aggregates (SumAP) from initial mAb1 sample was 1.22% in case of SEC-UPLC and 
1.28% in case of SEC-HPLC method results. 
 
 
Figure 13: A – Chromatogram and results for area percentage of original sample mAb1 obtained with 
SEC-UPLC method; B – Chromatogram and results for area percentage of original sample mAb1 
obtained with SEC-HPLC method  (AP – aggregate peak, Main peak or Purity – monomer peak, PRV 
– monomer product related variant peak, DP – degradation product peak). In each chromatogram 
total aggregate profile (SumAP) was emphasized with rectangle frame. 
Slika 13:   A – Kromatogram, ki prikazuje odstotek površine izhodnega vzorca mAb1, pridobljenega z 
metodo SEC-UPLC; B - Kromatogram in rezultati za odstotek površine izvirnega vzorca mAb1, 
pridobljenega z metodo SEC-HPLC (AP - Agregatni vrh, Glavni vrh ali Čistost - monomerni vrh, PRV 
– vse variante vrhov, povezane z monomernimi produkti, DP - vrh razgradnih produktov). V vsakem 
kromatogramu je skupni profil agregatov (SumAP) poudarjen s pravokotnim okvirjem. 
 
A: SEC UPLC Results  for %Area 
B: SEC HPLC Results for %Area 
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Moreover, original mAb1 sample has been analysed using non-reductive CE-SDS analysis 
to examine the possibility of using CE-SDS analysis for aggregate determination as a 
complementary analytical method to SEC. On obtained electropherogram High Molecular 
Weight species (HMW peak – analogue to SumAP in SEC-UPLC/HPLC chromatograms) 
were present in area percentage of circa 1.4% at approximate migration time of 35.6 min 
(Figure 14). However, better aggregate profile and greater resolution for determining 
aggregates was obtained using size exclusion chromatography methods.   
 
Figure 14: Electropherogram and results for area under the curve and percentage of area under the 
curve for Purity and HMW peak for original mAb1 sample. (LC: mAb1 light chain, HH: mAb1 heavy-
heavy chain, HHL: mAb1 heavy-heavy-light chain, Main: mAb1 monomer variant, HMW: mAb1 high 
molecular weight peaks – aggregate peaks). Within electropherogram High Molecular Weight species 
(HMW peak) were emphasized with rectangle frame. 
Slika 14: Elektroferogram in rezultati za površino pod krivuljo in odstotek površine pod krivuljo za 
Čistost in vrh HMW za izvirni vzorec mAb1. (LC: mAb1 lahka veriga, HH: mAb1 težka-težka veriga, 
HHL: mAb1 težka-težka-lahka veriga, Glavni vrh: mAb1 monomerni varianti, HMW: mAb1 vrhovi z 
visoko molekulsko maso - agregatni vrhovi). Znotraj elektroferograma je signal za zvrsti z visoko 
molekulsko maso (vrh HMW) nakazan s pravokotnim okvirjem. 
We concluded that both SEC-UPLC and SEC-HPLC methods are adequate for analysis of 
aggregate and monomer species, which are present in samples. For both SEC-UPLC and 
SEC-HPLC analysis data acquisition was performed at 280 and 210 nm, consequently 
better results and aggregate peak responses were accomplished using detection wavelength 
of 210 nm. However, since the percentage of area under the curve results between SEC 
UPLC and HPLC ware comparable, SEC-UPLC at acquisition wavelength at 210 nm was 
selected as method of choice as the run time was only 15 min and thus shorter that SEC-
HPLC analysis. 
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4.1 PRELIMINARY EXPERIMENTS 
In order to properly choose adequate light stress and freeze/thaw conditions necessary for 
generation of greater amount of aggregate entities required for characterization and 
determination of immunogenicity, preliminary prerequisite experiments have been 
conducted on original starting material, IgG monoclonal antibody – mAb1.  
 
Specifically, light stress study has been conducted on instrument Suntest XLS+, on which 
energy of radiation has been set to 750 W/m2 and black standard temperature was 40° C. 
Time of radiation was 22 h while 9 ml of starting material has been filled in vials type 6R 
(maximum capacity 10 ml) and 20R (maximum capacity 26 ml). These two types of vials 
have been deliberately chosen to see whether the exposed liquid surface of the sample has 
the influence in the rise of generated protein aggregates. Both vials were set in horizontal 
position as this represents the worst-case scenario and increases the sample surface 
exposed to radiation within vials. 
 
After light stress conditions original mAb1 sample and stressed samples in smaller vial – 
6R and larger vial – 20R have been analysed using aforementioned SEC-UPLC method. In 
Figure 15 comparative chromatograms are presented, where it is obvious that total 
aggregate area is the greatest upon conducting the experiment in larger 20R vial (Table 1). 
This observation and consequent rise in total aggregate percentage is due to the greater 
sample surface exposed to the energy of radiation within bigger 20R vial comparing to 
smaller 6R vial. Therefore, in order to produce suitable mAb1 aggregated material after 
light stress, we concluded that that sample volume also has influence over the overall 
aggregate generation and that 20R vials should be used for further research as sample 
containers during light stress experiment. 
Table 1: SEC-UPLC results for Area percentage for Purity, total aggregation products (SumAP), total 
degradation products (SumDP) and all monomer product related variants (SumPRV) of original 
mAb1 sample, mAb1 sample after light stress in 20R vial (mAb1-LS-v20R) and mAb1 sample after 
light stress in 6R vial (mAb1-LS-v6R). 
Preglednica 1: Rezultati SEC-UPLC za odstotek površine za Čistost, skupne produkte agregacije 
(SumAP), skupne produkte razgradnje (SumDP) in vse variante, povezane z monomernimi produkti 
(SumPRV) izvirnega vzorca mAb1, vzorca mAb1 po svetlobnem stresu v viali 20R (mAb1-LS-v20R) in 
vzorca mAb1 po svetlobnem stresu v viali 6R (mAb1-LS-v6R). 
SEC-UPLC 
Sample name Purity SumAP SumPRV SumDP 
mAb1-LS-v20R 94.91 4.55 1.22 0.54 
mAb1-LS-v6R 96.78 2.69 1.25 0.52 
Original mAb1 98.33 1.21 1.09 0.46 
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Figure 15: Chromatograms overlay of original sample (red chromatogram), mAb1 fraction after light 
stress in 20R vial (black chromatogram) and mAb1 fraction after light stress in 6R vial (green 
chromatogram) obtained with SEC-UPLC method; (AP – aggregate peak, Main peak – monomer 
peak, PRV – monomer product related variant peak, DP – degradation product peak, Purity 
represents sum of main monomer peak and monomer product related variant peaks (PRV). Within 
chromatogram overlay total aggregate profile was emphasized with rectangle frame. 
Slika 15: Prilegani kromatogrami izhodnega vzorca (rdeči kromatogram), mAb1 frakcije po 
svetlobnem stresu v viali 20R (črni kromatogram) in mAb1 frakcije po svetlobnem stresu v 6R viali 
(zeleni kromatogram), pridobljeni z metodo SEC-UPLC; (AP - agregatni vrh, Glavni vrh - monomerni 
vrh, PRV - variante povezane z monomernimi produkti, DP - vrh razgradnih produktov, Čistost 
predstavlja vsoto glavnega monomernega vrha in variantnih vrhov povezanih z monomernimi 
produkti (PRV). Skupni profil agregatov v okviru kromatografskega prekrivanja, je poudarjen s 
pravokotnim okvirjem. 
Similarly, most suitable conditions for mAb1 aggregate generation during freeze/thaw 
stress were investigated on Celsius S3 Cryo pilot freeze/thaw module, where mAb1 sample 
has been filled in 30 ml instrument bags. Original mAb1 material has been stressed for 7 
freeze thaw cycles, where each cycle included 2 hours of initial shock freeze to –70° C 
followed by gradual thawing up to 30° C during 4 hours. Sampling has been performed 
upon 1st, 3rd, 5th and 7th cycle. 
 
Vial 20R 
SEC UPLC 
Original mAb1 
Vial 6R 
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Legend: 
Colour Sample name Sample description 
 
mAb1-FT7 mAb1 sample after 7
th freeze/thaw cycle 
mAb1-FT5 mAb1 sample after 5
th freeze/thaw cycle 
mAb1-FT3 mAb1 sample after 3
rd freeze/thaw cycle 
mAb1-FT1 mAb1 sample after 1
st freeze/thaw cycle 
mAb1-LS-v6R mAb1 sample after light stress in 6R vials 
mAb1-LS-v20R mAb1 sample after light stress in 20R vials 
Original mAb1 sample 
Figure 16: Chromatograms overlay of original mAb1 sample, and mAb1 samples after light stress and 
freeze/thaw stress obtained with SEC-UPLC method; (AP – aggregate peak, Main peak– monomer 
peak, PRV – monomer product related variant peak, DP – degradation product peak, Purity 
represents sum of main monomer peak and monomer product related variant peaks PRV). Total 
aggregate profile was emphasized with rectangle frame. 
Slika 16:  Prilegani kromatogrami izhodnega vzorca mAb1 in vzorcev mAb1 po svetlobnem stresu in 
stresu zamrzovanja/odtajanja, pridobljenih z metodo SEC-UPLC; (AP - agregatni vrh, Glavni vrh - 
monomer, vrh PRV - variante povezane z monomernimi produkti, DP – razgradni produkti, Čistost 
predsatvlja vsoto glavnega monomernega vrha in variantnih vrhov povezanih z monomernimi 
produkti PRV). Skupni agregatni profil je poudarjen s pravokotnim okvirjem. 
 
From chromatogram overlay (Figure 16) and SEC-UPLC results of processed 
chromatograms presented in Table 2, it can be concluded that proposed preliminary 
freeze/thaw stressed conditions influenced total aggregate generation of up to 
approximately 2%. However, mAb1 aggregates were greatly formed during light stress 
condition (Figure 16), which led to overall assumption that for increased mAb1 aggregate 
generation during freeze/thaw study each freeze/thaw cycle should be intensified and that 
there should be considerably more freeze/thaw cycles.  
 
SEC UPLC 
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Table 2: SEC-UPLC results for Area percentage for Purity, total aggregation products (SumAP), total 
degradation products (SumDP) and all monomer product related variants (SumPRV) of original 
mAb1 sample, mAb1 sample after 1, 3, 5, and 7 preliminary freeze/thaw cycles. 
Preglednica 2: Rezultati SEC-UPLC za odstotek površine za Čistost, skupne produkte agregacije 
(SumAP), skupne produkte razgradnje (SumDP) in vse variante, povezane z monomernimi produkti 
(SumPRV) izvirnega vzorca mAb1, vzorca mAb1 po 1, 3, 5 in 7 ciklih zamrzovanja/odtajanja. 
SEC-UPLC 
Sample name Purity  SumAP  SumPRV  SumDP 
mAb1_FT1 98.17 1.32 1.13 0.51 
mAb1_FT3 97.86 1.61 1.13 0.52 
mAb1_FT5 97.57 1.90 1.14 0.53 
mAb1_FT7 97.39 2.09 1.15 0.52 
Original mAb1 98.33 1.21 1.09 0.46 
4.2 SIZE EXCLUSION CHROMATOGRAPHY RESULTS 
After preliminary experiments, the original sample of IgG monoclonal antibody - mAb1 
has undergone two types of intense stressful conditions Light Stress (LS) and Freeze/thaw 
(F/T) stress of up to 18 cycles. Both types of physical stresses have been chosen and 
adjusted to represent the extreme conditions in the downstream process and subsequent 
storage of final product. By means of SEC-UPLC method, mAb1 fraction after light stress 
(mAb1-LS in the continuation of the text) and mAb1 fraction after freeze/thaw stress of up 
to 18 cycles (mAb1-F/T18 in the continuation of the text) have been analysed and a 
significant rise in the aggregate percentage of area under the curve has been observed for 
both types of stresses (Figure 17, Table 3). Since greater amount of total aggregates was 
accomplished after 18 cycles of freeze/thaw stress instead of 9 cycles, mAb1 stressed 
sample after 18 cycles of freeze/thaw stress was used in further experiments as it 
represented the worst-case freeze/thaw stress scenario for aggregates generation.  
Table 3: SEC-UPLC results for Area percentage for Purity, total aggregation products (SumAP), total 
degradation products (SumDP), all monomer product related variants (SumPRV) and Main 
(monomer) peak of original mAb1 sample, mAb1 sample after light stress (mAb1-LS), mAb1 sample 
after 9 cycles (mAb1-F/T9) or 18 cycles (mAb1-F/T18) of freeze/thaw stress. 
Preglednica 3: Rezultati SEC-UPLC za odstotek površine za Čistost, skupnih produktov agregacije 
(SumAP), skupnih produktov razgradnje (SumDP), vseh variant, povezanih z monomernimi produkti 
(SumPRV), in glavnega (monomernega) vrha originalnega vzorca mAb1 (Main peak), vzorca mAb1 po 
izpostavljenosti svetlobnemu stresu (mAb1-LS) in vzorca mAb1 po 9 (mAb1-F/T9) in 18 ciklih stresa 
zamrzovanja/odtajanja (mAb1-F/T18). 
SEC-UPLC results for %Area 
Sample name Purity SumAP SumDP SumPRV Main peak 
Original mAb1 sample 98.19 1.28 0.53 0.92 97.26 
mAb1-LS  93.38 5.90 0.72 1.12 92.26 
mAb1-F/T9 cycles 97.56 1.84 0.59 0.96 96.60 
mAb1-F/T18 cycles 97.25 2.18 0.56 0.98 96.27 
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Figure 17: Chromatograms overlay of original sample (mAb1 – red chromatogram), mAb1 fraction 
after light stress (mAb1-LS – blue chromatogram), mAb1 fraction after 9 freeze/thaw cycles (mAb1-
F/T9 – green chromatogram) and mAb1 fraction after 18 freeze/thaw cycles (mAb1-F/T18 – black 
chromatogram) obtained with SEC-UPLC method; (AP – aggregate peak, Main peak– monomer peak, 
PRV – monomer product related variant peak, DP – degradation product peaks; Purity represents 
sum of main monomer peak and PRV monomer product related variant peaks). 
Slika 17: Prilegani kromatogrami izvirnega vzorca (mAb1 - rdeči kromatogram), mAb1 frakcije po 
svetlobnem stresu (mAb1-LS - modri kromatogram), mAb1 frakcije po 9 ciklih 
zamrzovanja/odtajanja (mAb1-F/T9 - zeleni kromatogram) in mAb1 frakcije po 18 ciklih 
zamrzovanja/odtajanja (mAb1-F/T18 - črni kromatogram), pridobljenih z metodo SEC-UPLC; (AP - 
agregatni vrh, Glavni vrh – vrh monomera (Main peak), PRV - variante povezane z monomernimi 
produkti, DP - razgradni produkti; Čistost predstavlja vsoto glavnega monomernega vrha in 
variantnih vrhov povezanih z monomernimi produkti PRV). 
 
Table 4: Area percentage results for the individual aggregate peaks (AP1, AP2 and AP3) within the 
aggregate profile (SumAP) for major stressed samples mAb1 fraction after light stress (mAb1-LS) and 
mAb1-F/T 18 cycles analysed with SEC-UPLC method. 
Preglednica 4: Odstotek površine posameznih agregatnih vrhov (AP1, AP2 in AP3) profila agregatov 
(SumAP) za vzorec frakcije mAb1 po izpostavljenosti svetlobnemu stresu (mAb1-LS) in mAb1 po 18 
ciklih zamrzovanja/odtajanja (mAb1-F/T18), analizirano z metodo SEC-UPLC. 
SEC-UPLC results for %Area for individual aggregate peaks 
Sample name SumAP (%) AP1 (%) AP2 (%) AP3 (%) 
mAb1-LS  5.90 0.54 5.02 0.34 
mAb1-F/T 18 cycles 2.18 0.48 1.43 0.27 
Rise in total Area percentage of aggregate peaks (SumAP) was evident after described 
light stress (from 1.28% up to 5.90% of SumAP value for mAb1-LS, comparing to original 
mAb1 sample) and 18 freeze/thaw cycles (from 1.28% up to 2.18% of SumAP value for 
mAb1-F/T18, comparing to original mAb1 sample). In addition, it has been confirmed that 
both light and freeze/thaw stresses induce a rise in individual aggregate peaks (AP1, AP2 
and AP3) within total aggregate profile (SumAP) which can be observed in Table 4. 
However, both applied freeze/thaw and light stresses are not expected in regular drug 
production as they represent extreme boundaries within downstream process and drug shelf 
SEC UPLC 
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life. Within this research those type of stresses have been used to produce mAb1 samples 
with higher aggregate titter. 
Using SEC-UPLC data for molecular weights (MW) from Molecular Weight Marker - 
MWM (Table 5) calibration curves have been constructed using different mathematical 
models: 
 Linear regression:  
y = -122.92x + 993.01  (R² = 0.6437) 
 Exponencial:  
y = 1662921.1694e-1.58x  (R² = 0.9062) 
 Logarithmic:  
y = -873ln(x) + 1811.2  (R² = 0.7407) 
 Polynomial 2nd order:  
y = 55.356x2 – 884.73x + 3498.5  (R² = 0.9355) 
 Polynomial 3rd order:  
y = -20.525x3 + 479.32x2 – 3715.1x + 9584.4  (R² = 0.9926) 
 Polynomial 4th order:   
y = 7.9462x4 – 239.83x3 + 2703.3x2 - 13523x + 25430  (R² = 0.9998) 
 Polynomial 5th order:  
y = -1.8064x5 + 70.414x4 - 1092x3 + 8432.3x2 - 32487x + 50137 (R² = 0.9999) 
Table 5: Molecular Weight Marker (MWM) components with their molecular weights of used proteins 
in kDa and their corresponding retention times obtained with  SEC-UPLC method. 
Preglednica 5: Komponente označevalca velikosti z molekulskimi masami (MW) uporabljenih 
proteinov v kilodaltonih (kDa) in s pripadajočimi retencijski časi (Rt), pridobljene z metodo SEC-
UPLC. 
MWM chromatogram 
Peak Name Rt (min) MW (kDa) 
Thyroglobulin 4.564 669 
IgG 5.696 150 
Holo-Transferrin 6.382 80 
Ovoalbumin 6.985 45 
Carbonic Anhydrase 7.552 29 
Aprotinin 8.201 6.5 
Histidine 9.201 0.2096 
Best fitting of calibration curve has been accomplished for calibration curve, which has 
been calculated by using polynomial 5th order regression: y = -1.8064x5 + 70.414x4 - 
1092x3 + 8432.3x2 - 32487x + 50137 with R² = 0.9999 (Figure 18), therefore that equation 
has been used for calculations of potential molecular weights of aggregates, while 
monomer peak weight represented a control of the results, which should be around 150 
kDa (Table 6). 
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Figure 18: Constructed calibration curve based on protein molecular weights and retention times in 
SEC-UPLC analysis. 
Slika 18: Kalibracijska krivulja molekulskih mas proteinov in njihovih retenzijskih časov pri analizi 
SEC-UPLC  
 
 
Table 6: Calculated potential molecular weights in kDa using polynomial 5th order regression based on 
MWM marker component’s molecular weights and retention times during proposed SEC-UPLC 
analysis. 
Preglednica 6: Izračunane molekulske mase v kDa z uporabo regresije polinoma 5. reda, ki temelji na 
molekuskih masah komponent označevalca velikosti MWM in retencijskih časih med analizo SEC-
UPLC. 
mAb1-LS sample 
Peak Name Rt (min) MW (kDa) Aggregate / monomer peak ratio 
Main peak 5.696 156.5 / / 
AP3 4.777 504.5 3.2 Trimeric mAb1 aggregate 
AP2 4.980 383.4 2.4 Dimeric mAb1 aggregate 
AP1 5.360 232.8 1.5 Modified dimeric mAb1 aggregate 
     
mAb1-F/T18 sample 
Peak Name Rt (min) MW (kDa) Aggregate / monomer peak ratio 
Main peak 5.700 155.8 / / 
AP3 4.893 431.2 2.8 Trimeric mAb1 aggregate 
AP2 5.086 332.6 2.1 Dimeric mAb1 aggregate 
AP1 5.367 230.8 1.5 Modified dimeric mAb1 aggregate 
 
According to calculations using proposed model it was concluded that present AP3 entity 
is trimeric mAb1 aggregate, accordingly AP2 entity is dimeric mAb1 aggregate while AP1 
entity is modified mAb1 dimeric form, which consists of combination of monomer mAb1 
with one additional heavy and light chain, since difference between size of monomeric 
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form (approximately 150 kDa) and calculated size of AP1 (approximately 230 kDa) is 
about 80 kDa, which corresponds to the size of combination of one heavy (cca. 50 kDa) 
and light chain (cca. 23 kDa). Other mathematical model with acceptable R2 values 
(Polynomial 2nd to 5th order regression) showed similar results. These conclusions for the 
size of aggregate products AP1, AP2 and AP3 were further challenged using different 
analytical methods. 
 
Figure 19: Overlaid chromatograms from light scattering MALS detection after SEC-HPLC analysis 
of original mAb1 sample (blue), mAb1-LS (green), mAb1-F/T 9 cycles (red) and mAb1-F/T 18 cycles 
(pink) with provided data for Molar Mass (g/mol). 
Slika 19: Prileganje rezultatov metode detekcije razprševanja svetlobe MALS po SEC-HPLC analizi 
izhodnega mAb1 vzorca (modra), mAb1-LS (zelena), mAb1-F/T 9 ciklov (rdeča) in mAb1-F/T 18 
ciklov (roza), opremljenih s podatki za molekulsko maso (g /mol).    
Native mAb1 sample and freeze/thaw or light stressed mAb1 samples have been analysed 
using SEC-HPLC analysis with MALS detection for the purpose of experimental 
determination of molecular weight of aggregate peaks comparing to monomer peak. Using 
Astra software all detected UV, light scattering and RI signals have been processed using 
adequate baseline, band broadening and normalization parameters. From Figure 19 an 
overlay of results for molar mass (g/ml) for original mAb1 sample, mAb1-LS, mAb1-F/T 
after 9 cycles and mAb1-F/T after 18 cycles, it can be seen that the consistent result are 
within the range of monomer (main) peak, while in the range of multimeric forms (left side 
of the chromatogram before monomeric peak) and in the range of degradation products 
(right side of the chromatogram after monomeric peak) there is great scattering of results 
which is due to low concentration of analytes of interest that are present in MALS 
detection cell. This scattering of values was expected since aggregates or degradation 
products were present in much lower concentrations in samples in comparison to main 
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peak. However, as it can be seen from normalized chromatograms combined with Light 
scattering and RI signals from mAb1-LS sample in the Figure 20, only aggregate peak 2 
(AP2) was present in greater concentration comparing to AP1 and AP3 which enabled 
adequate processing and results for aggregate AP2 (Table 7).  
 
Figure 20: Light scattering (red), UV (green) and RI (blue) results for sample mAb1-LS, which 
contains evident AP2 peak at approximately 17.5 min so that suitable processing of results could be 
performed. 
Slika 20: Rezultati svetlobne razpršitve (rdeča), UV (zelena) in RI (modra) signala za vzorec mAb1-LS, 
ki vsebuje očiten AP2 vrh pri približno 17,5 min, za potrebe izvedbe ustrezne obdelave rezultatov. 
 
 
Table 7: SEC-MALS results for molar masses for monomer and aggregate peak 2 (AP2) from mAb1-
LS (light stressed) and mAb1-F/T (freeze/thaw) sample after 18 cycles. 
Preglednica 7: Rezultati MALS za molarne mase monomera in agregatnega vrha 2 (AP2) iz vzorca 
mAb1-LS (svetlobni stres) in mAb1-F/T (stres zamrzovanja/odtajanja) po 18 ciklih. 
Sample name 
Main (monomer) peak AP2 peak 
MW (kDa) MW (kDa) 
mAb1-LS 148.7 336.2 
mAb1-F/T 18 cycles 149.4 316.8 
Average 149.05 326.5 
Standard deviation 0.49 13.72 
% RSD 0.33 4.20 
 
As expected, calculated molar mass for monomer peak in any type of sample was 
approximately 150 kDa, which confirms adequate processing of results. The aim of this 
analysis was to determine the molecular mass for aggregate peaks, which was 
accomplished for AP2 peak due to greater concentration of AP2 peak in all samples. 
Approximate molecular weight for AP2 peak was around 326 kDa, which implies that AP2 
peak was dimeric form of mAb1 protein since ratio comparing to monomer is 1 : 2.19. 
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Moreover, this implies that AP3 peak is potentially trimeric and AP1 peak is also a type of 
truncated dimeric mAb1 form. Those results were consistent to conclusions from MWM 
regression curve analysis.   
 
In addition, with the aim of collecting larger volumes of total aggregates from different 
samples, SEC ÄKTA analysis has been performed on ÄKTA explorer 10S system, using 
Superdex 200 10/300 GL column and PBS as mobile phase, flow was adjusted to 0.5 
ml/min and corresponding fractions for total aggregates sample (SumAP) and monomer 
samples were collected (Figure 21) and subsequently were analysed using DLS method.  
 
 
Figure 21: Chromatogram overlay from SEC ÄKTA analysis of sample mAb1-LS and fraction 
collection windows for monomer mAb1 and total aggregates fraction – SumAP. Blue colour – 
chromatogram obtained on 280 nm, red colour – chromatogram acquired on 260 nm and pink colour – 
chromatogram obtained on 220 nm.  
Slika 21: Prileganje kromatogramov iz analize SEC ÄKTA vzorca mAb1-LS in okna za zbiranje 
frakcij za monomer mAb1 in skupnih agregatnih frakcij - SumAP. Modra barva - kromatogram 
pridobljen pri 280 nm, rdeča barva - kromatogram pridobljen pri 260 nm in roza barva - 
kromatogram pridobljen pri 220 nm. 
Dynamic Light Scattering (DLS) method was performed on instrument ZetaSizer, 
processing was done with Malvern software. Results for average cumulate mean (Z value) 
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and obtained peak size were presented in Table 8. Collected fraction of total aggregate 
profile that contains all aggregate peaks AP1, AP2 and AP3 (AP2 peak by far prevails 
according to SEC-UPLC results in comparison to AP1 and AP2) was analysed on DLS. As 
expected, ratio of Z average value of total aggregate fraction SumAP-mAb1-LS compared 
to monomer was 1.78, while Peak size ratio of SumAP-mAb1-LS fraction in comparison to 
monomer was 1.95. Both Z average and peak size ratio values of SumAP fraction were 
approximately 2, which implies that the majority of the present entities in total mAb1 
aggregate fraction were dimers. This is consistent to SEC-MALS and MWM regression 
results and implies that AP2 peak is dimeric form of mAb1 protein considering that AP2 
peak is present in far greater amount within the total aggregate profile. 
 
Table 8: Comparison of obtained results for DLS analysis of total aggregates (SumAP) and monomer 
fractions of sample mAb1-LS. 
Preglednica 8: Primerjava pridobljenih rezultatov za DLS analizo skupnih agregatov (SumAP) in 
monomernih frakcij vzorca mAb1-LS. 
Sample name: Z-Average (d.nm) Peak Size (d.nm) 
SumAP-mAb1-LS 20.73 25.13 
Monomer MAb1-LS 11.64 12.85 
Ratio compared to monomer 1.78 1.95 
 
SEC ÄKTA method has also been further developed by using potassium-phosphate buffer 
with pH 6.5 as mobile phase instead of PBS with the aim of better resolution not only 
between monomer and total aggregate species, but also between individual aggregates. 
Obtained chromatograms (within Figure 22) show valley-to-valley separation between 
monomeric and aggregate species, however, on ÄKTA system for both types of stressed 
samples only one combined aggregate peak is noticeable. Therefore, we concluded that 
proposed and optimised SEC-ÄKTA system could be used for separation and subsequent 
collection of monomeric and total aggregate species but not for individual aggregate 
entities, since the individual aggregate species within total aggregate peak overlaped. 
 
Nevertheless, more accurate SEC-UPLC method for fraction collection of total aggregates 
– SumAP (Figure 23A) and individual aggregates: AP1, AP2 and AP3 (Figure 23B) or 
monomer (MP) fractions for samples mAb1-LS (light stressed mAb1 material) and mAb1-
F/T18 (stressed mAb1 material after 18 freeze/thaw cycles) has been developed on 
ACQUITY UPLC H-Class Bio System combined with Waters Fraction Collection 
Manager analytical module, using 150mM potassium-phosphate mobile phase, pH=6.5 and 
ACQUITY UPLC Protein BEH SEC Column, 200Å. This method included fraction 
concentration steps in Amicon Ultra 50 kDa filter units, as thoroughly described in chapter 
material and methods for each of the sample types.   
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Figure 22: Chromatogram overlay from SEC-ÄKTA analysis of light stressed sample mAb1-LS (figure 
A) and freeze/thaw stressed sample mAb1-FT18 (figure B). Blue colour – chromatogram obtained on 
280 nm, red colour – chromatogram acquired on 260 nm and pink colour – chromatogram obtained on 
210 nm.  
Slika 22: Prilegani kromatogrami iz analize SEC-ÄKTA vzorca mAb1-LS izpostavljenega svetlobnem 
stresu (slika A) in vzorca izpostavljenega stresu zamrzovanja/odtajanja mASb1-FT18 (slika B). Modra 
barva – kromatogram pridobljen pri 280 nm, rdeča barva – kromatogram pridobljen pri 260 nm in 
roza barva – kromatogram pridobljen pri 210 nm. 
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Figure 23: A: Example of SEC-UPLC fraction collecting windows for total aggregates fraction 
(SumAP-mAb1-LS) and monomer fraction (MP-mAb1-LS) from multiple 50 µl injections of mAb1 
light stressed sample (mAb1-LS). After fraction collection step, concentration procedure with 50 kDa 
Amicon filter units was performed in order to obtain concentrated total aggregates fraction (SumAP-
mAb1-LS), which was then used for the purpose of individual aggregates fraction collection. B: SEC-
UPLC fraction collection windows for individual aggregates fractions (AP3-mAb1-LS, AP2-mAb1-LS 
and AP1-mAb1-LS) which originate from multiple 50 µl injections of concentrated total aggregates 
fraction (SumAP-mAb1-LS). 
Slika 23: A: Primer oken za zbiranje skupne agregatne (SumAP-mAb1-LS) in monomerne frakcije 
(MP-mAb1-LS) iz večkratnih 50 µl injiciranj vzorca mAb1, izpostavljenega svetlobnemu stresu 
(mAb1-LS) in analiziranega po SEC-UPLC metodi. Po koraku zbiranja frakcij, je izveden postopek 
koncentriranja s 50 kDa Amicon filtrirnimi enotami, z namenom pridobitve koncentrirane skupne 
agregatne frakcije (SumAP-mAb1-LS), ki smo jo nato uporabili za zbiranje frakcij za posamezne 
agregate. B: Okna za zbiranje posameznih agregatnih frakcij (AP3-mAb1-LS, AP2-mAb1-LS in AP1-
mAb1-LS), ki izvirajo iz večkratnih 50 µl injiciranj koncentriranih skupnih agregatnih frakcij 
(SumAP-mAb1-LS), analiziranih po SEC-UPLC metodi. 
All collected fractions (total aggregate fraction – SumAP, individual aggregates - AP3, 
AP2 and AP1 and monomer – MP fractions) from both types of mAb1 original material, 
light stressed sample – mAb1-LS and mAb1 sample after 18 freeze/thaw stressed cycles – 
mAb1-F/T18, have been reanalysed using described SEC-UPLC method and their 
concentrations have been determined using NanoDrop and Trinean systems. The results for 
fractions purity and protein concentration are presented in Table 9. 
 
 
 
 
 A 
B 
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Table 9: Results of SEC-UPLC analysis for collected fraction’s purity and protein concentration. 
Preglednica 9: Rezultati analize SEC-UPLC za čistost in koncentracijo proteinov v zbranih frakcijah. 
  
Fraction name Description 
Fraction's Purity (percentage of 
area under the curve) Protein 
concentration 
(mg/ml) AP3 AP2 AP1 Monomer DP 
F
re
ez
e/
th
aw
 s
tr
es
s 
sa
m
p
le
s 
SumAP-mAb1-F/T18 
Total aggregate fraction from 
mAb1-F/T18 
8.69 70.44 12.90 7.97 / 3.50 
MP-mAb1-F/T18 
Monomer fraction from mAb1-
F/T18 
/ 1.23 1.06 98.89 0.83 8.06 
AP3-mAb1-F/T18 
Individual AP3 aggregate 
fraction from mAb1-F/T18 
99.03 / / 0.97 / 0.17 
AP2-mAb1-F/T18 
Individual AP2 aggregate 
fraction from mAb1-F/T18 
/ 98.29 / 1.71 / 2.55 
AP1-mAb1-F/T18 
Individual AP1 aggregate 
fraction from mAb1-F/T18 
/ 28.37 71.63 / / 1.03 
  
  
  
  
  
  
 L
ig
h
t 
st
re
ss
 s
am
p
le
s 
SumAP-mAb1-LS 
Total aggregate fraction from 
mAb1-LS 
10.51 75.95 6.15 7.39 / 7.94 
MP-mAb1-LS 
Monomer fraction from mAb1-
LS 
0.06 4.05 1.29 93.59 0.12 6.90 
AP3-mAb1-LS 
Individual AP3 aggregate 
fraction from mAb1-LS 
97.80 / / 2.20 / 0.53 
AP2-mAb1-LS 
Individual AP2 aggregate 
fraction from mAb1-LS 
17.04 78.07 / 4.89 / 4.16 
AP1-mAb1-LS 
Individual AP1 aggregate 
fraction from mAb1-LS 
2.85 63.14 12.67 21.33 / 3.38 
 
Reanalysis of collected fraction of monomer, total and individual aggregate fractions 
showed that majority of sample fractions contained various aggregate types in different 
ratios, which may imply that some of aggregates may be reversible into other aggregate 
types or monomer mAb1 species. However, even though fraction collection window for 
individual aggregates was correctly set and each individual aggregate sample contains the 
majority aggregate of interest, it was expected that all individual fractions could be 
contaminated with other individual aggregate types or monomer, as both were present in 
far greater concentration in the original sample used for fraction collection. This would not 
significantly influence the results of the assays used for immunogenicity predictions, 
considering the fact that potentially immunogenic forms of mAb1 aggregates could also 
influence the response of dendritic (DC) and peripheral blood mononuclear cells (PBMC) 
when present in lower concentrations. 
4.3 SDS-PAGE RESULTS 
Obtained fractions have been further characterised using described SDS-PAGE separation 
with (R – Reduced) and without (NR – Non-reduced) the presence of reducer dithiothreitol 
- DTT. Electropherogram is presented in Figure 24, where different intensities of colouring 
correspond to concentration of each individual fraction. DTT interacts with mAb1’s 
disulphide bonds and separates heavy and light chains of both monomer and aggregates, 
therefore in all lines with present DTT (lines marked with R – reduced SDS PAGE) there 
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were two distinct protein marks which correspond to the molecular weight of heavy and 
light mAb1 chains. On the other hand, in lines with individual aggregate and monomer 
fraction from freeze/thaw (FT) and light stressed (LS) sample without DTT (lines marked 
with NR – non reduced SDS-PAGE), samples separated according to their charge and size 
of intact components. Given the differences in protein sizes and the structural similarity of 
components, it is expected that the monomer and aggregate signals could stretch and 
overlap with each other. This overlapping was specific in case of monomer component 
(MP) and its modified form (AP1).  
 
 
 
Figure 24: SDS-PAGE electrophoresis results of individual aggregate (AP3, AP2 and AP1) and 
monomer (MP) fraction of light stressed (LS) or freeze/thaw stressed mAb1 sample after 18 cycles 
(FT). Lines marked with R correspond to reduced samples, and those marked with NR to non-reduced 
samples. Molecular weight marker sizes in kDa are presented on the left. 
Slika 24: Rezultati SDS-PAGE za posameznege agregatne produkte (AP3, AP2 in AP1) in frakcije 
monomera (MP) vzorca mAb1, izpostavljenega svetlobnemu stresu (LS) ali stresu 
zamrzovanja/odtajanja po 18 ciklih (FT). Vrstice, označene z R, ustrezajo reduciranim vzorcem, in 
tiste, označene z NR, nereduciranim vzorcem. Markerji velikosti molekulske mase v kDa so označeni 
na levi strani. 
Moreover, in individual aggregate three lanes for both sample types (AP3-FT and AP3-
LS), fractions trimer (AP3) and monomer (MP) components were present. However, in 
individual aggregate two lanes for both sample types AP2-FT and AP2-LS, trimeric (AP3), 
dimeric (AP2) and monomer (MP) components were detected. On the opposite, in 
individual aggregate 1 fraction from freeze/thawed sample (AP1-FT) dimeric (AP2) and 
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modified monomeric form (AP1) components were observed, while in individual 
aggregate 1 fraction from light stressed sample (AP1-LS) fraction sample all types trimeric 
(AP3), dimeric (AP2), modified dimeric mAb1 aggregate (AP1) and monomeric forms 
were observed. Results from SDS-PAGE analysis were consistent to those from SEC 
UPLC characterization analysis, even though both analysis showed present traces of 
variety of aggregate forms in each individual fraction sample. However, required aggregate 
form of interest was present in greatest concentration. After all, this is due to additional 
sample handling and preparation for analysis and may also be the outcome of the processes 
of aggregate reversibility. 
4.4 RESULTS FROM SIZE EXCLUSION CHOMATOGRAPHY COUPLED WITH 
ORBITRAP MASS DETECTION 
Furthermore, same individual aggregate and monomer fractions from SEC-UPLC fraction 
collection have been desalted and 5 µg of each sample was analysed using instrument 
Thermo Scientific UltiMate 3000 UHPLC+ Focused and Thermo Scientific MAbPACTM 
Size Exclusion LC, 300 Å, 5 µm column heated on 30º C. Isocratic conditions at flow 0.2 
ml/min of mobile phase with composition: 20% acetonitrile / 0.1% formic acid / 0.05% 
tetrafluoroacetic acid were set and detection was obtained with Orbitrap Mass 
Spectrometry detector on instrument Thermo Scientific Q Exactive Plus. 
 
From example of chromatograms overlay (Figure 25) of Orbitrap MS signal, it was 
observed that high molecular weight variants (AP1, AP2 and AP3) were separated from 
monomer species and that they did not decompose to mAb1 monomer. The probable 
reason for this behaviour could be strong covalent aggregation (or even non-covalent one 
such as hydrophobic interactions) which 20% ACN in SEC-MS mobile phase was not 
capable of separating. Because of high molecular weight species, obtained spectra were not 
fully usable for identification by applying mathematical deconvolution, which obviously is 
beyond Orbitrap mass detector capability.  
 
Monomer fraction sample contains intact mAb1 protein with characteristic glycans. In 
Deconvoluted spectra molecular variants with adducts are visible, which are likely K+ ions 
from SEC UPLC mobile phase, which was used within fraction collection method (Figure 
26). On the spectra, mAb1 variants are present, which are mAb+ glycans (2xbG0, 
1xbG0+1xbG1, 2xbG1, 1xbG1+1xbG2). Difference in mass of approximately 38 Da is 
probably adduct of K+ ions from SEC-UPLC mobile phase. 
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Figure 25: Example overlay of SEC-MS chromatograms of individual monomer (black) and individual 
aggregate AP1 (red), AP2 (green) and AP3 (blue) fractions from light stressed mAb1 sample acquired 
by Orbitrap MS detector. 
Slika 25: Primer prileganih SEC-MS kromatogramov individualnega monomera (črna) in 
individualnih agregatnih frakcij AP1 (rdeča), AP2 (zelena) in AP3 (modra) iz vzorca mAb1 
izpostavljenega svetlobnemu stresu, pridobljenim z detektorjem Orbitrap MS.  
 
 
Figure 26: Deconvoluted spectra of individual monomer fraction of mAb1 light stressed sample 
obtained with Orbitrap Mass Spectrometry detection on instrument Thermo Scientific Q Exactive 
Plus. 
Slika 26: Dekonvuliran spekter posamezne monomerne frakcije mAb1 vzorca izpostavljenega 
svetlobnemu stresu, pridobljenega z metodo Orbitrap masne detekcije na instrumentu Thermo 
Scientific Q Exactive Plus. 
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In general, there was a lack of quality of the raw spectrum of the deconvolution procedure 
for all individual aggregate samples (AP1, AP2 and AP3) due to limitations for spectra for 
Orbitrap mass detector and used top-down approach (analysing of intact molecules without 
enzyme digestion). For example, measured signals from samples AP1-mAb1-LS, AP2-
mAb1-LS and AP3-mAb1-LS do not have sufficient resolution to allow proper 
identification of the proteins (Figures 27, 28, 29). Consequently, measured masses in 
deconvoluted spectra do not correspond to expected mAb1 protein variants, which is 
shown as an example for individual aggregate 1 from mAb1 light stressed samples (Figure 
27B).  
 
 
 
Figure 27: Orbitrap MS raw spectra (A) and deconvoluted spectra (B) of individual aggregate 1 (AP1) 
fraction of light stressed mAb1 sample.   
Slika 27: Orbitrap MS spekter (A) in dekonvuliran spekter (B) individualne agregatne 1 frakcije (AP1) 
vzorca mAb1 izpostavljenega svetlobnemu stresu. 
 
A: 
B: 
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Lack of quality of raw orbitrap MS spectra and consequently deconvolution procedure is 
observable also in the case of individual aggregates 2 and 3 on Figures 28 A, 28 B and 
Figure 29, as presented for mAb1 light stressed samples. 
  
 
 
 
Figure 28: Orbitrap MS raw spectra (A) and deconvoluted spectra (B) of individual aggregate 2 (AP2) 
fraction of light stressed mAb1 sample.   
Slika 28: Orbitrap MS spekter (A) in dekonvuliran spekter (B) individualne agregatne 2 frakcije (AP2) 
vzorca mAb1 izpostavljenega svetlobnemu stresu. 
 
A: 
B: 
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Figure 29: Orbitrap MS spectra from individual aggregate 3 (AP3) fraction of light stressed mAb1 
sample. 
Slika 29: Orbitrap MS spekter iz individualne agregatne 3 frakcije (AP3) vzorca mAb1 izpostavljenega 
svetlobnemu stresu. 
The reason for this behaviour of individual aggregate samples compared to monomer 
samples may be specific aggregation, which a mobile phase is not able to break or because 
of the remains of mobile phase from the SEC fraction collection analysis. However, 
molecular masses of intact aggregates may be outside of MS detection range that implies 
that SEC MS Orbitrap analysis is not fully suitable for aggregate characterization and 
therefore proposed alternative methods should be used. In addition, initial intent was to 
analyse intact mAb1 molecule and its aggregates within top-down approach and do not 
perform additional enzymatic digestion. However, mAb1 aggregate ions must have been 
considerately large for the detection capacity of orbitrap mass spectrometer.  
4.5 HYDROPHOBIC INTERACTION CHROMATOGRAPHY RESULTS 
Even though SEC method is capable of separating different types of entities: aggregates 
(AP3, AP2 and AP1), monomer species (MP) and degradation products (DP) that have 
different hydrodynamic radii, for which separation on SEC columns occurs, this method 
does not provide an information about chemical differences between same types of entities 
with approximately same hydrodynamic radii (for example AP2 fraction from light 
stressed sample and AP2 fraction from freeze/thaw stressed sample). Thus, tested HIC-
HPLC method showed a great potential for characterization of fractions, since it was 
considered as orthogonal method in comparison to SEC method by providing additional 
information about chemical interactions of mAb1 aggregate groups with TSK gel Bythul 
matrix. Interactions of aggregates were enhanced using described gradient elution of 1.5 M 
ammonium-sulphate and 50 mM sodium-phosphate mobile phases. Upon injections of 50 
µg of samples, differences between fraction samples were observed in the presence of 
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Main Hydrophobic Variants (MHV) and different High Molecular Weight Hydrophobic 
Variants (HMWHV) which correspond to aggregate forms. For instance, pure fraction of 
monomer peak of original mAb1 sample (not stressed sample: MP-mAb1), monomer peak 
from light stressed sample (MP-mAb1-LS) and monomer fraction from stressed mAb1 
sample after 18 cycles (MP-mAb1-F/T18), which were all obtained by SEC-UPLC fraction 
collection method, were analysed with HIC method and chromatograms are showed in 
Figure 30. It is evident that monomer fraction from light stressed sample (MP-mAb1-LS) 
has two chemical entities (main hydrophobic variants: MHV and MHV1, corresponding to 
monomer) and are visible in HIC method chromatogram. Latter may be due to chemical 
modification of original mAb1 sample during light stress (Table 10). On opposite side, 
monomer fraction of original sample and freeze/thaw stressed sample was apparent as only 
one main hydrophobic variant MHV (Figure 30, Table 10). Therefore, the same entity, 
which was separated by similar hydrodynamic radii with SEC method, has a potential for 
further chemical characterization with proposed HIC method. 
 
 
Figure 30: Overlaid chromatograms from sample fractions obtained with SEC-UPLC method of 
monomer peak of original mAb1 sample (not stressed sample: MP-mAb1 – green colour), monomer 
peak from light stressed sample (MP-mAb1-LS – blue colour) and monomer fraction from stressed 
mAb1 sample after 18 cycles (MP-mAb1-F/T18 – black colour). 
Slika 30: Prilegani kromatogrami iz frakcij vzorca, pridobljenih z metodo SEC-UPLC monomernega 
vrha prvotnega vzorca mAb1 (vzorec, ki ni bil izpostavljen stresu: MP-mAb1 – zelena črta), vrha 
monomera vzorca, izpostavljenega svetlobnemu stresu (MP-mAb1-LS – modra črta), in monomerne 
frakcije mAb1 vzorca, izpostavljenega stresu po 18 ciklih (MP-mAb1-F/T18 – črna črta).  
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Moreover, described HIC method has a capacity of separating different High Molecular 
Weight Hydrophobic Variants (HMWHV – which correspond to different aggregate forms 
in analogue to SEC results), Main Hydrophobic Variant (MHV – which correlate to 
monomer peak from SEC analysis) and Low Molecular Weight Hydrophobic Variants 
(LMWHV – which are comparable to degradation products from SEC analysis). 
Differences in present HMWHV types (HMWHV 1 to 6) and its amounts are specific for 
each of the aggregate types from different fraction collected samples obtained using SEC-
UPLC fraction collection method (Figure 31, Table 10). Accordingly, capacity of HIC 
method to further separate different mAb1 aggregates, monomer or degradation products 
species by their chemical characteristics shows great potential for supplementary 
characterization.  
 
 
Figure 31: Example of overlaid chromatograms obtained by HIC method of individual aggregate 
fractions AP3-mAb1-F/T18 – red colour, AP2-mAb1-F/T18 – blue colour, AP1-mAb1-F/T18 – green 
colour and total mAb1 aggregates fractions of freeze/thawed stressed sample SumAP-mAb1-F/T18 – 
black colour. 
Slika 31: Primer prileganih kromatogramov, pridobljenih z metodo HIC iz skupnih agregatnih frakcij 
vzorca mAb1, izpostavljenega stresu zamrzovanja/odtajanja – SumAP-mAb1-F/T18 – črna črta in 
posamezne agregatne frakcije: AP1-mAb1-F/T18 – zelena črta, AP2-mAb1-F/T18 – modra črta in 
AP3-mAb1-F/T18 – rdeča črta. 
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Table 10: HIC analysis Area percentage results and retention times (Rt) of monomer (MP), individual 
aggregates (AP1, AP2 and AP3) and total aggregate (SumAP) fractions from original sample, which 
was not stressed (mAb1), light stressed sample (mAb1-LS) and freeze/thawed sample after 18 cycles 
(mAb1-F/T18). 
Preglednica 10: Rezultati analize HIC za odstotek površine in retencijskih časov (Rt) monomera (MP), 
posameznih agregatnih produktov (AP1, AP2 in AP3) in skupnih agregatnih frakcij (SumAP) iz: 
prvotnega vzorca, ki ni bil stresiran (mAb1), vzorca svetlobnega stresa (mAb1-LS) in vzorca 
zamrzovanja/odtajanja po 18 ciklih (mAb1-F/T18). 
Sample Name 
MHV MHV 1 HMWHV 1 HMWHV 2 HMWHV 3 HMWHV 4 HMWHV 5 HMWHV 6 
% 
Area 
Rt 
(min) 
% 
Area 
Rt 
(min) 
% 
Area 
Rt 
(min) 
% 
Area 
Rt 
(min) 
% 
Area 
Rt 
(min) 
% 
Area 
Rt 
(min) 
% 
Area 
Rt 
(min) 
% 
Area 
Rt 
(min) 
MP-mAb1-F/T18 98.18 7.38 / / / / 1.78 8.51 / / / / 0.03 11.25 0.01 11.47 
AP3-mAb1-F/T18 1.91 7.69 / / / / / / 30.71 9.04 54.06 9.87 13.29 10.89 / / 
AP2-mAb1-F/T18 2.96 7.64 / / 10.67 8.11 61.66 8.49 / / 20.01 9.42 4.70 11.12 / / 
AP1-mAb1-F/T18 4.97 7.65 / / 8.11 8.13 66.53 8.58 / / 15.29 9.33 5.11 11.01 / / 
SumAP-mAb1- 
F/T18 
17.03 7.51 / / 6.13 7.89 52.04 8.47 / / 19.72 9.43 5.07 11.08 / / 
MP-mAb1-LS 51.63 7.19 45.97 7.40 2.41 8.17 / / / / / / / / / / 
AP3-mAb1-LS 0.86 7.68 0.86 7.49 / / / / 33.73 8.75 53.39 9.50 11.16 10.88 / / 
AP2-mAb1-LS 2.47 7.36 / / 81.20 8.21 / / / / 13.37 9.50 2.96 10.75 / / 
AP1-mAb1-LS 5.02 7.58 7.56 7.38 74.93 8.23 / / / / 9.18 9.08 3.31 10.36 / / 
SumAP-mAb1- 
LS 
2.19 7.54 4.38 7.39 74.81 8.18 / / / / 15.53 9.52 3.08 10.73 / / 
MP-mAb1 98.63 7.36 / / / / 1.35 8.47 / / / / 0.02 11.27 / / 
Mean / 7.51 / 7.42 / 8.13 / 8.50 / 8.90 / 9.46 / 10.93 / 11.47 
σ 
 
0.16 
 
0.05 
 
0.11 
 
0.05 
 
0.21 
 
0.22 
 
0.28 
 
/ 
%RSD 2.16 0.64 1.39 0.56 2.31 2.33 2.52 / 
 
Both individual fractions of aggregate three from freeze/thaw sample (AP3-mAb1-F/T18) 
and light stressed sample (AP3-mAb1-LS) contain HMWHV 3, 4 and 5. Individual 
fraction of aggregate two from freeze/thaw sample (AP2-mAb1-F/T18) contains HMWHV 
1, 2, 4 and 5 in comparison to individual fraction of aggregate two from light stressed 
sample (AP2-mAb1-LS) which contains HMWHV 1, 4 and 5. This contributes to the fact 
that even though the same fraction type is separated using SEC principles, HIC method is 
capable of further separation of similar aggregate types by their chemical properties. This 
was also the case in individual aggregate fraction one from freeze/thaw stressed sample 
(AP1-mAb1-F/T18) for which HMWHV peaks 1, 2, 4 and 5 were present, whereas for 
aggregate fraction 1 from light stressed sample (AP1-mAb1-LS) only HMWHV peaks 1, 4 
and 5 were observed. As the HIC method is capable of separating protein entities by its 
chemical properties, retention time of each of the peaks determines the potential presence 
of different protein entities and thus can be used as an additional characterization marker 
(Table 10). 
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4.6 RESULTS FROM IN VITRO DC MATURATION ASSAYS 
After analytical characterization of aggregate entities, in vitro immunological assays were 
performed on dendritic cells (DC) and peripheral blood mononuclear cells (PBMC) using 
individual monomer (MP) and aggregate (AP1, AP2 and AP3) fractions from mAb1 light 
stressed (mAb1-LS) and freeze/thaw stressed sample after 18 cycles (mAb1-F/T18). 
 
Firstly, immunogenicity of total aggregates and monomer fractions was evaluated using 
described DC assay by fraction’s potential for upregulation of DC-cell co-stimulatory 
molecules CD40, CD80, CD86, CCR7 and HLA-DR. Obtained results were compared to 
LPS, sample medium (buffer) and non-treated cells, which were used as controls. 
Incubation of DC was performed at final concentration of 100 µg/ml of each total 
aggregate sample fraction. Maturation process was monitored by immunophenotyping 
using fluorescence activated cell sorting analysis (FACS) and results are presented in 
Figure 32. 
 
Figure 32: Mean fluorescence intensity (MFI) values for determining expression of dendritic cell’s 
CD40, CD80, CD86, CCR7 and HLA-DR markers for total aggregate fractions (SumAP) from mAb1 
light stressed (mAb1-LS) and freeze/thaw stressed mAb1 sample after 18 cycles (mAb1-F/T18). One 
representative experiment out of three independent experiments is shown. Numbers within histograms 
represent the mean fluorescence values (MFIs). 
Slika 32: Srednje vrednosti intenzivnosti fluorescence (MFI – mean fluorescence intensity) za določanje 
izražanja CD40, CD80, CD86, CCR7 na dendritičnih celicah in markerjev HLA-DR za skupne 
agregatne frakcije (SumAP), iz vzorca svetlobnega stresa mAb1 (mAb1-LS) in vzorca mAb1 po 18 
ciklih zamrzovanja/odtajanja (mAb1-F/T18). Prikazan je en reprezentativni eksperiment izmed treh 
neodvisnih eksperimentov. Številke v histogramih predstavljajo povprečne vrednosti fluorescence 
(MFI). 
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Secondly, individual monomer (MP) and aggregate (AP1, AP2 and AP3) fractions from 
mAb1 light stressed (mAb1-LS) and freeze/thaw stressed sample after 18 cycles (mAb1-
F/T18) had undergone the same assay and potential upregulation of dendritic cells’ 
markers CD40, CD80 and CD86 was evaluated. Incubation was performed at final 
concentration of 100 µg/ml for all samples, except for aggregate three fraction from light 
stressed sample (AP3-mAb1-LS) for which incubation was performed at final sample 
concentration of 50 µg/ml. In addition, aggregate 3 fraction from freeze/thaw stressed 
sample (AP3-mAb1-F/T18) incubation was performed at final sample concentration of 10 
µg/ml. Both light stressed and freeze/thaw stressed individual aggregate three fractions 
have lower protein concentrations, thus the DC assay incubations had to be performed at 
lower concentrations. Results for individual monomer and aggregates from mAb1 
freeze/thaw stressed sample after 18 cycles (mAb1-F/T18) are shown in Figure 33, while 
the results from light stressed (mAb1-LS) fractions were presented in Figure 34. 
 
Similarly as with the previous results from DC assay from total aggregate fractions, also 
individual monomer and aggregate fractions from freeze/thaw stressed sample did not 
greatly induce immunogenic maturation of DC cells by means of upregulation of markers 
CD40, CD80 and CD86 (Figure 33). However, all individual aggregate fractions (AP1, 
AP2 and AP3) from freeze/thaw stressed sample show only slight upregulation of CD40 
and CD80 marker, which obviously are more sensitive in comparison to CD86 marker. 
 
As it can be seen from the results for individual aggregate and monomer fractions from 
mAb1 light stressed sample (Figure 34), also individual aggregate fractions from light 
stressed samples do not greatly induce immunogenic maturation of DC by means of 
upregulation of markers CD40, CD80 and CD86. However, results of individual aggregate 
fractions from LS sample show only slight upregulation of CD40 in case of aggregate peak 
2 (AP2) fraction. In addition, also AP1 aggregate fraction shows only slight upregulation 
of CD80 and CD86. Furthermore, AP1 aggregate fraction induces considerate upregulation 
of CD40 marker. Since all aggregate fractions are not completely pure and contain 
different ratio of other aggregates or monomer, these results from DC assay lead to 
conclusion that immunogenicity potential of aggregates for activation DC cells may also be 
dependent of their chemical structure as well as the present combination and ratio of 
different individual aggregates. 
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Figure 33: Dendritic cell assay results of expression of CD40, CD80 and CD86 markers from 
individual monomer (MP) and aggregate (AP1, AP2 and AP3) fractions from mAb1 stressed sample 
after 18 freeze/thaw cycles (mAb1-F/T18). LPS abbreviation was used for lipopolysaharide control and 
NT for non-treated cells. One representative experiment out of three independent experiments is 
shown. Numbers within histograms represent the mean fluorescence values (MFIs). 
Slika 33: Rezultati na testa dendritičnih celicah, ki prikazujejo ekspresijo markerjev CD40, CD80 in 
CD86, ki jih sprožijo individualni monomeri (MP) in agregatne frakcije (AP1, AP2 in AP3) iz vzorca 
mAb1, ki je izpostavljen stresu po 18 ciklov zamrzovanja/odtajanja (mAb1-F/T18). Okrajšava »LPS« 
je uporabljena za kontrolno tretiranje z lipopolisaharidi in kratica za »NT (non-treated)« je 
uporabljena za netretirane celice. Prikazan je en reprezentativni eksperiment izmed treh neodvisnih 
eksperimentov. Številke v histogramih predstavljajo povprečne vrednosti fluorescence (MFI). 
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Figure 34: Dendritic cell assay results of expression of CD40, CD80 and CD86 markers from 
individual monomer (MP) and aggregate (AP1, AP2 and AP3) fractions from mAb1 light stressed 
sample (mAb1-LS). LPS abbreviation was used for lipopolysaharide control and NT for non-treated 
cells. One representative experiment out of three independent experiments is shown. Numbers within 
histograms represent the mean fluorescence values (MFIs). 
Slika 34: Rezultati ekspresije markerjev CD40, CD80 in CD86 testa dendritičnih celic iz individualne 
monomerne frakcije (MP) in agregatnih frakcij (AP1, AP2 in AP3) vzorca svetlobnega stresa mAb1 
(mAb1-LS). Okrajšava »LPS« je uporabljena za kontrolo lipopolisaharidov in kratica »NT (non-
treated)« je uporabljena za netretirane celice. Prikazan je en reprezentativni eksperiment izmed treh 
neodvisnih eksperimentov. Številke v histogramih predstavljajo povprečne vrednosti fluorescence 
(MFI). 
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4.7 RESULTS FROM IN VITRO DC STIMULATION ASSAYS 
In order to determine the capacity of stimulated DC to produce pro-inflammatory 
cytokines, DC supernatants after 48 hours of incubation with total aggregate fractions were 
performed at final concentration of 100 µg/ml. After incubation with total aggregate 
samples (SumAP) from mAb1 light stressed (mAb1-LS) and freeze/thaw stressed sample 
after 18 cycles (mAb1-F/T18), DC supernatants were analysed for the presence of IL-10 
(known as human cytokine synthesis inhibitory factor – CSIF), IL-8 (known as neutrophil 
chemotactic factor), and other pro-inflammatory cytokine response of IL-1β, IL-6, IL-
12p70 and TNF-α. Cytokine levels in the supernatants were analysed by flow cytometry 
using Cytometric Bead Array (CBA) Kit (BD biosciences) and results are presented as 
mean fluorescence intensity (Table 11, Figure 35). 
 
The results confirm that total aggregate samples from mAb1 freeze/thaw and light stress 
samples do not influence immune response by inducing production of cytokines IL-10, IL-
1β, TNFα, IL-12p70 by DC cells. Only minor upregulation of DC cell cytokine production 
of both total aggregate samples from freeze/thaw and light stressed samples for IL6 and 
IL8 was observed, but their values are not as high as LPS control. 
 
Table 11: Mean fluorescence intensity results for dendritic cell cytokines analysis after incubation with 
total aggregate fractions (SumAP) from mAb1 light stressed sample (SumAP-LS) and mAb1 sample 
after 18 freeze/thaw cycles (SumAP-F/T18). Lipopolysaharide – LPS, sample buffer and non-treated 
cells (NT) were used as controls. Data used to compile this table is provided within Appendix A in 
Appendices section. 
Preglednica 11: Povprečne vrednosti intenzitete fluorescence pri analizi citokinov iz dendritičnih celic 
po inkubaciji s skupnimi agregatnimi frakcijami (SumAP) iz mAb1 vzorca, ki je bil izpostavljen 
svetlobnemu stresu (SumAP-LS) in vzorca mAb1 po 18 ciklih zamrzovanja/odtajanja (SumAP-F/T18). 
Lipopolisaharid - LPS, vzorčni pufer in ne-tretirane celice (NT) so uporabljeni kot kontrolni vzorci. 
Podatki, uporabljeni za pripravo te tabele, so podani v Dodatku A v Dodatkih. 
Mean values for DC cytokines (pg/ml) 
Cytokine 
type 
NT LPS Buffer SumAP-F/T18 SumAP-LS 
IL12p70 19.00 ± 4.20 54.43 ± 9.90 15.67 ± 2.15 16.67 ± 3.05 15.70 ± 3.01 
TNFα 31.77 ± 3.51 448.67 ± 33.83 30.67 ± 4.01 29.40 ± 5.31  27.73 ± 8.02 
IL-10 42.30 ± 9.62 697.33 ± 164.26 45.10 ± 8.85 47.07 ± 9.58 41.70 ± 7.51 
IL-6 90.73 ± 10.01 15600.33 ± 2932.57 90.37 ± 13.30 118.33 ± 21.94 96.33 ± 11.21 
IL-1β 82.57 ± 18.91 119.47 ± 26.87 82.07 ± 11.95 88.87 ± 12.36 89.37 ± 8.82 
IL-8 417.00 ± 44.91 17459.67 ± 4337.63 261.33 ± 79.48 662.00 ± 157.77 314.33 ± 31.56 
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Figure 35: Graphical representation of dendritic cell cytokines analysis after incubation with total 
aggregate fractions (SumAP) from mAb1 light stressed sample (LS) and mAb1 sample after 18 
freeze/thaw cycles (FT18). LPS abbreviation was used for Lipopolysaccharide control and “NT” for 
non-treated cells. 
Slika 35: Grafična predstavitev analize citokinov dendritičnih celic po inkubaciji s skupnimi 
agregatnimi frakcijami (SumAP) iz vzorca mAb1, vzorca izpostavljenega svetlobnemu stresu (LS) in 
vzorca mAb1, po 18 ciklih zamrzovanja/odtajanja (FT18). Okrajšava »LPS« je uporabljena za 
kontrolo z lipopolisaharidom in kratica »NT« je uporabljena za netretirane celice. 
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Total aggregates samples from light stressed and freeze/thaw stressed mAb1 protein 
contain mixture of three individual aggregates AP1, AP1 and AP3. As this was shown not 
to influence significant immunogenic response, a step further in understanding the 
potential for immunogenicity of separated individual aggregates was required. Hence, in 
order to compare immunogenicity potential of total aggregate and individual aggregates 
paralel DC cytokines assay has been performed. DC supernatants after 48 hours of 
incubation with all samples at final concentration of 100 µg/ml were performed, except for 
aggregate 3 fraction from light stressed sample (AP3-mAb1-LS) for which incubation was 
performed at final sample concentration of 50µg/ml. Similarly, aggregate 3 fraction from 
freeze/thaw stressed sample (AP3-mAb1-F/T18) incubation was performed at final sample 
concentration of 10µg/ml. Both light stressed and freeze/thaw stressed individual aggregate 
3 fractions have lower protein concentrations, thus the DC cytokine assay incubations had 
to be performed at lower concentrations. The results are presented in Table 12 and Figure 
36. 
 
Table 12: Mean fluorescence intensity results for dendritic cell cytokines analysis after incubation with 
total aggregate fractions from mAb1 light stressed sample (SumAP-LS), freeze/thaw stressed sample 
(SumAP-F/T) and their individual aggregates (AP1, AP2 and AP3). Lipopolysaharide (LPS), sample 
buffer and non-treated cells (NT) were used as controls. Data used to compile this table is provided in 
Appendix B within Appendices section. 
Preglednica 12: Povprečne vrednosti intenzitete fluorescence pri analizi citokinov dendritičnih celic po 
inkubaciji s skupnimi agregatnimi frakcijami iz vzorca mAb1, izpostavljenega svetlobnemu stresu 
(SumAP-LS), vzorca izpostavljenega stresu zamrzovanja/odtajanja (SumAP-F/T) in njihovih 
individualnih agregatov (AP1, AP2 in AP3). Lipopolisaharid - LPS, vzorčni pufer in ne-tretirane celice 
(NT) so uporabljeni kot kontrolni vzorci. Podatki, uporabljeni za pripravo te tabele, so podani v 
Dodatku B v Dodatkih. 
Mean values for DC cytokines (pg/ml) 
Cytokine 
type 
NT Buffer LPS SumAP- F/T 
SumAP- 
LS 
IL-12p70 7.7 ± 0.3 7.5 ± 0.1 79.1 ± 10.0 7.5 ± 0.3 7.3 ± 0.3 
TNFα 10.6 ± 1.7 10.8 ± 0.6 140.8 ± 22.6 11.2 ± 0.4 18.4 ± 3.8 
IL-10 9.9 ± 2.1 11.8 ± 0.4 18.3 ± 1.2 12.5 ± 0.6 11.5 ± 0.7 
IL-6 19.7 ± 1.0 19.1 ± 0.4 2662.7 ± 518.7 18.6 ± 1.2 18.7 ± 1.6 
IL-1β 20.6 ± 1.1 19.8 ± 0.4 20.8 ± 0.4 20.7 ± 1.1 20.7 ± 0.8 
IL-8 54.1 ± 5.5 52.9 ± 10.4 5878.5 ± 261.7 89.1 ± 13.3 416.4 ± 196.9 
 
Mean values for DC cytokines (pg/ml) 
Cytokine 
type 
AP3-FT AP2-FT AP1-FT AP3-LS AP2-LS AP1-LS 
IL-12p70 6.9 ± 0.4 7.4 ± 0.2 7.3 ± 0.1 7.4 ± 0.2 7.6 ± 0.2 7.5 ± 0.1 
TNFα 13.1 ± 2.1 13.2 ± 2.1 13.1 ± 0.5 11.3 ± 0.8 10.9 ± 1.3 16.9 ± 4.0 
IL-10 14.0 ± 1.7 11.9 ± 0.5 12.1 ± 0.1 10.6 ± 1.9 11.6 ± 0.7 12.2 ± 0.4 
IL-6 19.4 ± 0.7 19.4 ± 0.8 17.9 ± 2.4 18.8 ± 0.5 18.7 ± 1.6 19.1 ± 0.9 
IL-1β 20.4 ± 0.9 20.0 ± 0.4 19.9 ± 0.3 20.1 ± 0.5 18.8 ± 1.3 19.9 ± 0.2 
IL-8 83.3 ± 8.0 105.6 ± 40.1 92.3 ± 36.9 72.1 ± 33.8 59.6 ± 20.7 253.4 ± 146.0 
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Figure 36:  Graphical representation of dendritic cell cytokines analysis after incubation with total 
aggregate fractions (SumAP) and individual aggregate fractions (AP3, AP2 and AP1) from mAb1 light 
stressed sample (LS) or mAb1 sample after 18 freeze/thaw cycles (FT). LPS abbreviation was used for 
Lipopolysaccharide control and “nt” for non-treated cells. One representative experiment out of three 
independent experiments is shown. Numbers within histograms represent the mean fluorescence 
values (MFIs). 
Slika 36: Grafična predstavitev analize citokinov iz dendritičnih celic po inkubaciji s skupnimi 
agregatnimi frakcijami (SumAP) in individualnimi frakcijami agregatov (AP3, AP2 in AP1) iz vzorca 
svetlobnega stresa mAb1 (LS) in vzorca mAb1 po 18 ciklih zamrzovanja/odtajanja (FT). Okrajšava 
»LPS« je uporabljena za kontrolo z lipopolisaharidom in kratica za »nt« je uporabljena za netretirane 
celice. Prikazan je en reprezentativni eksperiment od treh neodvisnih eksperimentov. 
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Results confirm that total aggregate samples from mAb1 freeze/thaw and light samples do 
not influence immune response by inducing production of cytokines IL-1β, IL-10, TNFα, 
IL-12p70 by DC cells. Only minor upregulation of DC cell cytokine production of both 
total aggregate samples from freeze/thaw and light stressed samples for IL8, IL10 and 
TNFα was observed, but their values are not as high as LPS control. Accordingly, for 
individual aggregate fractions AP1-LS and AP2-FT slight upregulation of IL8 and TNFα 
was noticed, however response of DC cells was not as high as any positive control. 
4.8 RESULTS FROM IN VITRO PBMC STIMULATION ASSAY 
With the aim to evaluate potential innate immune response of peripheral blood 
mononuclear cells (PBMC) cultures to mAb1 aggregates, IL-10 (human cytokine synthesis 
inhibitory factor – CSIF), IL-8 (neutrophil chemotactic factor), and other pro-inflammatory 
PBMC cytokine response of IL-1β, IL-6, IL-12p70 and TNF-α were measured during early 
exposure up to 48 hours within the proposed PBMC assay. Incubation of PBMC cells was 
performed with all samples at final concentration of 100 µg/ml, except for aggregate 3 
fraction from light stressed sample (AP3-mAb1-LS) for which incubation was performed 
at final sample concentration of 50 µg/ml. Moreover, aggregate three fraction from 
freeze/thaw stressed sample (AP3-mAb1-F/T18) incubation was performed at final sample 
concentration of 10 µg/ml. Since both light stressed and freeze/thaw stressed individual 
AP3 fractions have lower protein concentrations, so the incubations had to be performed at 
lower concentrations. Then, multiple cytokines were measured simultaneously using CBA 
Kit and results were analysed by flow cytometry. Results are presented in Table 13 and 
Figure 37. 
 
No significant rise in cytokine production was observed in total (SumAP) and individual 
aggregate (AP1, AP2, AP3) and monomer (MP) fractions from mAb1 freeze/thaw and 
light stressed samples. However, in comparison to non-treated PBMC cells slight rise was 
observed of TNFα for AP3-LS sample, of IL-10 for SumAP-FT sample and of IL-1β for 
SumAP-LS and MP-FT samples. Moreover, in comparison to non-treated PBMC cells 
greater rise was noticed of IL-6 for samples: AP2-FT, AP1-FT, AP3-LS, AP2-LS and rise 
of IL-8 for samples: SumAP-FT, SumAP-LS, MP-FT, MP-LS, AP3-FT, AP2-FT and AP1-
FT. 
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Table 13:  Results for PBMC cytokines analysis after incubation with total aggregate fractions from 
mAb1 light stressed sample (SumAP-LS) and mAb1 sample after 18 freeze/thaw cycles (SumAP-F/T). 
Table also contains PBMC assay results for individual monomer (MP) and aggregate (AP1, AP2 and 
AP3) from mAb1 light stressed sample (LS) and mAb1 sample after 18 freeze/thaw cycles (FT).  
Lipopolysaccharide – LPS, sample buffer, and non-treated cells (NT) were used as controls. The data 
used to compile this table is provided within Appendix C in Appendices section. 
Preglednica 13:  Rezultati analize citokinov iz PBMC po inkubaciji s skupnimi agregatnimi frakcijami 
iz mAb1 vzorca izpostavljenega svetlobnem stresu (SumAP-LS) in mAb1 vzorca po 18 ciklih 
zamrzovanja/odtajanja (SumAP-F/T). Tabela vsebuje tudi rezultate PBMC analize za posamezne 
monomerne (MP) in agregatne frakcije (AP1, AP2 in AP3) iz vzorca mAb1 izpostavljenega 
svetlobnemu stresu (LS) in vzorca mAb1, po 18 ciklih zamrzovanja/odtajanja (FT). Lipopolisaharid - 
LPS, vzorčni pufer in ne-tretirane celice (NT) so bili uporabljeni kot kontrolni vzorci. Podatki, 
uporabljeni za pripravo te tabele, so podani v Dodatku C v Dodatkih. 
 
Mean values for PBMC cytokines (pg/ml) 
Cytokine 
type 
NT LPS Buffer 
SumAP-
F/T 
SumAP-LS MP-FT MP-LS 
IL12p70 7.6 ± 1.4 9.6 ± 2.2 7.7 ± 0.9 7.7 ± 1.45 7.7 ± 1.2 7.8 ± 1.4 8.3 ± 1.6 
TNFα 13.3 ± 2.6 290.4 ± 52.1 12.2 ± 1.8 13.2 ± 1.3 13.6 ± 2.4 11.9 ± 1.3 13.6 ± 2.6 
IL-10 16.6 ± 3.6 306.0 ± 84.1 15.6 ± 1.4 18.1 ± 2.6 16.5 ± 2.6 17.4 ± 3.7 16.7 ± 4.5 
IL-6 29.5 ± 5.8 8881.7 ± 1905.9 30.9 ± 8.8 29.2 ± 4.5 31.0 ± 5.1 29.8 ± 2.6 30.1 ± 2.9 
IL-1ß 35.9 ± 4.5 774.3 ± 200.9 36.6 ± 5.0 33.5 ± 4.6 37.1 ± 4.5 37.1 ± 6.5 33.9 ± 4.9 
IL-8 64.2 ± 23.6 9010.3 ± 1964.4 67.8 ± 25.0 79.9 ± 19.4 76.7 ± 20.4 77.4 ± 19.9 105.0 ± 24.5 
 
Mean values for PBMC cytokines (pg/ml) 
Cytokine  
type 
AP3-FT AP2-FT AP1-FT AP3-LS AP2-LS AP1-LS 
IL12p70 7.4 ± 1.9 8.1 ± 2.0 7.5 ± 1.4 8.4 ± 1.3 8.2 ± 1.3 7.7 ± 1.3 
TNFα 12.7 ± 1.6 12.0 ± 1.0 13.1 ± 2.6 15.7 ± 1.6 12.7 ± 1.6 12.7 ± 1.2 
IL-10 16.2 ± 3.1 15.4 ± 4.1 14.9 ± 2.3 14.7 ± 2.4 16.4 ± 3.0 17.6 ± 1.1 
IL-6 29.1 ± 4.2 30.9 ± 8.4 34.3 ± 6.7 33.3 ± 4.3 32.5 ± 4.5 27.5 ± 6.2 
IL-1ß 34.7 ± 2.0 36.0 ± 3.5 35.0 ± 3.8 35.1 ± 3.6 34.3 ± 2.7 32.7 ± 5.8 
IL-8 113.5 ± 37.1 73.5 ± 24.3 102.9 ± 25.7 55.7 ± 21.1 58.5 ± 16.7 63.8 ± 22.1 
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Figure 37: Graphical representation of PBMC cytokines assay results after incubation with total 
aggregate fractions (SumAP), individual monomer fractions (MP) and individual aggregate fractions 
(AP3, AP2 and AP1) from mAb1 light stressed sample (LS) and mAb1 sample after 18 freeze/thaw 
cycles (FT). Lipopolysaccharide – LPS, sample buffer and non-treated cells (NT) were used as controls. 
One representative experiment out of three independent experiments is shown. Numbers within 
histograms represent the mean fluorescence values (MFIs). 
Slika 37: Grafična predstavitev analize citokinov kulture mononuklearnih celic periferne krvi (PBMC) 
po inkubaciji s skupnimi agregatnimi frakcijami (SumAP) in individualnimi agregatnimi frakcijami 
(AP3, AP2 in AP1) iz vzorca svetlobnega stresa mAb1 (LS) in vzorca mAb1 po 18 ciklih 
zamrzovanja/odtajanja (FT). Okrajšava »LPS« je uporabljena za kontrolo z lipopolisaharidom in 
kratica za »nt« je uporabljena za netretirane celice. Prikazan je en reprezentativni eksperiment od 
treh neodvisnih eksperimentov. 
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4.9 RESULTS FROM IN VITRO PBMC PROLIFERATION ASSAY 
PBMC cell proliferation assay also did not show any significant influence on tested total 
and individual aggregate fractions from both light and freeze-thaw stressed samples (Table 
14, Figure 38). Among other results, only aggregate fraction 1 from freeze/thaw stressed 
mAb1 sample (AP1-FT) had slightly higher cell count number per minute (mean value 
631.3 ± 369.8) comparing to non-treated PBMC cell culture (mean value 411.0 ± 77.0). 
Results for AP1-FT fractions were still in the range of buffer control (mean value 641.3 ± 
179.5) and not as high as immunogenic PHA (mean value 30606.0 ± 744.4). 
 
Table 14: Results for PBMC proliferation assay after incubation with total aggregate fractions from 
mAb1 light stressed sample (SumAP-LS) and mAb1 sample after 18 freeze/thaw cycles (SumAP-F/T). 
Table also contains PBMC assay results for individual monomer (MP) and aggregates (AP1, AP2 and 
AP3) from mAb1 light stressed sample (LS) and mAb1 sample after 18 freeze/thaw cycles (FT).  
Phytohemagglutinin (PHA), sample buffer, and non-treated cells (NT) were used as controls. Data 
used to compile this table is provided within Appendix D in Appendices section. 
Preglednica 14: Rezultati analize proliferacije PBMC po inkubaciji s skupnimi agregatnimi frakcijami 
iz vzorca mAb1 izpostavljenega svetlobnemu stresu (SumAP-LS) in vzorca mAb1 po 18 ciklih 
zamrzovanja/odtajanja (SumAP-F/T). Tabela vsebuje tudi rezultate PBMC analize za posamezne 
monomere (MP) in agregate (AP1, AP2 in AP3) iz vzorca mAb1 izpostavljenega svetlobnemu stresu 
(LS) in vzorca mAb1, po 18 ciklih zamrzovanja/odtajanja (FT). Fitohemaglutinin (PHA), vzorčni pufer 
in ne-tretirane celice (NT) so uporabljeni kot kontrolni vzorci. Podatki, uporabljeni za pripravo te 
tabele, so podani v Dodatku D v Dodatkih. 
 
Mean values for PBMC proliferation (counts/min) 
NT Buffer PHA SumAP- F/T SumAP-LS 
411.0 ± 77.0 641.3 ± 179.5 30606.0 ± 744.4 371.0 ± 148.0 320.7 ± 102.5 
     
 
 
 
 
Mean values for PBMC proliferation (counts/min) 
AP3-FT AP2-FT AP1-FT AP3-LS AP2-LS AP1-LS 
230.3 ± 23.5 225.3 ± 40.3 631.3 ± 369.8 200.0 ± 34.6 260.3 ± 74.6 280.7 ± 120.8 
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Figure 38: Graphical representation of PBMC proliferation assay results after incubation with total 
aggregate fractions (SumAP), individual monomer fractions (MP) and individual aggregate fractions 
(AP3, AP2 and AP1) from mAb1 light stressed sample (LS) and mAb1 sample after 18 freeze/thaw 
cycles (FT). Phytohemagglutinin (PHA), sample buffer and non-treated cells (nt) were used as controls. 
Shown is one representative experiment out of three independent experiments.  
Slika 38: Grafična predstavitev testa proliferacije kulture mononuklearnih celic periferne krvi 
(PBMC) po inkubaciji s skupnimi agregatnimi frakcijami (SumAP) in individualnimi agregatnimi 
frakcijami (AP3, AP2 in AP1) iz vzorca svetlobnega stresa mAb1 (LS) in vzorca mAb1 po 18 ciklih 
zamrzovanja/odtajanja (FT). Okrajšava »PHA« je uporabljena za kontrolo s fitohemaglutininom in 
kratica »nt« je uporabljena za netretirane celice. Prikazan je en reprezentativni eksperiment od treh 
neodvisnih eksperimentov. 
 
From both DC and PBMC cell assays it can be concluded that production of markers 
(CD40, CD80, CD86, CCR7 and HLA-DR) and cytokines (IL-1β, IL-6, IL-8, IL-10, IL-
12p70 and TNF-α) was not significant which implies that all tested fractions from mAb1 
light stressed sample and mAb1 stressed sample after 18 cycles of freeze/thaw were not 
immunogenic. This observation contributes to overall quality of mAb1 drug substance. In 
addition, markers: CD40 and HLA-DR and cytokines: IL-6, IL-8 and TNFα seem to be 
more sensitive in determination of potential immunogenicity within DC and PBMC assays. 
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5 CONCLUSIONS 
Development of new recombinant biopharmaceutical products has greatly expanded in the 
field of modern pharmacy and medicine. Since biological recombinant molecules are 
sensitive, simple or composed proteins, their function is heavily dependent of their 
structure. In addition to their effectiveness, biological products could show side effects 
such as potential immunogenicity. Therefore, development of appropriate techniques 
which enable separation of native from the rest of the non-optimal structural forms of the 
recombinant protein, together with the development of immunological methods which 
enable detection of dangerous immunogenic forms of recombinant protein are vital during 
development in pharmaceutical biotechnology, from the safety point of view.  
 
Within the scope of research of different sample types of mAb1 (native, light stressed and 
mAb1 sample after 18 cycles of freeze/thaw stress) conclusions have been drawn based on 
accomplishment of the following goals: 
 
By using proposed and developed analytical methods for mAb1 characterization such as: 
size exclusion chromatography on HPLC, UPLC or ÄKTA systems and HPLC system 
combined with multi angle light scattering detector (SEC-HPLC, SEC-UPLC, SEC-
ÄKTA, SEC-MALS), non-reduced capillary electrophoresis (CE-SDS),  hydrophobic 
interaction chromatography (HIC) and dynamic light scattering (DLS) we were able to 
designate and separate critical mAb1’s structural variants sets, such as mAb1 aggregate 
and degradation products, from the intact (monomer) mAb1.  
 
Moreover, individual aggregate entities within the profile of mAb1 aggregates’ structural 
variants have been further separated and characterized by means of aforementioned 
methods: size exclusion chromatography on UPLC and HPLC system combined with multi 
angle light scattering detector (SEC-UPLC, SEC-HPLC, SEC-MALS) and hydrophobic 
interaction chromatography (HIC). In addition, SEC-UPLC fraction collection and fraction 
concentration method has been developed and applied for the purpose of individual 
aggregates and monomer entity collection from different types of mAb1 samples. Those 
fractions have been successfully characterized using developed methods such as: 
hydrophobic interaction chromatography (HIC), SDS-PAGE and SEC-UPLC Orbitrap 
mass detection.  
 
Within the profile of mAb1 aggregates’ structural variants of different types of mAb1 
samples (native, light stressed and mAb1 sample after 18 cycles of freeze/thaw stress) 
three aggregate entities were observable by means of size exclusion chromatography: 
aggregate product 1, 2 and 3 (AP1, AP2 and AP3). After mathematical regression analysis 
of molecular weight markers (MWM) and confirmation of data by practical analytical 
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experimental tests (SEC-MALS, DLS, SDS-PAGE) of each mAb1 individual aggregate 
(AP1, AP2 and AP3) and monomer sample fractions originating from light and freeze/thaw 
stressed mAb1 samples, it can be concluded that AP3 entity is trimeric mAb1 aggregate, 
AP2 entity is dimeric mAb1 aggregate while AP1 entity is modified mAb1 dimeric form, 
which consists of combination of monomer mAb1 with one additional heavy and light 
chain. 
 
It was confirmed that proposed HIC-HPLC method has a capacity of separating different 
types of hydrophobic variants, in specific: high molecular weight hydrophobic variants 
(HMWHV – which correspond to different aggregate forms analogue to SEC analysis), 
main hydrophobic variant (MHV – which correlate to monomer peak from SEC analysis) 
and low molecular weight hydrophobic variants (LMWHV – which are comparable to 
degradation products from SEC analysis). It was concluded that the same entity, which was 
separated by its hydrodynamic radii with SEC method, has a potential for further chemical 
characterization with proposed HIC method, since differences in present HMWHV types, 
its amounts and retention times were observed. Accordingly, capacity of HIC method to 
further separate different mAb1 aggregates, monomer or degradation products species by 
their chemical characteristics shows great potential as supplementary characterization 
technique. 
 
Light stress conditions influence by far greater mAb1 aggregates generation comparing to 
mAb1 sample after 18 cycles of freeze/thaw stress conditions. Proposed HIC-HPLC 
method analysis also revealed that light stress conditions influence chemical changes in the 
mAb1 monomeric structure, which was observed as monomer peak splitting. Latter effect 
was not evident after applied freeze/thaw stress, which implies that the main course of 
aggregate formation within mAb1 freeze/thaw sample were mechanical modifications of 
mAb1 protein. Acordingly, this implies that light stress causes formation of mAb1 
aggregates by means of chemical modifications and interactions between monomeric 
stuctures of mAb1. Within total mAb1 aggregate profile in each type of tested sample, 
aggregate product 2 (AP2) was present in highest percentage, meaning that during 
freeze/thaw and light stressing of mAb1 samples conversion to dimeric aggregate forms is 
favored. 
 
Potential capacity of the mAb1 aggregates to induce maturation of dendritic cells in terms 
of phenotype and cytokine producing capacity has been determined. However, one has to 
have in mind slight uncertainty of results in spite of using non-treated DC or PBMC cells 
and medium buffer as negative controls. Accordingly, immunogens LPS and PHA were 
used as intensive positive controls for assessing the experimental validity of the proposed 
DC and PBMC assays. LPS and PHA are highly immunogenic and both have completely 
different way of activating DC and PMBC cells and inducing immune response in 
comparison to potential immunogenic proteins. Nevertheless, proposed in vitro DC 
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maturation and stimulation assays as well as PBMC stimulation and proliferation assays 
can be considered as introductory in vitro cellular models for assessing immunogenicity 
potential of proteins and should be further developed and improved in future. For instance, 
certain optimizations should include implementation of general and standardized protein or 
mAb positive controls. 
 
Results for in vitro DC assay confirmed that total aggregate fractions of both light stressed 
and freeze/thaw stressed mAb1 samples do not greatly induce immunogenic maturation of 
DC cells by means of upregulation of markers CD40, CD80, CD86, CCR7. Only slight 
upregulation of marker HLA-DR was observable for total aggregate fractions of both light 
stressed and freeze/thaw stressed samples, since from all tested markers, HLA-DR had the 
highest sensitivity. 
 
Also, individual monomer and aggregate fractions from freeze/thaw and light stressed 
sample did not greatly induce immunogenic maturation of DC cells by means of 
upregulation of CD markers. CD40 marker was proven to be more sensitive in comparison 
to CD80 and CD86 marker. Since all individual aggregate fractions contained traces and 
different ratios of other aggregate types or monomer, these results from DC assay lead to 
conclusion that immunogenic potential of aggregates for activation of DC cells may also 
be dependent of their chemical structure, but also due to present combination and ratio of 
different individual aggregates. 
 
Capacity of the mAb1 aggregates to induce IL-10 and antiinflamatory cytokines (IL-1β, 
IL-6, IL-8, IL-12p70 and TNF-α) production within DC assay and during potential short-
term (innate) immune responses in peripheral blood mononuclear cells (PBMC) assay has 
been investigated. It was confirmed that total and individual aggregate samples from mAb1 
freeze/thaw and light samples do not influence immunogenic response by inducing 
production of IL-10 nor other antiinflamatory cytokines IL-1β, TNFα, IL-12p70 by DC 
cells, as only minor upregulation for IL6, IL8 and TNFα was observed. In addition, PBMC 
cytokine production analysis showed no significant rise in cytokine production in total and 
individual aggregate and monomer fractions from both types of mAb1 stressed samples. 
However in comparison to non-treated PBMC cells slight rise of IL6 and IL8 was 
observed. PBMC cell proliferation assay results also did not show any significant influence 
of tested total and individual aggregate fractions from both light and freeze-thaw stressed 
samples. 
 
Based on the results from DC and PBMC cell assays for determining potential 
immunogenicity, final conclusion is that there was no significant production of markers 
(CD40, CD80, CD86, CCR7 and HLA-DR) nor cytokines (IL-10, IL-1β, IL-6, IL-8, IL-
12p70 and TNF-α) proving that all tested fractions from mAb1 light stressed sample and 
mAb1 stressed sample after 18 cycles of freeze/thaw were not immunogenic, which 
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contributes to overall quality of mAb1 drug substance. In addition, markers: CD40 and 
HLA-DR and cytokines: IL-6 and IL-8 seem to be more sensitive in determination of 
potential immunogenicity within DC and PBMC assays.  
 
All obtained data contribute to the confirmation of high quality of original mAb1 drug 
substance, since even extremely stressed mAb1 material with intense light and freeze/thaw 
conditions and subsequent generated aggregate entities of mAb1 did not show potential for 
inducing immune response.  
 
Accordingly, all developed and proposed analytical methods and immunological in vitro 
DC and PBMC assays within this doctoral dissertation, can be used as platform for 
complementary analytical characterization and determination of potential for 
immunogenicity for all biopharmaceutical products which contain monoclonal antibodies 
as active pharmaceutical ingredients. Such comprehensive proposed plathform (diagram 
presented in Figure 39) is based on results from a variety of tested analytical methods. 
Firstly SEC-UPLC analysis should be performed as it was concluded that SEC UPLC 
method provides fast, robust and relatively simple separation of all mAb entities. 
Moreover, this method can be used as a single method for determination of size of the 
mAb1 entities based on entity retention time, under condition that MWM solution is 
analysed together with the samples and that suitable calibration curve for determination of 
molecular sizes based on protein retention times is constructed. Optionally, SEC-MALS 
analysis could be performed with the aim of additional conformation of entity size. 
Afterwards, we propose collection of monomeric, individual and total aggregate fractions 
using SEC-UPLC fraction collection method in combination fraction concentration 
procedure with Amicon ultra 50 kDa filter units. Next step includes determination of 
protein concentration for collected fractions prior executing HIC-HPLC analysis with the 
aim of assessing chemical properties for entities of interest. Afterwards, potential for 
immunogenicity could be determined by performing in vitro DC maturation and 
stimulation assays in parallel with PBMC stimulation and proliferation assays. Once all 
data on entity on size (obtained from SEC-UPLC method and MWM calibration curve), its 
chemical properties (acquired from HIC-HPLC method) and immunogenicity potential 
from all in vitro DC and PBMC assays is collected, overall understanding of 
immunogenicity potential for entities of interest could be achieved. 
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Figure 39: Flowchart for proposed plathform of analytical (blue) and immunological (green) methods 
that can be used for characterization of mAb aggregates and determination of their immunogenicity 
potential. 
Slika 39: Hodogram predlagane platforme analitskih (modra barva) in imunoloških (zelena barva) 
metod, ki so lahko uporabljene za potrebe karakterizacije agregatov mAb in določitve njihovega 
imunološkega potenciala. 
 
Start
Perform SEC-UPLC analysis 
on mAb material and 
molecular weight marker 
(MWM). 
Determine monomer mAb, 
total aggregates and 
degradation products on 
acquired chromatograms.
Optional step: 
Perform SEC-MALS analysis for 
additional confirmation of entity size 
which was previously determined using 
MWM calibration curve.
Size determination of entities of interest:
Construct MWM calibration curve and 
determine size of individual mAb entities.
Perform SEC-UPLC fraction collection 
method in combination with fraction 
sample concentration with Amicon ultra 
50 kDa filter devices. 
Fractions to be collected:
- monomer mAb
- total aggregate fraction
- individual aggragate fractions.
Reanalyse all collected fractions using SEC-UPLC 
method in order to confirm suitability of fraction 
collection procedure and to assess potential 
aggregate reversibility to monomer mAb and/or 
other aggregate forms.
Determine protein concentration for each  
fraction (e.g. using Nanodrop or Trinean 
system).
Assessing chemical properties for entities of interest:
Perform HIC-HPLC analysis for each fraction using 
data for protein content. Assess the results for each  
entity by determing types of present hydrophobic 
variants and its retention times.
Immunogenicity evaluation:
Determine immunogenicity potential for each of the 
collected fractions (entities) using:
- in vitro DC maturation and stimulation assays 
- in vitro PBMC stimulation and proliferation assays. 
Understanding immunigenicity potential for entities of 
interest:
For each entity collect and assess data on their size (from 
SEC-UPLC method and MWM calibration curve), chemical 
properties (from HIC-HPLC method) and immunogenicity 
potential (from all in vitro DC and PBMC assays).
End
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6 SUMMARY (POVZETEK) 
6.1 SUMMARY  
Development and optimizations of analytical and immunological techniques, which could 
be applied as certain platform approaches in pharmaceutical industry for common 
addressing of monoclonal antibody structural variants' separation, identification, 
characterization from the analytical point of view and connection of those results with tests 
for determining potential for immunogenicity, represent a great impact in the field of 
safety, quality and effectiveness of biotherapeutics in pharmaceutical industry. Therefore, 
developing and proposing such a comprehensive platform that consists of certain analytical 
and immunological techniques that jointly provide deep insights and connection of 
monoclonal antibody structural variants to their potential for immunogenicity is from the 
safety point of view, vital during drug development in pharmaceutical biotechnology.  
 
Within the scope of research were different sample types of mAb1: native, light stressed 
and mAb1 sample after 18 cycles of freeze/thaw stress. Each sample type contained 
different amounts of aggregates for which characterization following analytical methods 
were proposed and developed: size exclusion chromatography on HPLC, UPLC or ÄKTA 
systems and HPLC system combined with multi angle light scattering detector (SEC-
HPLC, SEC-UPLC, SEC-ÄKTA, SEC-MALS), non-reduced capillary electrophoresis 
(CE-SDS), hydrophobic interaction chromatography (HIC) and dynamic light scattering 
(DLS). By employing these analytical methods, we were able to designate and separate 
critical mAb1’s structural variants sets, such as mAb1 aggregate and degradation products, 
from the intact (monomer) mAb1. Moreover, individual aggregate entities within the 
profile of mAb1 aggregates’ structural variants have been further separated and 
characterized by means of aforementioned methods. In addition, SEC-UPLC fraction 
collection and fraction concentration method has been developed and applied for the 
purpose of individual aggregates and monomer entity collection from different types of 
mAb1 samples.  
 
Within the profile of mAb1 aggregates’ structural variants of different types of mAb1 
samples (native, light stressed and mAb1 sample after 18 cycles of freeze/thaw stress) 
three aggregate entities were observable by means of size exclusion chromatography: 
aggregate product 1, 2 and 3 (AP1, AP2 and AP3). After mathematical regression analysis 
of molecular weight markers (MWM) and confirmation of data by practical analytical 
experimental tests (SEC-MALS, DLS, SDS-PAGE) of each mAb1 individual aggregate 
(AP1, AP2 and AP3) and monomer sample fractions originating from light and freeze/thaw 
stressed mAb1 samples, it can be concluded that AP3 entity is trimeric mAb1 aggregate, 
AP2 entity is dimeric mAb1 aggregate while AP1 entity is modified mAb1 dimeric form, 
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which consists of combination of monomer mAb1 with one additional heavy and light 
chain. 
 
It was confirmed that proposed HIC-HPLC method has a capacity of separating different 
types of hydrophobic variants, in specific: high molecular weight hydrophobic variants 
(HMWHV – which correspond to different aggregate forms analogue to SEC analysis), 
main hydrophobic variant (MHV – which correlate to monomer peak from SEC analysis) 
and low molecular weight hydrophobic variants (LMWHV – which are comparable to 
degradation products from SEC analysis). It was concluded that the same entity, which was 
separated by its hydrodynamic radii with SEC method, has a potential for further chemical 
characterization with proposed HIC method, since differences in present HMWHV types, 
its amounts and retention times were observed. Accordingly, capacity of HIC method to 
further separate different mAb1 aggregates, monomer or degradation products species by 
their chemical characteristics shows great potential as supplementary characterization 
technique. 
 
Light stress conditions influence by far greater mAb1 aggregates generation comparing to 
mAb1 sample after 18 cycles of freeze/thaw stress conditions. Proposed HIC-HPLC 
method analysis also revealed that light stress conditions influence chemical changes in the 
mAb1 monomeric structure, which was observed as monomer peak splitting. Within total 
mAb1 aggregate profile in each type of tested sample, aggregate product 2 (AP2) was 
present in highest percentage, meaning that during freeze/thaw and light stressing of mAb1 
samples conversion to dimeric aggregate forms is favored. 
 
Potential capacity of the mAb1 aggregates to induce maturation of dendritic cells in terms 
of phenotype and cytokine producing capacity has been determined. Based on the results 
from DC and PBMC cell assays for determining potential immunogenicity, final 
conclusion is that there was no significant production of markers (CD40, CD80, CD86, 
CCR7 and HLA-DR) nor cytokines (IL-10, IL-1β, IL-6, IL-8, IL-12p70 and TNF-α) 
proving that all tested fractions from mAb1 light stressed sample and mAb1 stressed 
sample after 18 cycles of freeze/thaw were not immunogenic, which contributes to overall 
quality of mAb1 drug substance. In addition, markers: CD40 and HLA-DR and cytokines: 
IL-6 and IL-8 seem to be more sensitive in determination of potential immunogenicity 
within DC and PBMC assays.   
 
All obtained data contribute to the confirmation of high quality of original mAb1 drug 
substance, since even extremely stressed mAb1 material with intense light and freeze/thaw 
conditions and subsequent generated aggregate entities of mAb1 did not show potential for 
inducing immune response. 
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6.2 POVZETEK 
UVOD 
Monoklonska protitelesa (mAb – monoclonal antibodies) se lahko specifično vežejo z 
visoko afiniteto na različne molekulske tarče. To lastnost monoklonskih protiteles 
iskoristimo za pregled in izdelavo bioterapevtikov, ki vsebujejo rekombinantna 
monoklonska protitelesa kot aktivne farmacevtske učinkovine (API). Zato se je v zadnjih 
letih precej povečal razvoj biofarmacevtskih izdelkov, ki so hitro izboljšali oskrbo 
bolnikov, ki imajo različne bolezni. Velike molekule, kot so monoklonska protitelesa, 
lahko tvorijo različne agregate, ki se razlikujejo po velikosti in morfologiji (Shire in sod., 
2004; Hong in sod., 2012; Curtis in sod., 1998; Skamris in sod., 2016; Van Buren in sod., 
2009). Zato je zelo pomembno, da odkrijemo in označimo proteinske agregate med 
razvojem, proizvodnjo in kontrolo kakovosti biofarmacevtskih izdelkov (Kastelic in sod., 
2015; Chi in sod., 2003; Arosio in sod., 2013; Obrezanova in sod., 2015). 
 
Številne entitete, prisotne na mikroskopski površini agregatov mAb, lahko delujejo kot 
sprožilni ligandi za antigen-predstavitvene celice epitopom celic B. Ta proces lahko 
povzroči grozdenje receptorjev, kar lahko aktivira celice B in pri bolnikih sproži nastanek 
protiteles, ki učinkujejo proti zdravilom (Rombach-Riegraf in sod., 2014). Zato je 
pomembno pri razvoju biofarmacevtskih zdravil čim prej odkriti, količinsko opredeliti in 
določiti naravo strukturne variantne vrste, da bi lahko kontrolirali morebitna tveganja 
(Zhang in sod., 2014). Glavni cilj pri proizvodnji biofarmacevtikov, ki vsebujejo 
monoklonska protitelesa, je, da imajo končni izdelki želene biološke učinke in so tudi 
stabilni in varni (Kohli in sod., 2015).  
 
Običajne modifikacije proteinskih zdravil se pojavijo med fermentacijo, čiščenjem, 
skladiščenjem in ravnanjem z zdravili (Liu in sod., 2005; Kanai in sod., 2008; Luo in sod., 
2011). Te spremembe vključujejo encimsko ali kemijsko posttranslacijsko modifikacijo, 
agregacijo ali proteolitično cepitev (Haverick in sod., 2014). Zato je treba opraviti vse 
potrebne analize za spremljanje in odkrivanje morebitnih nepravilnosti v strukturi 
proteinov (Latypov in sod., 2012; Sahin in sod., 2012; Chennamsetty in sod., 2009). 
 
Za odkrivanje proteinskih variant obstaja več kromatografskih metod. Vendar pa je med 
njimi gelska izključitvena kromatografija na sistemu z visoko učinkovito tekočinsko 
kromatografijo (SEC-HPLC – size exclusion chromatography on high performance liquid 
chromatography system) najbolj robustna in primerna za ločevanje monomernih in 
multimernih oblik mAb (Fekete in sod., 2014; Goyon in sod., 2017). V nasprotju z 
izključitveno kromatografijo po velikosti (SEC), katere mehanizem ločevanja temelji na 
proteinsko učinkovitem hidratiranem radiju v raztopini (Stokesov radij), je hidrofobna 
interakcijska kromatografija (HIC – hydrophobic interaction chromatography) primerna 
metoda za karakterizacijo molekulskih variant (Valliere-Douglass in sod., 2008). 
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Zadrževanje ciljnih proteinov, pridobljenih s HIC-kromatografijo, je specifično zaradi 
hidrofobnega značaja aminokislinskih ostankov, ki so na površini molekule, in njihovih 
interakcij z matriko kolone. Tako so razlike v retencijskem času med različicami ciljnega 
proteina posledica posttranslacijskih modifikacij, hidrolize ali agregacije (Haverick in sod., 
2014). 
 
Pri bioproizvodnji aktivne farmacevtske učinkovine in v končni fazi formulacije zdravila z 
mAb je treba zmanjšati potencialno imunogenost, ki je neželen stranski učinek (Franey in 
sod., 2010). Po drugi strani pa vse odstopajoče oblike proteinov niso imunogene (Gilliland 
in sod., 1999). Vzporedno z razvojem analitskih tehnik je uvedena celična tehnologija in se 
opira na preučevanje dogodkov, ki jih v kontaktu z potencialnim antigenom povzročajo 
dendritične celice (DC), ki lahko sprožijo označevalce pripadnosti (CD – cluster of 
differentiation) humoralnega adaptivnega imunskega odziva, odvisnega od celic T, tipa 
CD4+. Ta funkcija bi se lahko vključila v nadzorovanje morebitne imunogenosti. Znano je, 
da lahko visokoagregirani proteini povzročijo odziv T-celic in vitro, kar lahko vodi v 
nastanek specifičnih protiteles proti ciljnemu proteinu (Rombach-Riegraf in sod., 2014). 
 
Ta doktorska disertacija vključuje razvoj in optimizacijo metod analitskih in imunoloških 
metod za določitev tistih strukturnih izoform, ki bi potencialno lahko predstavljale osnovo 
za pojav neželene imunogenosti. Predlaga se detekcija in karakterizacija modificiranih 
oblik, kot so agregati izbranega imunoglobulina G (IgG) monoklonskega protitelesa (v 
nadaljnjem besedilu: mAb1 kot posledica pravil podjetja Novartis) z izključitveno 
kromatografijo po velikosti (SEC – size-exclusion chromatography), s pomočjo analitskega 
ultracentrifugiranja in s hidrofobno interakcijsko kromatografijo (HIC). 
 
Po izolaciji in separaciji smo opravili poskuse z izbranimi agregati in modificiranimi 
oblikami mAb1 ter pregledali proteine dendritičnih celic. Eksperimentalni model DC smo 
izbrali, saj so celice DC najbolje opremljen tip imunske celice za zaznavanje mikrookolja 
za molekulske vzorce, povezane z nevarnostjo ali patogenom. Poleg tega je dokazano, da 
je imunogenost agregatov človeških rekombinantnih mAb v neposredni povezavi z DC-
funkcijo in zorenjem, pri čemer dokazano nekatere oblike agregatov mAb pomembno 
spodbujajo aktivacijo DC, pridobljenih iz monocitov, induciranih s povečanim izražanjem 
tipičnih markerjev zorenja, kot so CD80, CD83 in CD86 (Rombach-Riegraf in sod., 2014). 
Dodatno smo ocenili potencialni prirojen imunogenski odziv kulture mononuklearnih celic 
periferne krvi (PBMC – peripheral blood mononuclear cell) na agregatne frakcije mAb1 z 
merjenjem provnetnega odziva citokina pri zgodnji izpostavitvi PBMC-jem in učinku na 
njihovo proliferacijo. 
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MATERIALI IN METODE 
Aktivna farmacevtska sestavina 
Eksperimentalno monoklonsko protitelo IgG (imenovano mAb1 kot posledica pravil 
podjetja Novartis), uporabljeno v tej znanstveni raziskavi, je proizvedeno in prečiščeno na 
oddelku Novartis Biopharmaceutics Downstream v Mengšu, Slovenija. Končna 
koncentracija aktivnega materiala, določena z uporabo afinitetne tekočinske 
kromatografije, je 116,94 mg/ml. 
Oblikovanje in izolacija agregatov mAb1 in izoform 
Monoklonsko protitelo – mAb1 – smo razdelili na dva dela in izpostavili fizično stresnim 
razmeram, kot so stresni cikli zamrzovanja/odtajanja (F/T – freeze/thaw) in svetlobni stres 
(LS – light stress), da bi proizvedli agregirane vzorce proteinov mAb1, ki bi jih bilo možno 
zlahka zaznati v primerjavi z drugimi strukturnimi variantami mAb1. 
 
Prvo frakcijo originalnega vzorca mAb1, napolnjeno v viali 20R, smo izpostavili 
svetlobnemu stresu (LS) z uporabo instrumenta SunTest XLS+ za 22 ur na 40 °C 
standardne temperature črnega telesa (BST – black standard temperature), medtem ko je 
energija sevanja bila nastavljena na 750W/m2. V nadaljnjem besedilu je vzorec 
svetlobnega stresa poimenovan mAb1-LS. 
 
Drugo frakcijo vzorca mAb1 smo izpostavili intenzivnemu stresu zamrzovanja/odtajanja v 
obsegu do 18 ciklov zamrzovanja/odtajanja, pri katerih se je temperatura v času enega 
cikla spremenila z –70 °C na 35 °C. Bolj specifično se je en cikel zamrzovanja/odtajanja 
začel z dvema urama šok zamrzovanja na –70 °C, ki so mu sledile štiri ure hitrega 
odtaljevanja pri 35 °C. Poskuse smo opravili na instrumentu Celsius S3 Freeze/Thaw Cryo 
Pilot, pri čemer smo vzorec mAb1 napolili v 30-mililitrske instrumentne vreče s 
temperaturno sondo. Za poenostavitev v nadaljnjem besedilu je frakcija mAb1, ki je bila 
izpostavljena 18 stresnim ciklom zamrzovanja/odtajanja, poimenovana mAb1-F/T18. 
Metode karakterizacije 
Izključitvena kromatografija po velikosti (SEC) 
Metodo SEC na visokozmogljivem tekočinskem kromatografskem sistemu (HPLC) smo 
izvedli na instrumentu HPLC Agilent 1200/1260 (Agilent Technologies, Santa Clara, CA, 
ZDA) in na analitski koloni TSKgel G3000SWXL (7,8 × 300 mm, Tosoh Corporation, 
Tokyo, Japonska) pri 30 º C. Uporabili smo mobilno fazo 150 mM kalijevega fosfatnega 
pufra, pH = 6,5 s pretokom 0,4 ml/min. V kolono smo injicirali 10 μl vzorcev mAb1 s 
koncentracijo 0,75 mg/ml. Čas izvedbe analize je bil 35 min. Absorbanco UV smo izmerili 
pri 280 nm (Rombach-Riegraf in sod., 2014) in testirali alternativno predlagano valovno 
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dolžino detekcije 210 nm. Pridobljene podatke smo obdelali s programsko opremo 
Empower 3. 
 
Analizo SEC-HPLC smo izvedli v enakih kromatografskih razmerah tudi na Wyatt 
Technology Coorporation miniDAWN TREOS 427-TS Multi-angle static light scattering 
detector (MALS) v kombinaciji z instrumentom RI Wyatt Optilab rEX za prikaz velikosti 
agregatov mAb1. Po kromatografski ločitvi na sistemu HPLC smo vrhove analizirali na 
detektorju MALS, opremljenem z vzorčnimi celicami Fused Silica na 656 nm. Detektor je 
pridobil dodatne podatke iz Generic UV-instrumenta, zbrane pri 280 nm v celici dolžine 1 
cm in temperaturi 25 °C. Detekcijo RI smo izvedli pri 658 nm in temperaturi 25 °C. Vse 
podatke iz detektorja MALS smo obdelali s programsko opremo Astra z določitvijo 
ustreznih parametrov za normalizacijo bazne linije in širitev pikov za UV, RI in signala 
svetlobne razpršitve (light scattering). 
 
Za optimizacijo in primerjavo z metodo SEC-HPLC smo metodo SEC na ultra zmogljivem 
tekočinskem kromatografskem sistemu (UPLC – ultra performance liquid chromatography 
system) izvedli v podobnih okoliščinah na sistemu ACQUITY UPLC H-Class Bio System 
(Waters Milford, Massachusetts, ZDA) in na koloni ACQUITY UPLC Protein BEH SEC, 
(200 Å, 1,7 μm, 4,6 mm × 300 mm, 1/pkg) pri 30 °C. Uporabili smo mobilno fazo 150 mM 
kalijevega fosfatnega pufra, pH = 6,5 s pretokom 0,4 ml/min. Na kolono smo injicirali 5 μl 
vzorcev mAb1 s koncentracijo 0,75 mg/ml. Čas izvedbe analize je bil 15 min. Absorbanco 
UV smo izmerili pri 210 nm. Podatke smo obdelali s programsko opremo Empower 3. 
 
Zbiranje frakcij vseh agregatnih vzorcev mAb1 smo opravili z uporabo razvite metode 
SEC-UPLC na sistemu ACQUITY UPLC H-Class, nadgrajenim z modulom Waters 
Fraction Manager. Detekcijo pred zbiranjem frakcij smo izvedli pri 210 nm, z predhodnim 
injiciranjem 50 μl vzorca s koncentracijo 116,94 mg/ml. Poleg tega smo uporabili 15 ml in 
4 ml Amicon Ultra 50 kDa centrifugalno filtrirno napravo za koncentriranje skupne 
agregatne frakcije mAb1. V skladu s tem je bil končni volumen koncentriranih skupnih 
agregatov mAb1 iz svetlobnega stresa (mAb1-LS) in 18 stresnih ciklov 
zamrzovanega/odtajanega vzorca (mAb1-F/T18) uporabljen za dodatno zbiranje frakcij 
posameznih agregatov z uporabo metode zbiranja frakcij SEC-UPLC. 
Metode za hitro določanje koncentracije proteinov 
Koncentracijo monoklonskega protitelesa 1 (mAb1) smo določili spektrofotometrično v 
triplikatih pri 280 nm z uporabo naprave NanoDrop 8000 z nanosom 2,5 μl vzorca, 
vključno s slepim (blank) vzorcem. Koeficient ekstinkcije je bil nastavljen z ustrezno 
vrednostjo za mAb1, parameter normalizacije pa je bil nastavljen na 340 nm. Poleg tega 
smo koncentracijo mAb1 določili tudi pri 280 nm z uporabo sistema Trinean Xpose z 
aplikacijo 2,5 μl vzorca v Xpose 200 slide, dolžina poti mikrokivete je bila 0,5 mm. 
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Hidrofobna interakcijska kromatografija (HIC) 
Analizo HIC smo izvedli z uporabo instrumenta Agilent HPLC 1260 (Agilent 
Technologies, Santa Clara, CA, ZDA). Poleg tega smo ločitev izvedli s komercialno 
dostopno kolono HIC TSK Butyl, velikosti delcev 2,5 μm; 4,56 mm ID × 10,0 cmL 
proizvajalca Tosoh. Temperaturo smo nastavili na 25 °C, pretok na 1 ml/min v gradientnih 
pogojih mobilne faze A (1,5 M amonijevega sulfata/50 mM natrijevega fosfatnega pufra 
pH = 7,00) in mobilne faze B (50 mM natrijevega fosfatnega pufra pH = 7,00). Uporabili 
smo specifične pogoje gradienta, ki so sledili 1 min zadržanju pri 0 % mobilne faze B, ko 
je približno 50 μg injiciranega proteina mAb1, eluirano z uporabo linearnega gradienta od 
0 do 100 % mobilne faze B v trajanju 15 minut. Kolono smo nato spirali s 100 % mobilne 
faze B v trajanju 5 min in jo ponovno uravnotežili na 0 % mobilne faze B za dodatnih 5 
minut pred injiciranjem naslednjega vzorca mAb1. Separacijo smo nadzorovali z 
detektorjem DAD-pri 210 nm. 
SDS-PAGE – natrijev dodecil sulfat poliakril-amid gel elektroforeza 
Analizo SDS-PAGE smo izvedli z uporabo 10-odstotnega gela za separacijo, ki je 
vseboval 40 % akrilamida/bis-akrilamida 37 v razmerju 5 : 1, 1,5 M Tris HCl (pH 8,8), 
10 % amonijevega persulfata, 10 % SDS, TEMED in vodo. Zgornji del gela SDS-PAGE je 
bil 5-odstotni gel za nalaganje (stacking gel), ki je bil pripravljen iz 40 % akrilamida/bis-
akrilamida 37 v razmerju 5 : 1, 1,5 M Tris HCl (pH 8,8), 10 % amonijevega-persulfata, 
10 % SDS, TEMED in vode. Nereducirane in reducirani vzorce smo razredčili v 
nanašalnem pufru, katerega sestava je bila 10 mM imidazola, 50 mM natrijevega-fosfata, 
300 mM NaCl s pH = 7,4. Analizo smo izvedli z uporabo tekočega pufra, ki je vseboval 
24mM Trisa, 190 mM glicina, 3,5 mM SDS in vodo (pH 8,3). Nereducirane vzorce smo 
pripravili z uporabo 10 μl vsake individualne agregatne frakcije (razen za monomerno 
frakcijo, pri kateri smo uporabili volumen 2 μl zaradi višje koncentracije monomernega 
vzorca) ter razredčili v 5,3 μl nanašalnega pufra in 2,7 μl vode. Podobno smo pripravili 
tudi reducirane vzorce in sicer z uporabo 10 μl vsake posamezne agregatne frakcije (razen 
za monomerno frakcijo, pri kateri je uporabljen volumen 2 μl zaradi višje koncentracije 
monomernega vzorca) ter 5,3 μl nanašalnega pufra, 2,7 μl vode in 2,7 μl 1M DTT 
(dithiothreitol). 
In vitro imunološki testi 
In vitro pridobivanje dendritičnih celic (DC – dendritic cell) in testi stimulacije DC na 
frakcijah strukturnih variant mAb1 
Različne koncentracije izbranih vzorcev so bile ocenjene glede na njihove sposobnosti, da 
spodbudijo zorenje ali kakor koli drugače modulirajo stanje aktivacije nezrelih dendritičnih 
celic, pridobljenih iz monocitov (iDC). Na kratko smo mononuklearne celice periferne krvi 
(PBMC) izolirali iz zgornjih, lažjih delov krvnega strdka (tako imenovani “buffy coat”), 
pridobljenih iz venske krvi zdravih darovalcev v Centru za transfuzijo krvi v Sloveniji v 
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skladu z institucionalnimi smernicami in etičnim dovoljenjem za ta poskus s številko 0120-
279 / 2017-3 KME 74/06/17, ki ga je izdala Nacionalna komisija za medicinsko etiko 
(KME). Monocite smo izolirali iz PBMC z imunomagnetno selekcijo z mikrokroglicami 
CD14 (MACS, Miltenyi Biotec). Diferenciacijo monocitov v iDC smo sprožili v 5-dnevni 
kulturi z uporabo stimulirajočega dejavnika granulocitno-monocitne kolonije (GM-CSF – 
granulocyte-monocyte colony stimulating factor) in interlevkina 4 (IL-4), kot so že prej 
opisali Švajger in sod., (2014). 
 
Da bi ocenili imunogeno zmogljivost agregatnih vzorcev mAb1 glede zorenja DC, smo 
iDC tretirali s 100 μg/ml agregatnih pripravkov mAb1. Postopek zorenja smo nato 
spremljali z določanjem fenotipa s pomočjo pretočne citometrije (FACS – fluorescence 
activated cell sorting analysis) ali pretočno-citometričnimi kvantitativnimi testi (Švajger in 
sod., 2015). Potencialno imunogene oblike mAb1 bi domnevno povečale izražanje 
označevalcev zrelosti, kot so kostimulacijske molekule CD80, CD40 in CD86 (glede na 
slepo negativno kontrolo ali pravilno zloženo mAb1). Poleg tega smo izmerili tudi 
površinske molekule, povezane z zorenjem DC, kot je kemokinski receptor CCR7, ki 
usmerja imunske celice v sekundarna limfatična tkiva in HLA-DR. 
 
Da bi ocenili sposobnost stimuliranih DC, da proizvedejo IL-10 in provnetne citokine, smo 
48 ur po stimulaciji analizirali supernatante DC za prisotnost IL-1β, IL-6, IL-8, IL-12p70 
in TNF-α (Švajger in sod., 2011). Vrednosti citokinov v supernatantih smo analizirali s 
pretočno citometrijo z uporabo Human Inflammatory Cytometric Bead Array (CBA) Kita 
(Human Inflammatory Cytokines Kit Instruction Manual, 2017. San Diego, BD 
Biosciences). 
 
V vseh testih smo za kontrolo uporabili monomer frakcije mAb1 in mobilno fazo SEC. Za 
pozitivno kontrolo analize zorenja DC smo uporabili klasični imunogenski lipopolisaharid 
(LPS, 20 ng/ml). 
In vitro stimulacijski test mononuklearnih celic periferne krvi (PBMC) in PBMC 
proliferacijski test na mAb1 frakcijah strukturnih variant 
Namen testov je bil ovrednotiti potencial prirojenega imunskega odziva kultur PBMC na 
agregatne frakcije mAb1. Med zgodnjo izpostavitvijo (48 ur) PBMC-jev vzorcem mAb1 
smo izmerili vnetni citokinski odziv. Frakcijo “buffy coat” venske krvi normalnih zdravih 
darovalcev smo pridobili v Centru za transfuzijo krvi v Sloveniji v skladu z 
institucionalnimi smernicami in upoštevanjem etičnega dovoljenja za ta poskus s številko 
0120-279 / 2017-3 KME 74/06/17, ki jo je izdala Nacionalna komisija za medicinsko etiko 
(KME). PBMC-je smo izolirali s ficoll centrifugiranjem gradienta gostote, prešteli in 
nanesli v 96 vdolbinic s 3 × 105 celicami po vdolbinici. Aklimatizirane PBMC-je smo 
izzvali s 100 μg/ml frakcij agregatnega vzorca mAb1. 
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V okviru simulacijskega testa PBMC za določanje prirojene imunske reaktivnosti smo 
celice gojili še dodatnih 48 ur. Po izzivu smo supernatante celične kulture zbrali in 
analizirali za prisotnost IL-1β, IL-6, IL-8, IL 10, IL-12p70 in TNF-α (Švajger in sod., 
2011). Citokine smo hkrati merili tudi z uporabo Human Inflammatory Cytometric Bead 
Array (CBA) Kita (Human Inflammatory Cytokines Kit Instruction Manual, 2017. San 
Diego, BD Biosciences). 
 
V okviru testa proliferacije PBMC smo celice PBMC podobno izolirali in inkubirali s 
celotnimi in posameznimi frakcijami strukturnih variant mAb1. Dobljene rezultate smo 
predstavili kot število celic na minuto (count per minute). Za namen negativne kontrole 
smo uporabili netretirane celice ali celice tretirane z normalnim monomerom mAb1. Za 
pozitivno kontrolo za test produkcije citokinov, povezan s PBMC-ji, smo izbrali celice, 
tretirane z imunogenim lipopolisaharidom (LPS, 20ng/ml), pri testu za proliferacijo PBMC 
pa s fitohemaglutininom (PHA, 2 μg/ml). 
REZULTATI IN RAZPRAVA 
Izvirni izhodiščni material, IgG monoklonsko protitelo – mAb1, smo analizirali z uporabo 
metod SEC-UPLC in SEC-HPLC, da bi določili začetni profil agregatov in odstotek 
celotnih agregatnih vrst, prisotnih v začetnem materialu mAb1. 
 
Isti profil agregatnih entitet (poimenovanih AP1, AP2 in AP3) je prisoten v obeh 
kromatogramih SEC-UPLC in SEC-HPLC v primerljivih razmerjih (sliki 13A in 13B). 
Povprečen delež skupnih agregatnih frakcij (SumAP) z metodo SEC je 1,28 % 
(Preglednica 3). 
 
Ugotovili smo, da sta obe metodi (SEC-UPLC in SEC-HPLC) primerni za analizo 
agregatnih in monomernih vrst, ki so prisotne v vzorcih. Pri obeh analizah, s SEC-UPLC in 
SEC-HPLC, smo pridobivanje podatkov izvedli pri 280 in 210 nm. Boljši rezultati in 
najvišji agregatni odzivi smo dosegli z uporabo valovne dolžine zaznavanja pri 210 nm. 
Ker pa so rezultati za odstotek površine pod krivuljo med SEC-UPLC in SEC-HPLC 
primerljivi, je SEC-UPLC pri valovni dolžini 210 nm določen kot izbrana metoda, saj je 
čas delovanja le 15 minut in tako krajši od analize SEC-HPLC. 
 
Originalni vzorec monoklonskega protitelesa IgG – mAb1 smo izpostavili dvema vrstama 
intenzivnih stresnih stanj – svetlobnemu stresu in zamrzovanju/odtajanju do 18 ciklov. Obe 
vrsti fizičnega stresa smo izbrali in prilagodili tako, da sta predstavljali ekstremne razmere 
v nadaljnjem procesu proizvodnje zdravila in poznejšem skladiščenju končnega izdelka. Z 
metodo SEC-UPLC smo analizirali frakcijo mAb1 po svetlobnem stresu (mAb1-LS) in po 
stresu zamrzovanja/odtajanja do 18 ciklov (mAb1-F/T18). Pri obeh vrstah stresa smo 
opazili povečanje rezultata za odstotek površine pod krivuljo v agregatnem območju 
(Preglednica 3). 
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Povišanje v skupnem rezultatu za odstotek površine agregatnih vrhov (SumAP) je očitno 
po opisanem svetlobnem stresu (od 1,28 % do 5,90 % vrednosti SumAP za mAb1-LS v 
primerjavi z izvirnim vzorcem mAb1) in po stresu 18 ciklov zamrzovanja/odtajanja (od 
1,28 % do 2,18 % vrednosti SumAP za mAb1-F/T18 v primerjavi s prvotnim vzorcem 
mAb1). Prav tako smo potrdili, da sta svetlobni stres in stres zamrzovanja/odtajanja 
povzročila povišanje posameznih agregatnih vrhov (AP1, AP2 in AP3) v skupnem profilu 
agregata (SumAP), ki ga lahko vidimo v Preglednici 4. Vendar pa pri redni proizvodnji 
zdravila ne bi pričakovali obeh uporabljenih stresnih okoliščin, stresa zamrznitve/odtajanja 
in svetlobnega stresa, saj predstavljata ekstremni meji v nadaljnjem procesu proizvodnje in 
roku uporabe zdravila. V okviru te raziskave smo ti vrsti stresa uporabili le za proizvodnjo 
vzorcev mAb1 z višjim agregatnim titrom. 
 
Z uporabo podatkov SEC-UPLC za molekulske mase (MW – molecular weights) iz 
markerjev molekulske teže (MWM – molecular weight marker) (Preglednica 5) smo izvedli 
najboljšo kalibracijsko krivuljo, ki smo jo izračunali z regresijo polinoma 5. reda:  
y = -1,8064 x5 + 70,414 x4 – 1092 x3 + 8432,3 x2 – 32487 x + 50137 z R² = 0,9999, zato 
smo to enačbo uporabili za izračun potencialnih molekulskih velikosti agregatov, medtem 
ko je teža monomernega vrha predstavljala nadzor rezultatov in bi morala biti približno 
150 kilodaltonov (kDa) (Preglednica 6). 
 
Po izračunih z uporabo predlaganega modela smo ugotovili, da je sedanja entiteta AP3 
potencialno trimerni agregat mAb1. Ustrezno temu je entiteta AP2 dimerni agregat mAb1, 
medtem ko je entiteta AP1 modificirana dimerična oblika mAb1, ki je sestavljena iz 
kombinacije monomera mAb1 z eno dodatno težko in lahko verigo, saj je razlika med 
velikostjo monomerne oblike (okoli 150 kDa) in izračunano velikostjo AP1 (okoli 230 
kDa) približno 80 kDa. To ustreza velikosti kombinacije ene težke (okoli 50 kDa) in lahke 
verige (okoli 23 kDa). Drugi matematični modeli s sprejemljivimi vrednostmi R2 
(polinomska regresija 2. do 5. reda) so pokazali podobne rezultate. Te ugotovitve o 
velikosti agregatnih produktov AP1, AP2 in AP3 smo dodatno izzvali z uporabo različnih 
analitskih metod. 
 
Analizo SEC-HPLC z detekcijo MALS smo izvedli za eksperimentalno določanje 
molekularne velikosti agregatnih vrhov v primerjavi z vrhom monomera. Stabilni rezultati 
molske mase (g/ml) za izvirni vzorec mAb1, mAb1-LS in mAb1-F/T po 18 ciklih so v 
območju monomernega (glavnega) vrha, medtem ko je bilo v obsegu multimernih oblik in 
razgradnih produktov videti veliko razpršenost rezultatov. To je posledica nizke 
koncentracije pomembnih analitov, prisotnih v detekcijski celici MALS. Ta razpršenost 
vrednosti je pričakovana, saj so agregati ali produkti razgradnje prisotni v veliko nižjih 
koncentracijah v vzorcih v primerjavi z glavnim vrhom. V normaliziranih kromatogramih 
v kombinaciji s signalom razpršene svetlobe in refrakcijskim indeksom (RI) iz vzorca 
mAb1-LS je bil samo agregatni vrh 2 (AP2) prisoten v večji koncentraciji v primerjavi z 
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AP1 in AP3, kar je omogočilo ustrezno obdelavo rezultatov za agregat AP2 (Preglednica 
7). 
 
Kot smo pričakovali, je izračunana molska masa za vrh monomera v kateri koli vrsti 
vzorca okoli 150 kDa, kar potrjuje ustrezno obdelavo rezultatov. Namen te analize je bil 
določitev molekulske mase za agregatne vrhove, kar je doseženo pri vrhu AP2. Približna 
molekulska masa za vrh AP2 je bila približno 326 kDa, kar potrjuje, da je vrh AP2 dimerna 
oblika proteina mAb1. To tudi pomeni, da je vrh AP3 potencialno trimeren in da je vrh 
AP1 vrsta okrnjene dimerične oblike mAb1. Ti rezultati so bili v skladu s sklepi analize 
regresijske krivulje MWM. 
 
Dodatno smo izpeljali in razvili metodo SEC-UPLC za zbiranje frakcij skupnih agregatov 
(SumAP) in individualnih agregatov: AP1, AP2 in AP3 ali monomernih (MP) frakcij iz 
vzorcev mAb1-LS (mAb1 materiala, izpostavljenega svetlobnemu stresu) in mAb1-F/T18 
(materiala mAb1 izpostavljenega stresu po 18 ciklih zamrzovanja/odtajanja). Vse zbrane 
frakcije smo pozneje ponovno analizirali z uporabo opisane metode SEC-UPLC in njihove 
koncentracije določili z uporabo sistemov Nano-Drop in Trinean. Rezultati čistosti in 
koncentracije proteinov v posameznih frakcijah so predstavljeni v Preglednici 9. 
 
Ponovna analiza zbranih frakcij monomera, skupnih in individualnih agregatnih frakcij z 
metodo SEC-UPLC je pokazala, da je večina vzorčnih frakcij vsebovala različne vrste 
agregatov v različnih razmerjih. To bi lahko pomenilo, da so nekateri agregati lahko 
reverzibilni in prehajajo v druge agregatne oblike ali monomer mAb1. Poleg tega se lahko 
zgodi, da izključitvena kromatografija po velikosti ne razdeli molekule s podobnim 
Stocksovim radijem v celoti, kar lahko privede do prekrivanja agregatnih entitet. 
 
Pridobljene frakcije smo okarakterizirali z uporabo SDS-PAGE brez (NR – nereduciran) in 
z reduktorjem DTT (R – reduciran). Elektroferogram je predstavljen na Sliki 24, kjer 
različne intenzitete barvanja ustrezajo koncentraciji vsake posamezne frakcije. Reducirno 
sredstvo DTT deluje na disulfidne vezi mAb1 ter ločuje težke in lahke verige monomerov 
in agregatov, zato v vseh pasovih s sedanjim DTT (pasovi, označeni z R – reduciran SDS-
PAGE) obstajata dve različni proteinski oznaki, ki ustrezata molekulskim masam težkih in 
lahkih verig mAb1. Po drugi strani pa so v skladu s posameznim agregatom in monomerno 
frakcijo iz vzorca zamrzovanja/odtajanja (FT) in svetlobnega stresa (LS) brez DTT (pasovi 
označeni z NR – nereduciran SDS-PAGE) vzorci razdeljeni glede na naboj in velikost 
nedotaknjenih komponent. Glede na razlike v velikosti proteinov in strukturni podobnosti 
komponent pričakujemo, da se monomerni in agregatni signali lahko raztegnejo in 
prekrijejo drug drugega. To prekrivanje smo opazili pri monomerni komponenti (MP) in 
njegovi modificirani obliki (AP1). 
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V pasu za posamezne agregate 3 za oba tipa vzorca (AP3-FT in AP3-LS) so prisotne 
frakcije trimernih (AP3) in monomernih (MP) komponent. V pasu za individualne agregate 
2 so za oba tipa vzorcev AP2-FT in AP2-LS smo zaznali trimerne (AP3), dimerne (AP2) in 
monomerne komponente (MP). Nasprotno smo v posameznem agregatu frakcije 1 iz 
vzorca zamrzovanja/odtajanja (AP1-FT) opazili komponente dimernih (AP2) in 
modificiranih monomernih oblik (AP1), medtem ko smo v individualnem agregatu frakcije 
1 iz vzorca svetlobnega stresa (AP1-LS) opazili vse tipe: trimerni (AP3), dimerni (AP2), 
modificirani dimerni mAb1 agregat (AP1) in monomerno obliko mAb1. Rezultati analize 
SDS-PAGE so skladni s tistimi iz analize karakterizacije SEC UPLC. Čeprav sta obe 
analizi pokazali prisotne sledi različnih agregatnih oblik v vsakem posameznem 
frakcijskem vzorcu, je še vedno v največji koncentraciji prisotna agregatna oblika, ki nas je 
zanimala. Končno je to posledica dodatnega ravnanja z vzorci in priprav za analizo ter je 
lahko tudi rezultat procesov reverzibilnosti agregata. 
 
Čeprav je metoda SEC sposobna grobega ločevanja različnih tipov entitet na podlagi 
njihovih različnih Stokesovih radijev: agregatni produkti (AP3, AP2 in AP1), monomerne 
vrste (MP) in produkti razgradnje (DP); ta metoda ne zagotavlja informacij o kemijskih 
razlikah med istimi tipi entitet s približno enakimi Stokesovimi radiji v raztopini (npr. 
frakcija AP2 iz vzorca svetlobnega stresa in frakcija AP2 iz zamrzovanega/odtajenega 
vzorca). Tako je predlagana metoda HIC-HPLC pokazala velik potencial za karakterizacijo 
frakcij, saj je v primerjavi z metodo SEC obravnavana kot ortogonalna metoda z 
zagotavljanjem dodatnih informacij o kemijskih interakcijah agregatnih skupin mAb1 z 
matriko kolone. 
 
Ob injiciranju 50 μg vzorca smo opazili razlike med vzorci frakcij v prisotnosti glavnih 
hipodofobnih variant (MHV – main hydrophobic variants) in različnih hidrofobnih variant 
z visoko molekulsko maso (HMWHV – high molecular weight hydrophobic variants), ki 
ustrezajo agregatnim produktom. Primeri kromatogramov čiste frakcije monomernega vrha 
originalnega vzorca mAb1 (vzorec, ki ni bil izpostavljen stresu: MP-mAb1), monomernega 
vrha iz vzorca svetlobnega stresa (MP-mAb1-LS) in monomerne frakcije iz vzorca mAb1, 
izpostavljenega stresu po 18 ciklih zamrzovanja/odtajanja (MP- mAb1-F/T18), ki so 
pridobljeni z metodo zbiranja frakcij SEC-UPLC in analizirani z metodo HIC so prikazani 
na Sliki 30. Očitno je, da ima monomerna frakcija iz vzorca svetlobnega stresa (MP-
mAb1-LS) dve kemijski entiteti (glavni hidrofobni varianti: MHV in MHV1, ki ustrezata 
monomeru), vidni na kromatogramu metode HIC. Slednje je lahko posledica kemične 
modifikacije originalnega vzorca mAb1 med svetlobnim stresom. V nasprotju s tem je 
monomerna frakcija originalnega vzorca in vzorca, izpostavljenega stresu 
zamrzovanja/odtajanja, očitna kot samo ena glavna hidrofobna varianta MHV (Slika 30, 
Preglednica 10). Zato ima enaka entiteta, ki je ločena na podlagi svojega Stokesovega 
radija z metodo SEC, potencial za nadaljnjo kemijsko karakterizacijo s predlagano metodo 
HIC. 
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Obe individualni frakciji agregata 3 iz vzorca zamrzovanja/odtajanja (AP3-mAb1-F/T18) 
in vzorca svetlobnega stresa (AP3-mAb1-LS) vsebujeta HMWHV 3, 4 in 5. Individualna 
frakcija agregata 2 iz vzorca zamrzovanja/odtajanja (AP2-mAb1-F/T18) vsebuje HMWHV 
1, 2, 4 in 5 v primerjavi z individualno frakcijo agregata 2 iz vzorca svetlobnega stresa 
(AP2-mAb1-LS), ki vsebuje HMWHV 1, 4 in 5. Tako je tudi pri individualni agregatni 
frakciji 1 za AP1-mAb1-F/T18, kjer so prisotni vrhovi 1, 2, 4 in 5 HMWHV, medtem ko 
so pri agregatni frakciji 1 iz vzorca svetlobnega stresa AP1-mAb1-LS opaženi samo vrhovi 
1, 4 in 5 HMWHV (Slika 31, Preglednica 10). Kot je prikazano tukaj, je razvita metoda 
HIC sposobna ločiti proteinske entitete glede na njihove kemijske lastnosti, zato se kot 
parameter za dodatni karakterizacijski marker lahko uporabi tudi retencijski čas vsakega od 
vrhov, ki določajo potencialno prisotnost različnih proteinskih variant. 
 
Po analitski karakterizaciji agregiranih entitet smo opravili in vitro imunološke teste na 
dendritičnih celicah (DC) in mononuklearnih celicah periferne krvi (PBMC). Najprej smo 
ovrednotili imunogenost skupnih agregatnih frakcij z uporabo opisanega testa DC s 
frakcijskim potencialom za nadregulacijo DC-celičnih kostimulatornih molekul CD40, 
CD80, CD86 in CCR7 in HLA-DR. Dobljene rezultate smo primerjali z LPS, vzorčnim 
medijem (pufrom) in netretiranimi celicami, ki smo jih uporabili kot kontrole. Inkubacijo 
DC smo izvedli pri končni koncentraciji 100 μg/ml od vsake skupne agregatne frakcije 
vzorca (SumAP). Postopek zorenja smo nadzorovali z imunofenotipiranjem z uporabo 
analize razvrščanja fluorescenčno aktiviranih celic (FACS – fluorescence activated cell 
sorting analysis). Rezultati so prikazani na Sliki 32. 
 
Manjše izražanje CD40 smo opazili v vzorcih pufersko obdelanih DC-jev. Potencialni 
razlog za to je težko opredeliti in bi lahko bil posledica redčenja medija v celični kulturi 
zaradi dodanega pufra, saj je dokazano, da so fenotipi diferenciacije DC in zorenja močno 
odvisni od sestave kulture medija. Rezultati za teste DC kažejo, da skupne agregatne 
frakcije vzorcev, izpostavljenih svetlobnemu stresu, in vzorcev mAb1, izpostavljenih 
stresu zamrzovanja/odtajanja, ne inducirajo močno imunogenega zorenja celic DC s 
povečanim izražanjem markerjev CD40, CD80, CD86, CCR7. Samo majhno nadregulacijo 
markerja HLA-DR smo opazili za skupne agregatne frakcije vzorcev, izpostavljenih 
svetlobnemu stresu, in vzorcev, izpostavljenih stresu zamrzovanja/odtajanja. 
 
Nato smo enako testirali tudi frakcije posameznih monomerov (MP) in agregatov (AP1, 
AP2 in AP3) iz vzorca svetlobnega stresa mAb1 (mAb1-LS) in vzorca, izpostavljenega 
stresu zamrzovanja/odtajanja po 18 ciklih (mAb1-F/T18). Ocenili smo potencialno 
nadregulacijo markerjev dendritičnih celic CD40, CD80 in CD86. Inkubacijo smo izvedli 
pri končni koncentraciji 100 μg/ml za vse vzorce, razen agregatne frakcije 3 iz vzorca 
svetlobnega stresa (AP3-mAb1-LS), za katerega smo inkubacijo izvedli pri končni 
koncentraciji 50 μg/ml. Prav tako smo pri končni koncentraciji vzorca 10 μg/ml izvedli 
inkubacijo s tretjo agregatno frakcijo vzorca, izpostavljenega stresu zamrzovanja/odtajanja 
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(AP3-mAb1-F/T18). Tako imajo individualni agregati tretje frakcije, izpostavljene 
svetlobnemu stresu, in tisti, izpostavljeni zamrzovanju/odtajanja, nižjo začetno 
koncentracijo proteinov. Na račun tega smo inkubacijske teste DC opravili pri nižjih 
koncentracijah. Rezultati za individualne monomere in agregate iz 
zamrznjenega/odtajanega vzorca mAb1 po 18 ciklih (mAb1-F/T18) so prikazani na Sliki 
33, medtem ko so rezultati frakcij svetlobnega stresa (mAb1-LS) prikazani na Sliki 34. 
 
Prav tako individualne monomerne in agregatne frakcije iz vzorca, izpostavljenega 
zamrzovanju/odtajanju, niso povzročile močnega imunogenskega zorenja celic DC z 
nadregulacijo markerjev CD40, CD80 in CD86 (Slika 33). Vendar pa vse individualne 
agregatne frakcije iz vzorca, izpostavljenega zamrzovanju/odtajanju, kažejo le rahlo 
nadregulacijo markerjev CD40 in CD80, ki so očitno občutljivejši v primerjavi z 
markerjem CD86. 
 
Kot je razvidno iz rezultatov za posamezne agregatne in monomerne frakcije iz vzorca 
svetlobnega stresa mAb1 (Slika 34), tudi individualne agregatne frakcije iz vzorcev 
svetlobnega stresa niso močno spodbudile imunogenega zorenja celic DC z nadregulacijo 
markerjev CD40, CD80 in CD86. Vendar pa rezultati posameznih agregatnih frakcij iz 
vzorca svetlobnega stresa kažejo le rahlo nadregulacijo CD40 v primeru frakcije 
agregatnega vrha 2 (AP2). Poleg tega tudi agregatna frakcija AP1 kaže le rahlo 
nadregulacijo v CD80 in CD86. Čeprav je AP1-mAb1 LS povzročila večjo izraznost CD86 
v primerjavi z netretirano kulturo, tega ne moremo povezati z občutnim zorenjem DC. 
Razlog za to je narava ekspresije CD86 na površini DC, ki je v času zorenja DC veliko bolj 
nadregulirana (več kot 20-kratno povečanje je bilo prikazano za imunogeno kontrolo LPS 
v primerjavi z DC, tretiranim z AP1-mAb1 LS). Agregatna frakcija AP1 povzroči tudi 
opazno nadregulacijo markerja CD40. Ker vse agregatne frakcije niso popolnoma čiste in 
vsebujejo različna razmerja drugih agregatov ali monomerov, so rezultati testa DC 
pokazali, da je imunogenski potencial različnih agregatov mAb1 za aktivacijo celic DC 
lahko odvisen od njihove kemijske strukture, trenutne kombinacije in razmerij različnih 
posameznih agregatov v frakcijah vzorca. 
 
Da bi določili sposobnost stimuliranih DC, da proizvedejo provnetne citokine, smo po 48 
urah inkubacije ovrednotili supernatante DC z vsemi vzorci, pri končni koncentraciji 100 
μg/ml. Vendar pa smo inkubacijo za agregat 3 frakcije iz vzorca svetlobnega stresa (AP3-
mAb1-LS) in vzorca, izpostavljenega stresu zamrzovanja/odtajanja (AP3-mAb1-F/T18), 
izvedli pri končni koncentraciji vzorca od 50 μg/ml oziroma pri 10 μg/ml, saj imajo 
posamezne frakcije agregata 3 nižje začetne koncentracije proteinov. Po inkubaciji skupnih 
agregatnih vzorcev (SumAP) iz vzorca svetlobnega stresa mAb1 (mAb1-LS) in vzorca, 
izpostavljenega zamrznjenju/odtajanju po 18 ciklih (mAb1-F/T18), smo analizirali 
supernatante DC za prisotnost IL-1β, IL-6, IL-8, IL-10, IL-12p70 in TNF-α. Vrednosti 
citokinov v supernatantih smo analizirali s pretočno citometrijo z uporabo Cytometric 
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Bead Array (CBA) Kit (BD bioscience) in rezultati smo predstavili na Sliki 36 kot srednjo 
intenzivnost fluorescence.  
 
Rezultati potrjujejo, da skupni agregatni vzorci iz mAb1, ki so bili izpostavljeni 
zamrzovanju/odtajanju, in vzorci, izpostavljeni svetlobi, ne vplivajo na imunogeni odziv z 
indukcijo proizvodnje citokinov IL-10, IL-1β, TNFα, IL-12p70 celic DC. Pri obeh 
skupinah agregatnih vzorcih, tistih, izpostavljenih zamrzovanju/odtajanju, in vzorcih, 
izpostavljenih svetlobi, smo opazili le manjšo nadregulacijo proizvodnje citokinov celice 
DC za IL8, IL10 in TNFα, vendar njihove vrednosti niso bile niti približno tako visoke kot 
imunogenska LPS-kontrola. V skladu s tem smo opazili rahlo nadregulacijo IL8 in TNFα 
za individualne agregatne frakcije AP1-LS in AP2-FT, vendar odziv celic DC ni tako visok 
kot pri drugih pozitivnih kontrolah. 
 
Za ovrednotenje potencialno prirojenega imunogenskega odziva kultur mononuklearnih 
celic periferne krvi (PBMC) na agregate mAb1 smo merili IL-10 in protivnetni PBMC 
citokinski odziv IL-1β, IL-6, IL-8, IL-12p70 in TNF-α med zgodnjo izpostavljenostjo do 
48 ur v predlaganem testu PBMC. Inkubacijo celic PBMC smo izvedli z vsemi vzorci pri 
končni koncentraciji 100 μg/ml, pri čemer je za agregatno frakcijo 3 iz vzorca svetlobnega 
stresa (AP3-mAb1-LS) inkubacija izvedena pri 50 μg/ml in za vzorec, izpostavljen 
zamrzovanju/odtajanju (AP3 -mAb1-F/T18), pri 10 μg/ml. Multiple citokine smo izmerili z 
uporabo CBA Kit. Rezultati so analizirani s pretočno citometrijo in grafično prikazani na 
Sliki 37. 
 
V skupnih (SumAP) in individualnih agregatnih (AP1, AP2, AP3) ter monomernih (MP) 
frakcijah mAb1 zamrzovanega/odtajanega vzorca ter vzorcih svetlobnega stresa nismo 
opazili pomembnega povečanja proizvodnje citokinov. V primerjavi z netretiranimi 
celicami PBMC smo opazili rahlo zvišanje pri TNFα za vzorec AP3-LS, IL-10 za vzorec 
SumAP-FT in IL-1α za vzorca SumAP-LS in MP-FT. Poleg tega smo v primerjavi z 
netretiranimi celicami PBMC opazili povečanje IL-6 za vzorce: AP2-FT, AP1-FT, AP3-
LS, AP2-LS in povečanje IL-8 za vzorce: SumAP-FT, SumAP-LS, MP-FT, MP-LS, AP3-
FT, AP2-FT in AP1-FT. 
 
Test PBMC za proliferacijo celic prav tako ni pokazal pomembnega vpliva testiranih 
skupnih in individualnih agregatnih frakcij iz vzorcev svetlobnega stresa in vzorcev, 
izpostavljenih stresu zamrzovanja/odtajanja (Slika 38). Med preostalimi rezultati je le 
agregatna frakcija 1 iz vzorca mAb1, ki je bil izpostavljen zamrzovanju/odtajanju (AP1-
FT), imela nekoliko več celic na minuto v primerjavi z netretirano celično kulturo PBMC. 
Rezultati za frakcijo AP1-FT so še vedno primerljivi z rezultati pufra, ki smo ga 
uporabljali kot kontrolo, a ne tako visoki kot imunogeni PHA. 
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SKLEP 
Z uporabo predlaganih in na novo razvitih analitskih metod za karakterizacijo mAb1 smo 
ugotovili, da so v profilu strukturnih variant agregatov različnih tipov mAb1 (naravni 
vzorec, vzorec svetlobnega stresa in vzorec mAb1 po 18 ciklih izpostavitve stresu 
zamrzovanja/odtajanja) prisotne tri agregirane entitete: agregatni produkti 1, 2 in 3 (AP1, 
AP2 in AP3). Po matematični regresijski analizi označevalcev molekulske mase (MWM) 
in potrditvi podatkov s analitskimi eksperimentalnimi testi (SEC-MALS in SDS-PAGE) 
vsakega individualnega agregata mAb1 (AP1, AP2 in AP3) in frakcij monomerov, smo 
ugotovili, da je entiteta AP3 trimerni agregat mAb1, entiteta AP2 je dimerni agregat 
mAb1, medtem ko je entiteta AP1 modificirana dimerna oblika mAb1, ki jo sestavlja 
kombinacija monomera mAb1 z eno dodatno težko in lahko verigo. 
 
Izpostavitev svetlobnemu stresu je povzročila večje nastajanje agregatov mAb1 v 
primerjavi z vzorcem mAb1 po 18 ciklih stresa z zamrzovanjem/odtajanjem. Predlagana 
analiza metode HIC-HPLC je pokazala tudi, da svetlobni stres povzroča kemijske 
spremembe v monomerni strukturi mAb1, katere so opazne kot razcepljenje monomernega 
vrha. Ta učinek ni viden po uporabi stresa zamrzovanja/odtajanja, kar pomeni, da je glavni 
način tvorbe agregata v zamrzovanem/odtajanem vzorcu mAb1 mehanska sprememba 
proteina. V celotnem agregatnem profilu mAb1 je v vsakem tipu testiranega vzorca v 
največjem odstotku prisoten agregatni produkt 2 (AP2), kar pomeni, da imajo med 
izpostavitvijo stresu z zamrzovanjem/odtajanjem in svetlobnemu stresu vzorcev mAb1 
prednost konverzije v dimerno agregatno obliko. 
 
Določili smo tudi potencialno kapaciteto agregatov mAb1, da inducirajo zorenje 
dendritičnih celic v smislu produkcije fenotipov in citokinov. Iz celičnih raziskav DC in 
PBMC ter dobljenih rezultatov skupnih in posameznih agregatnih frakcij iz vzorcev 
svetlobnega stresa in zamrznjenih/odtajanih vzorcev mAb1 lahko sklepamo, da produkcija 
markerjev (CD40, CD80, CD86, CCR7 in HLA-DR) in citokinov (IL-10, IL-1β, IL-6, IL-
8, IL-12p70 in TNF-α) ni bila visoka. Ta ugotovitev implicira, da vse testirane skupne in 
posamezne agregatne frakcije iz vzorca svetlobnega stresa mAb1 in vzorca mAb1, 
izpostavljenega 18 ciklom zamrzovanja/odtajanja, niso imunogene. To prispeva k splošni 
visoki kakovosti zdravilne snovi mAb1. Poleg tega se markerji (CD40 in HLA-DR) in 
citokini (IL-6, IL-8 in TNFα) zdijo občutljivejši za agregate mAb pri določanju potencialne 
imunogenosti v testih DC in PBMC. Prav tako test PBMC za proliferacijo celic ni pokazal 
nobenega pomembnega vpliva testiranih skupnih in individualnih agregatnih frakcij iz 
obeh vrst vzorcev mAb1, izpostavljenih stresu. 
 
Vsi pridobljeni podatki prispevajo k potrditvi visoke kakovosti izvirne zdravilne 
učinkovine mAb1, saj tudi zelo visok stres mAb1 materiala s svetlobo in 
zamrzovanjem/odtajanjem in posledično nastalimi agregiranimi entitetami mAb1 ni 
pokazal potenciala za indukcijo imunogenega odziva. V skladu s tem bi se lahko vse 
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razvite in predlagane analitske metode ter imunološki in vitro testi DC in PBMC uporabili 
kot platforma (predstavljena na Sliki 39) za dopolnilno analitično karakterizacijo in 
določanje potenciala za imunogenost za vse biofarmacevtske izdelke, ki kot aktivno 
farmacevtsko sestavino vsebujejo monoklonska protitelesa. 
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APPENDIX A 
Mean fluorescence intensity results for dendritic cell cytokines analysis after incubation with total 
aggregate fractions (SumAP) from mAb1 light stressed sample (SumAP-LS) and mAb1 sample after 
18 freeze/thaw cycles (SumAP-F/T). Lipopolysaharide – LPS, sample buffer, and non-treated cells 
(NT) were used as controls. All presented results were used to compile Table 11. 
Rezultati povprečne intenzitete fluorescence analize citokinov dendritičnih celic po inkubaciji s 
skupnimi agregatnimi frakcijami (SumAP) iz vzorca mAb1 izpostavljenega svetlobnemu stresu 
(SumAP-LS) in vzorca mAb1 po 18 ciklih zamrzovanja/odtajanja (SumAP-F/T). Lipopolisaharid - 
LPS, vzorčni pufer in ne-tretirane celice (NT) so uporabljeni kot kontrolni vzorci. Vsi predstavljeni 
rezultati so uporabljeni za pripravo Preglednice 11. 
 
IL12p70 
 
IL-6 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
1. 19.2 43.5 18.1 19.3 19.0 
 
1. 90.2 15039.0 87.1 111.0 92.3 
2. 23.1 57.0 14.9 13.2 13.1 
 
2. 101.0 18773.0 79.0 143.0 109.0 
3.  14.7 62.8 14.0 16.3 15.0 
 
3.  81.0 12989.0 105.0 101.0 87.7 
Mean 
value 
19.00 54.43 15.67 16.27 15.70 
 
Mean 
value 
90.73 15600.33 90.37 118.33 96.33 
σ 4.20 9.90 2.15 3.05 3.01 
 
σ 10.01 2932.57 13.30 21.94 11.21 
%RSD 22.12 18.19 13.75 18.75 19.18 
 
%RSD 11.03 18.80 14.72 18.54 11.63 
      
 
      
TNFα 
 
IL-1β 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
1. 31.0 436.0 29.9 30.3 20.4 
 
1. 86.5 109.0 85.4 89.3 87.4 
2. 35.6 487.0 35.0 34.2 36.3 
 
2. 99.2 150.0 68.8 101.0 99.0 
3.  28.7 423.0 27.1 23.7 26.5 
 
3.  62.0 99.4 92.0 76.3 81.7 
Mean 
value 
31.77 448.67 30.67 29.40 27.73 
 
Mean 
value 
82.57 119.47 82.07 88.87 89.37 
σ 3.51 33.83 4.01 5.31 8.02 
 
σ 18.91 26.87 11.95 12.36 8.82 
%RSD 11.06 7.54 13.06 18.05 28.92 
 
%RSD 22.90 22.50 14.57 13.90 9.87 
      
 
      
IL-10 
 
IL-8 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
1. 43.6 772.0 41.4 44.4 42.1 
 
1. 410.0 16041.0 247.0 696.0 303.0 
2. 51.2 509.0 55.2 57.7 34.0 
 
2. 376.0 22329.0 347.0 800.0 350.0 
3.  32.1 811.0 38.7 39.1 49.0 
 
3.  465.0 14009.0 190.0 490.0 290.0 
Mean 
value 
42.30 697.33 45.10 47.07 41.70 
 
Mean 
value 
417.00 17459.67 261.33 662.00 314.33 
σ 9.62 164.26 8.85 9.58 7.51 
 
σ 44.91 4337.63 79.48 157.77 31.56 
%RSD 22.73 23.56 19.62 20.36 18.00 
 
%RSD 10.77 24.84 30.41 23.83 10.04 
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APPENDIX B 
Combined mean fluorescence intensity results for dendritic cell cytokines analysis after incubation 
with total aggregate fractions from mAb1 light stressed sample (SumAP-LS), freeze/thaw stressed 
sample (SumAP-F/T) and their individual aggregates (AP1, AP2, and AP3). Lipopolysaharide – LPS, 
sample buffer, and non-treated cells (NT) were used as controls. All presented results were used to 
compile Table 12. 
Kombinirana srednja vrednost intenzitete fluorescence analize citokinov dendritičnih celic po 
inkubaciji s skupnimi agregatnimi frakcijami iz vzorca mAb1, izpostavljenega svetlobnemu stresu 
(SumAP-LS), vzorca izpostavljenega stresu zamrzovanja/odtajanja (SumAP-F/T) in njihovih 
individualnih agregatov (AP1, AP2 in AP3). Lipopolisaharid - LPS, vzorčni pufer in ne-tretirane celice 
(NT) so uporabljeni kot kontrolni vzorci. Vsi predstavljeni rezultati so uporabljeni za pripravo 
Preglednice 12. 
IL-12p70 
No NT Buffer LPS 
SumAP- 
F/T 
SumAP-
LS 
AP3-
FT 
AP2-
FT 
AP1-
FT 
AP3-
LS 
AP2-
LS 
AP1-
LS 
1. 7.4 7.4 67.7 7.7 7.1 7.2 7.1 7.3 7.5 7.6 7.7 
2. 7.7 7.5 83.8 7.2 7.2 6.4 7.6 7.2 7.5 7.4 7.4 
3. 8.0 7.6 85.9 7.5 7.6 7.1 7.4 7.3 7.2 7.8 7.5 
Mean 
value 
7.71 7.48 79.12 7.47 7.29 6.92 7.39 7.28 7.40 7.62 7.52 
σ 0.28 0.09 9.97 0.27 0.26 0.42 0.23 0.05 0.19 0.20 0.11 
% 
RSD 
3.66 1.18 12.60 3.63 3.54 6.06 3.17 0.69 2.57 2.67 1.48 
            
TNFα 
No NT Buffer LPS 
SumAP- 
F/T 
SumAP-
LS 
AP3-
FT 
AP2-
FT 
AP1-
FT 
AP3-
LS 
AP2-
LS 
AP1-
LS 
1. 10.1 10.3 116.1 10.8 22.8 12.0 12.5 12.8 10.5 12.3 12.4 
2. 12.5 10.6 146.0 11.3 16.2 11.9 11.5 12.9 11.1 10.6 20.1 
3. 9.2 11.4 160.3 11.6 16.4 15.5 15.5 13.7 12.2 9.7 18.2 
Mean 
value 
10.61 10.76 140.76 11.22 18.45 13.13 13.17 13.14 11.27 10.87 16.90 
σ 1.69 0.58 22.55 0.43 3.77 2.06 2.08 0.53 0.84 1.28 4.02 
% 
RSD 
15.92 5.43 16.02 3.83 20.46 15.66 15.77 4.04 7.42 11.81 23.78 
            
IL-10 
No NT Buffer LPS 
SumAP- 
F/T 
SumAP-
LS 
AP3-
FT 
AP2-
FT 
AP1-
FT 
AP3-
LS 
AP2-
LS 
AP1-
LS 
1. 11.8 12.2 17.0 12.2 12.3 12.8 11.6 12.0 11.6 12.1 12.6 
2. 7.6 11.9 19.4 12.2 11.4 13.2 11.6 12.1 8.4 11.8 11.9 
3. 10.3 11.4 18.6 13.2 10.9 15.9 12.4 12.0 11.9 10.8 12.0 
Mean 
value 
9.89 11.84 18.32 12.54 11.53 13.97 11.89 12.05 10.60 11.56 12.15 
σ 2.09 0.43 1.20 0.60 0.69 1.67 0.48 0.07 1.94 0.68 0.40 
% 
RSD 
21.18 3.61 6.57 4.82 6.03 11.94 4.01 0.57 18.27 5.92 3.27 
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IL-6 
No NT Buffer LPS 
SumAP- 
F/T 
SumAP-
LS 
AP3-
FT 
AP2-
FT 
AP1-
FT 
AP3-
LS 
AP2-
LS 
AP1-
LS 
1. 18.6 19.3 2084.6 19.4 19.8 18.8 19.5 18.7 19.1 19.6 20.2 
2. 19.9 19.4 3087.4 19.2 19.5 20.2 18.7 15.2 19.1 19.8 18.7 
3. 20.5 18.6 2816.2 17.2 16.8 19.2 20.2 19.8 18.2 16.9 18.4 
Mean 
value 
19.65 19.10 2662.72 18.58 18.69 19.40 19.44 17.89 18.81 18.74 19.12 
σ 0.96 0.41 518.71 1.17 1.62 0.70 0.76 2.37 0.49 1.58 0.94 
% 
RSD 
4.87 2.14 19.48 6.31 8.67 3.63 3.90 13.22 2.62 8.43 4.90 
            
IL-1β 
No NT Buffer LPS 
SumAP- 
F/T 
SumAP-
LS 
AP3-
FT 
AP2-
FT 
AP1-
FT 
AP3-
LS 
AP2-
LS 
AP1-
LS 
1. 20.5 20.0 20.7 19.8 20.5 19.5 19.9 20.2 19.8 19.3 20.0 
2. 21.7 20.1 21.3 22.0 20.0 20.4 19.6 19.8 19.8 19.8 20.0 
3. 19.6 19.4 20.4 20.4 21.6 21.2 20.4 19.6 20.8 17.3 19.7 
Mean 
value 
20.62 19.83 20.79 20.72 20.70 20.37 19.97 19.90 20.13 18.80 19.87 
σ 1.06 0.41 0.44 1.15 0.81 0.89 0.42 0.33 0.55 1.33 0.15 
% 
RSD 
5.16 2.08 2.09 5.55 3.93 4.36 2.12 1.64 2.71 7.06 0.78 
            
IL-8 
No NT Buffer LPS 
SumAP- 
F/T 
SumAP-
LS 
AP3-
FT 
AP2-
FT 
AP1-
FT 
AP3-
LS 
AP2-
LS 
AP1-
LS 
1. 49.3 47.0 5670.6 103.3 624.1 92.4 151.5 88.2 39.5 81.4 86.1 
2. 60.2 64.8 5792.6 86.8 232.4 77.4 77.2 57.7 107.0 40.3 319.3 
3. 52.7 46.8 6172.4 77.1 392.7 80.1 88.0 131.1 69.7 57.2 354.9 
Mean 
value 
54.06 52.86 5878.54 89.08 416.42 83.30 105.61 92.31 72.06 59.63 253.41 
σ 5.54 10.38 261.73 13.26 196.89 8.03 40.14 36.87 33.82 20.69 145.96 
% 
RSD 
10.24 19.64 4.45 14.88 47.28 9.63 38.01 39.95 46.93 34.69 57.60 
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APPENDIX C 
Results for PBMC cytokines analysis after incubation with total aggregate fractions from mAb1 light 
stressed sample (SumAP-LS) and mAb1 sample after 18 freeze/thaw cycles (SumAP-F/T). The table 
also contains PBMC assay results for individual monomer (MP) and aggregates (AP1, AP2, and AP3) 
from mAb1 light stressed sample (LS) and mAb1 sample after 18 freeze/thaw cycles (FT).  
Lipopolysaharide – LPS, sample buffer, and non-treated cells (NT) were used as controls. All 
presented results were used to compile Table 13. 
Rezultati PBMC analize citokinov po inkubaciji s skupnimi agregatnimi frakcijami iz mAb1 vzorca 
izpostavljenega svetlobnem stresu (SumAP-LS) in mAb1 vzorca po 18 ciklih zamrzovanja/odtajanja 
(SumAP-F/T). Tabela vsebuje tudi rezultate PBMC analize za posamezne monomerne (MP) in 
agregatne frakcije (AP1, AP2 in AP3) iz vzorca mAb1 izpostavljenega svetlobnemu stresu (LS) in 
vzorca mAb1, po 18 ciklih zamrzovanja/odtajanja (FT). Lipopolisaharid - LPS, vzorčni pufer in ne-
tretirane celice (NT) so uporabljeni kot kontrolni vzorci. Vsi predstavljeni rezultati so uporabljeni za 
pripravo Preglednice 13. 
IL12p70 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
MP-FT MP-LS AP3-FT AP2-FT AP1-FT AP3-LS AP2-LS AP1-LS 
1. 7.6 7.9 7.4 7.7 7.3 7.8 8.2 7.7 8.0 7.5 8.1 7.8 7.4 
2. 9.0 12.1 8.7 9.1 9.1 9.2 9.9 9.1 10.1 8.9 9.8 7.1 9.1 
3.  6.2 8.7 6.9 6.2 6.8 6.5 6.7 5.3 6.1 6.1 7.3 9.6 6.5 
Mean 
value 
7.60 9.57 7.67 7.67 7.73 7.83 8.27 7.37 8.07 7.50 8.40 8.17 7.67 
σ 1.40 2.23 0.93 1.45 1.21 1.35 1.60 1.92 2.00 1.40 1.28 1.29 1.32 
%RSD 18.42 23.31 12.12 18.92 15.64 17.24 19.37 26.09 24.80 18.67 15.20 15.79 17.22 
              TNFα 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
MP-FT MP-LS AP3-FT AP2-FT AP1-FT AP3-LS AP2-LS AP1-LS 
1. 12.4 289.0 11.5 11.8 11.5 11.8 13.6 12.8 11.0 12.4 14.0 13.2 11.7 
2. 16.2 343.1 14.3 14.3 13.2 13.2 16.2 14.2 13.0 16.0 17.1 14.0 14.0 
3.  11.2 239.0 10.9 13.5 16.2 10.7 11.1 11.0 12.0 11.0 16.0 11.0 12.3 
Mean 
value 
13.27 290.37 12.23 13.20 13.63 11.90 13.63 12.67 12.00 13.13 15.70 12.73 12.67 
σ 2.61 52.06 1.81 1.28 2.38 1.25 2.55 1.60 1.00 2.58 1.57 1.55 1.19 
%RSD 19.68 17.93 14.83 9.67 17.46 10.53 18.71 12.66 8.33 19.64 10.01 12.20 9.42 
              IL-10 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
MP-FT MP-LS AP3-FT AP2-FT AP1-FT AP3-LS AP2-LS AP1-LS 
1. 17.0 287.0 15.6 17.2 16.7 17.2 17.5 16.4 17.2 15.6 16.4 17.2 16.8 
2. 12.9 398.0 17.0 21.0 19.0 21.2 20.8 19.2 10.7 17.0 12.0 18.9 17.3 
3.  20.0 233.0 14.2 16.1 13.9 13.8 12.0 13.1 18.3 12.0 15.8 13.1 18.8 
Mean 
value 
16.63 306.00 15.60 18.10 16.53 17.40 16.77 16.23 15.40 14.87 14.73 16.40 17.63 
σ 3.56 84.12 1.40 2.57 2.55 3.70 4.45 3.05 4.11 2.58 2.39 2.98 1.04 
%RSD 21.43 27.49 8.97 14.20 15.45 21.29 26.51 18.81 26.67 17.35 16.20 18.18 5.90 
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IL-6 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
MP-FT MP-LS AP3-FT AP2-FT AP1-FT AP3-LS AP2-LS AP1-LS 
1. 28.8 7128.0 30.3 29.9 31.1 32.0 30.3 29.4 29.5 34.2 32.3 31.9 28.2 
2. 35.6 10910.0 40.0 24.4 36.0 27.0 27.1 33.1 23.4 41.0 38.1 37.3 33.3 
3.  24.2 8607.0 22.5 33.3 25.9 30.4 32.8 24.7 40.0 27.7 29.6 28.3 20.9 
Mean 
value 
29.53 8881.67 30.93 29.20 31.00 29.80 30.07 29.07 30.97 34.30 33.33 32.50 27.47 
σ 5.74 1905.90 8.77 4.49 5.05 2.55 2.86 4.21 8.40 6.65 4.34 4.53 6.23 
%RSD 19.42 21.46 28.34 15.38 16.29 8.57 9.50 14.48 27.12 19.39 13.03 13.94 22.69 
              IL-1β 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
MP-FT MP-LS AP3-FT AP2-FT AP1-FT AP3-LS AP2-LS AP1-LS 
1. 34.2 712.0 35.0 33.5 34.7 36.0 33.2 34.4 35.2 34.3 33.0 34.2 33.6 
2. 41.0 999.0 42.2 38.1 42.3 44.0 39.2 33.0 39.8 39.1 33.4 37.0 38.1 
3.  32.6 612.0 32.6 28.9 34.4 31.2 29.5 36.9 33.0 31.6 39.0 31.7 26.6 
Mean 
value 
35.93 774.33 36.60 33.50 37.13 37.07 33.97 34.77 36.00 35.00 35.13 34.30 32.77 
σ 4.46 200.89 5.00 4.60 4.48 6.47 4.90 1.98 3.47 3.80 3.35 2.65 5.80 
%RSD 12.41 25.94 13.65 13.73 12.06 17.45 14.41 5.68 9.64 10.85 9.55 7.73 17.69 
              IL-8 
No NT LPS Buffer 
SumAP 
F/T 
SumAP 
LS 
MP-FT MP-LS AP3-FT AP2-FT AP1-FT AP3-LS AP2-LS AP1-LS 
1. 58.3 8100.0 59.0 75.6 69.4 70.1 94.4 97.2 64.6 93.3 44.4 44.0 45.3 
2. 90.1 11232.0 96.0 101.0 99.7 100.0 133.0 156.0 101.0 132.0 42.7 76.7 88.2 
3.  44.1 7699.0 48.3 63.0 61.0 62.2 87.6 87.3 55.0 83.4 80.1 54.7 58.0 
Mean 
value 
64.17 9010.33 67.77 79.87 76.70 77.43 105.00 113.50 73.53 102.90 55.73 58.47 63.83 
σ 23.55 1934.44 25.03 19.36 20.36 19.94 24.49 37.14 24.27 25.68 21.12 16.67 22.04 
%RSD 36.71 21.47 36.93 24.24 26.54 25.75 23.32 32.72 33.00 24.96 37.89 28.52 34.52 
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APPENDIX D 
Results for PBMC proliferation assay after incubation with total aggregate fractions from mAb1 light 
stressed sample (SumAP-LS) and mAb1 sample after 18 freeze/thaw cycles (SumAP-F/T). The table 
also contains PBMC assay results for individual monomer (MP) and aggregates (AP1, AP2, and AP3) 
from mAb1 light stressed sample (LS) and mAb1 sample after 18 freeze/thaw cycles (FT).  
Phytohemagglutinin – PHA, sample buffer, and non-treated cells (NT) were used as controls. All 
presented results were used to compile Table 14. 
Rezultati analize PBMC proliferacije po inkubaciji s skupnimi agregatnimi frakcijami iz vzorca mAb1 
izpostavljenega svetlobnemu stresu (SumAP-LS) in vzorca mAb1 po 18 ciklih zamrzovanja/odtajanja 
(SumAP-F/T). Tabela vsebuje tudi rezultate PBMC analize za posamezne monomerne (MP) in 
agregatne frakcije (AP1, AP2 in AP3) iz vzorca mAb1 izpostavljenega svetlobnemu stresu (LS) in 
vzorca mAb1, po 18 ciklih zamrzovanja/odtajanja (FT). Fitohemaglutinin - PHA, vzorčni pufer in ne-
tretirane celice (NT) so uporabljeni kot kontrolni vzorci. Vsi predstavljeni rezultati so uporabljeni za 
pripravo Preglednice 14. 
Values for PBMC proliferation (counts/min) 
No NT Buffer PHA 
SumAP- 
F/T 
SumAP-
LS 
AP3-
FT 
AP2-
FT 
AP1-
FT 
AP3-
LS 
AP2-
LS 
AP1-
LS 
1. 496 842 29952 541 286 210 271 210 240 210 165 
2. 346 496 30450 301 436 256 210 782 180 346 271 
3.  391 586 31416 271 240 225 195 902 180 225 406 
Mean 
value 
411.0 641.3 30606.0 371.0 320.7 230.3 225.3 631.3 200.0 260.3 280.7 
σ 77.0 179.5 744.4 148.0 102.5 23.5 40.3 369.8 34.6 74.6 120.8 
% RSD 18.7 28.0 2.4 39.9 32.0 10.2 17.9 58.6 17.3 28.6 43.0 
 
